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Abstract
The human endometrium is a highly dynamic tissue that undergoes cyclical tissue
injury and repair. The function of the endometrium across the menstrual cycle is
tightly regulated by steroid hormones, both system ically and locally derived. Local
steroid availability is modulated by a number of steroid-jnctabolising enzymes,
particularly members of jiydroxysteroid dehydrogenase (HSD) families, In addition,
steroid hormone action is also governed by the availability of the appropriate cognate
receptors.
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Key steroids of the endometrium are gstrogens, androgens, progestogens and
glucocorticoids. These are modulated at a local level by a, number of steroid







Deleted: vital in the precise
As all these steroids are prucial for normal control of endometrial function, it is
desirable to understand the enzymes jegulating their availability and action across the
menstrual cycle, in early pregnancy, and following clinical treatments. Thus, the
aims of this studvTwere to investigate the expression (quantitative real-time PCR) and
immunolocalisation of steroid metabolising enzymes and receptors in human
endometrium across the menstrual cycle, in first trimester decidua, and in two
clinical situations - use of a,levonorgcstrcl intra-uterine system (LNG-IUS) to
control uterine bleeding;, and following recombinant FSH and GnRH antagonist






enzyme families, ,lipHSDs. and corresponding receptors, GR and MR, was ! Deleted: the
investigated in vitro.
This work has shown that lipHSD-1 mRNA is present at highest levels in the
menstrual phase of the cycle and in first trimester decidua, the times when an
inflammatory response is evident,. llpHSD-2 mRNA and protein are present at all
Deleted: required )
stages of the cycle, and plso in first trimester decidua. GR mRNA and protein are
.! Deleted: also )
highly expressed throughout the cycle. MR mRNA expression varies across the cycle
in a pattern similar to progesterone secretion. lipHSD-1 mRNA expression is
increased in response to IL-la and Cortisol, and GR mRNA shows a similar trend.
11PHSD-2 and MR expression are not altered by IL-la or Cortisol. 3PHSD-1 mRNA




detectable by these methods. Immunohistochemistry using an antibody which detects
both 3PHSD-1 and -2 has shown low levels of protein in the tissues studied.
AKRlCl;p mRNAspre,expressed throughout the menstrual cycle; all three enzymes
( Deleted: , 1C2 and 1C
(Deleted: i H
are predominantly expressed in the secretory phase. AKR1C3 is localised to the
f Deleted: s )
glandular and surface epithelial cells, and vascular endothelium. AKR1C4 mRNA is
not detectable in the endometrium at any stage of the menstrual cycle.
Expression of steroid^pietabolising enzymes is perturbed in the endometrium of users
[ Deleted: )
of a LNG-IUS, and also following GnRH antagonist treatment for sub-fertility.
These studies have shown that the endometrium has the ability to precisely regulate
its balance of steroid hormone availability at a local level, and that this balance may
iv
be altered following administration of exogenous steroids. Further functional studies
such as knockout or knockdown of these enzymes would expand this knowledge and
fully elucidate steroid hormone metabolism and pre-receptor signalling.
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Chapter 1:
General Introduction and Literature Review
i
1.1 The Female Reproductive Tract
The female reproductive tract consists of the cervix, uterus, ovaries, fallopian tubes
and vagina. This system is the site of the events that occur in the reproductive cycle.
The ovaries are the site of ovulation, and are also responsible for much of the steroid
action that occurs in the reproductive system. After ovulation, the ovum travels along
the fallopian tube to the uterus, and if successfully fertilised, implants in the
endometrium, the lining of the uterus. A schematic diagram showing the anatomy of
the female reproductive tract is shown in Figure 1.1.
Fallopian tube Uterus
Figure 1.1 Schematic of the female reproductive tract (from
Encarta.msn.com)
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1.1.1 Regulation of female reproductive tract function
Key events in the female reproductive system, including ovulation, implantation and
menstruation are tightly regulated by a number of factors. Two of these factors are
the gonadotrophins, luteinising hormone (LH) and follicle stimulating hormone
(FSH), produced by the pituitary gland (Heffner, 2006).
A primary regulator of FSH and LH secretion is Gonadotrophin Releasing Hormone
(GnRH), released by the hypothalamus. GnRH is released in pulses to stimulate FSH
and LH secretion. The frequency of this pulsing controls which hormone is secreted
(Heffner, 2006). These hormones are responsible for the control of ovulation, and
GnRH is viewed as probably the most important single factor in mediating the events
of the reproductive system. Abnormalities in GnRH synthesis or release result in
varying degrees of failure of gonadal function (Johnson & Everitt, 2000).
In addition to the gonadotrophins, sex steroid hormones play a vital role in regulation
of the menstrual cycle. These are generated by the ovary in females, in response to
LH and FSH. The adrenal gland is also a source of sex steroid production.
Cholesterol is the precursor of the various steroid hormones. A number of steroid
biosynthetic steps are involved in producing the three classes of sex steroids -
progestins, estrogens and androgens. LH and FSH act to control the synthesis and
release of sex steroids estradiol and progesterone from the ovary, that in turn operate
a feedback loop to regulate FSH and LH via GnRH.
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The early part of the menstrual cycle, the menstrual and proliferative phases, are
characterised by increased estradiol secretion from the ovaries, leading to a peak of
estradiol around day 14, triggering a peak of LH and subsequently ovulation (Jones
& Lopez, 2006). Following ovulation, a smaller peak of FSH occurs and
progesterone levels rise in the secretory phase, peaking around day 21 in the mid
secretory stage of the cycle. Control of the menstrual cycle involves intricate
feedback loops. GnRH induces secretion of LH and FSH, and estradiol has a
negative feedback effect on GnRH secretion. High estradiol levels at the end of the
proliferative phase exert positive feedback on GnRH secretion, which in turn induces
the LH surge (Jones & Lopez, 2006). In the secretory phase, estradiol and
progesterone both cause negative feedback of both FSH and LH secretion. The ratio
of estradiol:progesterone is key in determining whether the feedback is negative or
positive; a ratio in favour of high estradiol and low progesterone causes positive
feedback, whereas low estradiol and high progesterone cause negative feedback
(Jones & Lopez, 2006). Thus, the reproductive cycle can be said to be under the
control of the hypothalamic-pituitary-gonadal (HPG) axis, whereby the
hypothalamus secretes GnRH, which activates release of gonadotrophins from the
pituitary. Gonadotrophins act in turn to modulate release of sex steroids which feed
back to control GnRH pulsatility. Expression of the gonadotrophins, estradiol and
progesterone across the menstrual cycle is shown in Figure 1.2.
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Figure 1.2 Schematic representation of the menstrual cycle, compiled by Ted
Pinner, MRC Human Reproductive Sciences Unit, Edinburgh. Stages of the
cycle are separated by dotted lines.
The role of androgens in the female reproductive tract is less well understood,
however testosterone expression does not vary significantly across the menstrual
cycle (Mertens et ah, 2001). It has, however, been reported that testosterone can be
found in the endometrium at concentrations 10-fold greater than estrogen
5







Figure 1.3 Chemical structures of sex steroids. A - Estradiol, B -
Progesterone, C - Testosterone
1.1.2 The endometrium
The human endometrium is the lining of the uterus, and the site of embryo
implantation. It consists of two layers, namely the basal and functional layers. There
are morphological differences between these layers, and it is the uppermost part of
the functional layer that is sloughed off and shed each month at menstruation in the
absence ofpregnancy. Figure 1.4 shows an Fl&E stained endometrial section
6
illustrating the functional and basal layers during the early secretory stage of the
cycle.
Figure 1.4 H&E stained early secretory stage endometrial section showing
functional and basal layers of human endometrium. Scale bar=10 microns.
1.1.2.1 Component cells of the endometrium
The endometrium is a multi-cellular heterogeneous tissue. The major cell
components are surface and glandular epithelia (the site of protein secretion), a
stromal component consisting of fibroblast-like cells and immune cells, and a well
defined vascular system. The vasculature is composed of endothelial cells and
smooth muscle perivascular cells. Of particular interest are the spiral arterioles, a
vessel type unique to menstruating primates and humans, and thought to have an
important role in menstruation. Figure 1.5 shows a schematic diagram showing the
7















Figure 1.5 Schematic diagram showing endometrial cells. CD56=marker for
uNK cells aka large granular lymphocytes (LGL). From Loke & King, 1995.
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Figure 1.6 H&E stained endometrium showing component endometrial cell
types during the proliferative stage of the cycle. G= gland, S=stroma,
SE=surface epithelium. Arrow indicates blood vessels. Scale bar=10
microns.
1.1.2.2 Changes In Endometrial Morphology Across The Menstrual Cycle
The endometrium is a dynamic organ that undergoes a number of morphological
changes throughout the menstrual cycle (Noyes et al., 1950; Buckley & Fox, 1989).
The first day ofmenstruation is taken to be day 1 of the cycle, with menses lasting
until day 5-7. The first half of the menstrual cycle is known as the proliferative
phase, as it is the time when the functional layer regenerates after menstruation. This
corresponds to the follicular phase of the ovarian cycle. During this phase, the glands
9
are small, round, and regular in shape and the stroma is tightly packed in appearance.
Ovulation occurs around day 14, following a peak in estrogen secretion.
The subsequent part of the cycle is known as the secretory phase and corresponds to
the luteal phase of the ovarian cycle. This phase can be sub-divided into early, mid,
and late secretory phases. The glands elongate and become "jagged" in appearance,
and the stromal cells become further apart. Progesterone secretion peaks in the mid-
secretory phase, signalling to the endometrium to prepare for pregnancy. In the
absence of implantation, with luteal regression, progesterone levels fall again and
menstruation occurs.
Figure 1.7 shows H&E stained endometrial sections across the menstrual cycle.
If implantation does occur, progesterone levels remain elevated, and a number of
morphological changes occur in the endometrium. Stromal cells become enlarged
and squamous, and glands become atrophic and less well defined. The epithelial cells
lose their cuboidal shape and become flatter. This process is known as
decidualisation and pregnant (implanted) endometrium is referred to as decidua.
Figure 1.8 shows an H&E stained decidual section.
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Figure 1.7 H&E stained sections across the menstrual cycle. M=menstrual,
P=proliferative, ES=early secretory, MS=mid secretory, LS=late secretory.
Scale bar=10 microns.
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Figure 1.8 H&E Stained decidua section. G=atrophic gland, D=decidualised
stromal cells. Scale bar=10 microns
1.1.3 Key Reproductive Events in the Endometrium
The two primary events of importance in the human endometrium are the alternative
end-points to each menstrual cycle; implantation or menstruation.
If a successfully fertilised embryo is detected, the endometrium undergoes
decidualisation to prepare for implantation. Progesterone levels thus remain high and
a degree of tissue remodelling occurs. If fertilisation does not take place, the corpus
luteum degrades, progesterone levels decline and menstruation occurs - a process
involving tissue injury and repair.
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Menstruation can be described as the shedding of the functional layer of the
endometrium, accompanied by bleeding. This is induced by steroid hormone
withdrawal at the end of each menstrual cycle (Salamonsen, 2003). The basal lamina
has been observed to degenerate in the late secretory phase (Roberts et al., 1992) and
lesions can be seen on the epithelium at the end of the cycle (Ludwig & Spornitz,
1991). The functional layer is destroyed rapidly leaving blood vessels and glands
exposed, thus loss of integrity of vasculature is a consequence of menstruation
(Salamonsen, 2003). The endometrium must then be regenerated to prepare to
receive an embryo during the next menstrual cycle.
Finn (1986) first proposed that menstruation was an inflammatory process, due to
similarities with inflammatory events in other tissues. It is now accepted that this is
the case and thought that, due to the remodelling involved, inflammation is also
involved in implantation.
The characteristics of inflammation are tissue oedema, the recruitment of
inflammatory cell types, and release of pro-inflammatory cytokines (Salamonsen,
2003). The inflammation response that occurs following tissue damage consists of a
series of events leading to either a specific immune response or clearance of invading
cells (Goldsby et al., 2003). In the case of menstruation, this principle can be applied
to the clearing of the shed functional layer of the endometrium. There are three major
events that occur in inflammation. Firstly vasodilation, where the diameter of
capillaries increases. Capillary permeability also increases leading to an influx of
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fluid and immune cells into the tissue. This then leads to oedema. There is then an
influx of phagocytes, and release of pro-inflammatory cytokines (Salamonsen, 2003).
Inflammation is mediated by a complex series of events, not all of which are well
understood (Goldsby et al., 2003). When the inflammatory response subsides, the
process of tissue repair and regeneration begin. In most cases, this involves the
formation of scar tissue however the endometrium does not display this
characteristic.
It has been shown that there is an increase in leukocyte population prior to
menstruation (Salamonsen & Woolley, 1999). Leukocytes make up around 40% of
the total cells in the endometrial stroma (Salamonsen & Woolley, 1999).
Specifically, there are large numbers of neutrophils, eosinophils, macrophages and
monocytes. This is thought to be due to migration of cells from the blood, and cell
proliferation within the tissue. Leukocyte phenotype and state of activation play a
role in determining endometrial function (Salamonsen et al., 2002). This influx of
leukocytes occurs when progesterone is up-regulated, suggesting this event is
progesterone-dominated. However, most leukocytes lack progesterone receptors
(King et al., 1996; Monsour et al., 1994; Marx et al., 1999; Tabibzadeh &
Satyaswaroop, 1989), thus cells which do express PR, the stromal, epithelial and
endothelial cells mediate the leukocyte influx. Salamonsen et al. (2002) proposed
that these leukocytes may act as effector cells to mediate destruction and remodelling
of endometrial tissue along with factors produced by endometrial cells.
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Glucocorticoids are steroid hormones that play an important role in the inflammatory
process. The primary active glucocorticoid in humans is Cortisol, which has an anti¬
inflammatory effect. Cortisol is secreted by the adrenal gland and travels to the site
of action via the circulatory system. Local modulation of Cortisol expression also
occurs by a number of factors which will be discussed in section 1.2.
Cortisol acts by binding to its receptor and activating downstream signalling
pathways. Progesterone also has some anti-inflammatory activity (van der Burg &
van der Saag, 1996). As progesterone has a relatively weak anti-inflammatory action,
increased local Cortisol levels are required to modulate the inflammatory response in
the ovary (Hillier & Tetsuka, 1998). As there are many similarities between the
ovary and endometrium, i.e. they both go through inflammation-associated cycles of
tissue injury and repair, the expression and action of Cortisol in the endometrium is
an area of interest.
1.1.4 Endometrial Leukocytes
Leukocytes make up around 40% of the total cells in the endometrial stroma
(Salamonsen & Woolley, 1999). Specifically, there are large numbers of neutrophils,
eosinophils, macrophages and monocytes. This is thought to be due to migration of
cells from the blood, and cell proliferation within the tissue. Leukocyte phenotype
and state of activation play a role in determining endometrial function (Salamonsen
et al., 2002). Salamonsen et al. (2002) also proposed that these leukocytes may act as
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effector cells to mediate destruction and remodelling of endometrial tissue along wih
factors produced by endometrial cells.
The number and type of endometrial leukocytes vary across the menstrual cycle. The
main types of leukocytes found in the endometrium are T cells, B cells, mast cells,
macrophages and neutrophils (Jabbour et al., 2006). There is also a population of
phenotypically unique lymphocytes with a CD56+, CD16-, CD3- phenotype. These
are uterine Natural Killer (uNK) cells, and their numbers increase in the late
secretory phase of the cycle, and again in first trimester decidua (King et al., 1989). It
is unknown whether this increase in uNK cell expression is due to in situ
proliferation or migration from a circulatory population. A possible precursor cell
type has been identified by Lanier et al. (1986); in the form of a subset of peripheral
NK cells that express a similar phenotype to uNK cells. However Kammerer et al.
(1999) found CD56+ uNK cells to express the proliferation marker Ki67, suggesting
these cells undergo proliferation.
There are few neutrophils in the endometrium, but numbers do increase pre-
menstrually (Poropatich et al., 1987). It is thought that progesterone withdrawal may
be the key to neutrophil influx. Leukocytes are responsible for the synthesis of
immunoregulatory cytokines that initiate immune responses (Staples et al., 1983;
King et al., 2003). Macrophages increase in number in the late secretory phase, and
are thought to be under indirect control by sex steroids. They could possibly have a
role via matrix metalloproteinases in endometrial breakdown and menstruation
(Jabbour et al., 2006).
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1.2 Steroid hormone metabolism and pre-receptor signalling
The functional and morphological changes that the human endometrium undergoes
in each menstrual cycle to prepare for pregnancy are the result of a complex series of
molecular events, not all of which are well defined. The events are under the control
of sex steroids and their cognate receptors. In addition to control by sex steroids,
glucocorticoids are also involved in key reproductive events.
The local availability of steroid hormones is regulated by a number of factors,
primarily locally expressed steroid metabolising enzymes such as the hydroxysteroid
dehydrogenases (HSDs). The majority of HSDs act in an intracrine manner to
regulate local steroid expression (Labrie., 1991). In the context of this thesis, of
particular interest in the endometrium are the enzymes that control glucocorticoid
metabolism, the 11P-hydroxysteroid dehydrogenases (1 lpHSDs), and those that
control sex steroid metabolism, the 3a-hydroxysteroid dehydrogenases (3aHSDs),




The 11p-hydroxysteroid dehydrogenase (1 lpHSD) family are enzymes that catalyze
glucocorticoid metabolism, regulating the availability of active glucocorticoid
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(Cortisol in humans, corticosterone in rodents) and their inactive metabolites
(cortisone and dehydrocorticosterone, respectively). The chemical structures of
Cortisol and cortisone are shown in Figure 1.9.
Figure 1.9 Reactions catalysed by 11 (3HSD-1 and -2.
Glucocorticoids are crucial to the inflammatory response that accompanies tissue
remodelling. Pro-inflammatory cytokines elicit an increased resynthesis ofCortisol
from cortisone in many tissues, suggesting local Cortisol activation, by 11 (3HSDs.
This was first shown by Escher et al. (1997) in renal glomerular mesangial cells.
Studies on up- and down-regulation of Cortisol levels by 1 ipHSD-1 and -2 in
inflammatory responses at ovulation (Hillier & Tetsuka, 1998), in kidney, liver and
fat (Seckl & Walker, 2004), and in bone (Cooper et al., 2001) have been described.
Deficiencies in the regulation of 11PHSD can cause problems including liver failure,
obesity, metabolic and cardiac disorders. In the reproductive tract, tissue injury and
repair occur on a cyclical basis, and conditions including ovarian cancer and heavy
and painful menstrual bleeding are associated with this. Rapid resolution of
inflammation at these times of tissue injury and repair is thus essential, and this is
likely to be mediated by Cortisol, which in turn is mediated by the 11 pHSDs.
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There are two characterized lipHSDs in humans, encoded by two separate genes,
located on different chromosomes, and with only 14% homology (Albiston et al.,
1994). 1 ipHSD-1 was first cloned in 1991 by Tannin et al. This gene was found to
be expressed at greatest levels in the liver and acts predominantly as an NADPH-
dependent reductase, although in the presence of NADP+ it can also act as a
dehydrogenase converting Cortisol to cortisone. Human lipHSD-2 was cloned in
1994 by Albiston and colleagues (Albiston et al., 1994) and was first identified in
kidney. This enzyme is a unidirectional NAD+-dependent dehydrogenase.
1.2.1.1 11BHSD expression in the endometrium
Studies have been carried out on the expression patterns of 11 (3HSD enzymes in the
female reproductive tract. Studies on the expression of lipHSDs in the endometrium
were conducted by Smith et al. (1997). They performed immunohistochemistry on
endometrial tissue samples, collected at curettage from women with regular
menstrual cycles, supported by western immunoblotting and activity assays to build
an expression profile. It was found that llpHSD-2 protein was expressed in the
luminal and glandular epithelia, with heterogeneous expression in some tissue
sections. Levels of lipHSD-2 activity were found to be higher in the secretory phase
than in proliferative phase endometrium. The activity of lipHSD-1 in endometrium
was also assayed with constant levels of activity found across the cycle; however, the
overall level of 11PHSD-1 activity was lower than that of lipHSD-2. This study did
not investigate 1 ipHSD-1 protein across the menstrual cycle, nor were any mRNA
studies included.
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Hitherto there has been no definitive study of the expression profile of llpHSD-1
protein in endometrium, due to the lack of an antibody suitable for western
immunoblotting and immunohistochemistry of endometrial samples. Arcuri and
colleagues (Arcuri et al., 1996) studied the effects of various steroid treatments on
endometrial stromal cells and found progesterone increased expression of llpHSD-
1. Estrogen alone had no effect while the combination of estrogen and progesterone
potentiated the effect of progesterone. They also found lipHSD-1 up-regulation to
be a feature of decidualisation in these cultured cells. Koyama and Krozowski (2001)
assayed the enzymic activity of Ishikawa cells, an endometrial carcinoma cell line.
They found lipHSD activity increased in a dose-dependent manner when measured
with Cortisol as substrate. NAD+ was preferred to NADP+ as a cofactor, suggesting
predominant lipHSD-2 activity.
1.2.2 Regulation of Glucocorticoid Signalling
The steroid metabolising enzymes are tightly controlled by a number of factors,
including steroid hormones themselves, cytokines, chemokines, and many other
factors. Of particular interest in the context of this thesis is the regulation of the
11PHSD system and glucocorticoid signalling by cytokines.
1.2.2.1 Cytokines in the Endometrium
It has now been accepted following the work of Finn (1986) that implantation and
menstruation are inflammatory events. Cytokines are among the factors involved in
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these events (Kelly et al., 2001). Cytokines are produced by many cell types,
including epithelia and endothelia (Tabibzadeh, 1994), and have been described to be
protein cell regulators involved in physiological responses. There are many cytokine
factors, including interleukins, colony-stimulating factors and tumour necrosis
factors. Cytokines are able to act in intracrine, autocrine and paracrine manners
(Tabibzadeh, 1994; Labrie et al., 1988; Labrie, 1991). It was Labrie et al., (1988),
who first coined the term intracrinology to describe the synthesis of active steroids in
peripheral target tissues where the action is exerted in the same cells where synthesis
takes place without release of the active steroids in the extracellular space and
general circulation.
A number of cytokines have been reported to have involvement in endometrial
processes via the hypothalamic-pituitary-gonadal (HPG) axis, including interferon-y,
interleukin-1 (IL-1), IL-6, tumour necrosis factor-a, transforming growth factor-p
and others (reviewed by Tabibzadeh, 1994). Tabibzadeh & Sun (1992) investigated
expression of a number of cytokines in endometrium across the menstrual cycle.
They found IL-1a protein to be expressed throughout the cycle, in both the glands
and stroma. IL-lp was also detected, but at much lower levels. Transforming growth
factor-a (TGFa) was expressed in the epithelial, stromal and endothelial cells; IL-6
was strongly expressed in the epithelia and weakly expressed in stromal cells.
Levels of IL-1 in human serum were found to be greatest in the secretory phase
(Cannon & Dinarello, 1985).
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1.2.2.2 lnterleukin-1
There are two isoforms of IL-1, IL-la and IL-ip. Both isoforms act via the IL-1R
receptor (IL-1R), ofwhich there are two known types, designated type 1 and type 2.
Both IL-1 isoforms bind IL-1R type 1, whereas type 2 binds IL-ip (Corlotta et al.,
1993). IL-1 has been implicated in the key inflammatory events in the endometrium.
IL-1 has been postulated to have a role in blastocyst implantation and can be
identified in both trophoblast and decidual stromal cells (Simon et al., 1994; 1995).
There has also been a suggestion that IL-la stimulates MMP production and release,
thereby having an effect on the initiation ofmenstruation (Cole et al., 1995; Rossi et
al., 2005). Further indications of the involvement of IL-1 in the endometrium can be
inferred from reports of alterations in IL-1 production in conditions affecting the
endometrium and decidua such as pre-eclampsia. Pre-eclampsia is a likely
consequence of impaired trophoblast invasion. This condition can lead to maternal
and fetal death. Endometriosis, a common endometrial disease whereby endometrial
lesions form ectopically, has also been linked to altered IL-1 production (Mori et al.,
1992; Lockwood et al., 2006). This condition can cause severe pain and is associated
with fertility problems.
Previous studies have focussed on the effect of IL-la on the female reproductive
tract, in particular in the ovarian surface epithelium (OSE). Yong et al. (2002) found
1 ipHSD-1 expression to be increased in the presence of IL-la in cultured OSE cells.
This was followed up by the work of Rae et al. (2004a), who found 11PHSD-1 to be
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up-regulated following ILla treatment, but found the same treatment to have no
effect on 1 l(3HSD-2 expression. II-la caused a small but significant increase in GR
expression. A further interesting finding of this study was that the addition of Cortisol
in the presence of IL-la caused a further enhancement of 1 ipHSD-1 expression (Rae
et al., 2004a). However little is currently known about the effect of IL-la on
glucocorticoid metabolism and associated signalling in the endometrium.
1.2.3 Sex Steroid Metabolism
A number of enzymes are involved in the metabolism and control of sex steroids. Of
particular interest in this thesis are the 3(3HSDs, which convert pregnenolone to
progesterone and are involved in androgen metabolism, 3aHSDs (AKRs) and
17(3HSDs, which have many roles in the metabolism of androgens and estrogens.
1.2.3.1 3BHSDs
3(3-hydroxysteroid dehydrogenase/A5-A4-isomerase (3[3HSD) catalyses the
conversion of A4-3-ketosteroids from A5-3P-hydroxysteroids e.g. pregnenolone and
dehydroepiandrosterone (DHEA). This is a key step in synthesis of androgens,
estrogens, mineralocorticoids and glucocorticoids (Readhead et al., 1983).
Additionally, 3PHSDs can also act on downstream sex steroids, predominantly
androgens, converting dihydroepiandrosterone (DHEA) to androstenedione, androst-
5-ene-3P,17P-diol to testosterone, and dihydrotestosterone (DHT) to 3P-diol. 3PHSD
is also capable of acting on 17a-hydroxypregnenolone, converting it to the more
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active 17a-hydoxyprogesterone. These reactions are summarised in the diagram in
Figure 1.10.
There are two known human isoforms of 3PHSDs, namely type 1 and type 2. Human
type 1 was first cloned from placenta by Thomas et al., (1989), while human type 2
3PHSD was identified in adrenal glands and gonads of humans. Two functional
human 3PHSD genes have been identified, part of a closely related gene family
(Rheaume et al., 1991). The 3PHSD isoforms are part of the short-chain
dehydrogenase/reductase (SDR) gene superfamily, the same family as the llpHSDs.
There have been three reports of 3PHSD expression in the human endometrium.
Rhee et al. (2003) recently published a report whereby they found 3PHSD expression
in the glandular epithelium of the endometrium, with the intensity of
immunoreactivity increasing across the cycle. Staining was weak in proliferative
phase endometrium, moderate in secretory phase, and intense in decidua; the
expression of 3PHSD increased as progesterone levels increased. This was
investigated by immunohistochemistry and confirmed by RT-PCR.
Seki et al., (1987), cited by Rhee et al. (2003), and Tang et al. (1993) studied enzyme
activity of 3PHSD in human endometrium. Tang et al. (1993) found that 3PHSD was




Figure 1.10 Reactions catalysed by 3(3HSD. A - pregnenolone to
progesterone, B - DHEA to androstenedione, C - androstenediol to
testosterone, D - DHT to 5a-androstanediol
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1.2.3.2 Aldo-keto Reductases
The aldo-keto reductase enzyme superfamily are closely related to the SDR family.
The AKR1C family (3aHSDs) are involved in many steroid metabolising reactions.
They are a promiscuous group of enzymes; their ability to act on a particular
substrate is governed by the relative availability of potential substrates and the
appropriate regulatory cofactors. Among the many substrates 3aHSD/AKRlC
enzymes can act on, are the three main groups of sex steroids, androgens, estrogens
and progestins, which are all of relevance in the endometrium.
There are four identified members of the AKR1C family, designated AKR1C1-1C4.
Each AKR1C enzyme has a number of alternative names, as well as being named
3aHSDs; AKR1C1 is also known as 20aHSD, and AKR1C3 is 17pHSD-5. Table 1.1
depicts the alternative nomenclature for the AKR1C enzymes.
Table 1.1: AKR1C nomenclature













From now on the AKR1C nomenclature will be used for these enzymes.
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Table 1.2 depicts the many reactions performed by the AKR1C enzymes, and
highlights those that predominate in intact cells.


























AKR1C4 (in liver) 5a/5P-dihydrosteroids 5a/5P-tetrahydrosteroids
Penning et al. (2000) have found all 4 AKR1C enzymes to be expressed at low levels
in the uterus, by RT-PCR. AKR1C1 and AKR1C2 were found to be expressed in the
lung, whereas AKR1C3 (17J3HSD-5) was highly expressed in the mammary gland,
and AKR1C4 only detectable at significant levels in the liver. This correlates with
previous studies which have declared AKR1C4 to be almost entirely liver-specific
(Penning et al., 2000)
Ito et al. (2006) have reported on the expression of AKR1C3 (17(3HSD-5) in human
endometrium. They found the protein to be expressed in both proliferative and
secretory phases of the endometrium; however there is currently little else known
about the expression of the AKR1C enzymes in the human endometrium.
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1.2.3.3 17BHSDs
There are 13 human 17PHSD enzymes currently identified. These are a large family
of enzymes with a wide variety of steroid metabolising activities. Various 17PHSDs
are involved in the regulation of sex steroids. Of particular interest here is 17PHSD-
2, which performs the reverse of the reactions catalysed by AKR1C3/17PHSD-5,
predominantly the inactivation of estradiol and testosterone.
There have been a number of studies on 17PHSD-2 in the endometrium reported.
Casey et al. (1994) and Burton et al. (2003) described 17pHSD-2 protein to be
expressed in the glandular epithelia of the endometrium in the secretory stage of the
cycle, with negligible expression in proliferative endometrium. However a recent
molecular phenotyping study (Talbi et al., 2006) showed 17PHSD-2 to be highly up-
regulated in early secretory endometrium compared to the proliferative phase, but
down-regulated in mid-secretory endometrium compared to the early secretory stage.
Figure 1.11 shows a summary of the key endometrial steroid metabolism pathways
involving the enzymes discussed in this thesis.
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Figure 1.11 Key steroid metabolic pathways in human endometrium.
Enzymes of interest in this thesis are shown in bold, with those that have not
been investigated in human endometrium in grey.
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1.2.4 Steroid hormone receptors
1.2.4.1 Glucocorticoid Receptors
There are separate receptors for glucocorticoids and mineralocorticoids, GR and MR
respectively. However Cortisol can bind to the MR and thereby act as a
mineralocorticoid.
GR is almost ubiquitously expressed in all human tissues and organs (Kino &
Chrousos, 2001). There are two alternative splicing variants, GRa and GRP. GRa is
the classical GR, whereas GRP is thought to act as a dominant negative inhibitor of
GRa and does not bind glucocorticoids (Kino & Chrousos, 2001). GRa is expressed
in endometrial stromal cells across the menstrual cycle (Bamberger et al., 1995;
Henderson et al., 2003). GR is not expressed in the glandular or surface epithelium in
endometrium, but has been observed in these cells in first trimester decidua
(Henderson et al., 2003).
Cortisol also binds with high affinity to the mineralocorticoid receptor (Stewart &
Mason, 1995). The function ofMR is to mediate aldosterone effects and thus
regulate the balance of sodium and water in the body. In the CNS, MR has been
proposed to have a role in regulation of the stress response and feedback control of
the hypothalamus-pituitary-adrenal axis (de Kloet et al., 1990). Activation ofMR by
excess ligands, usually resulting from Cortisol binding, can lead to conditions such as
apparent mineralocorticoid excess. This can cause persistent hypertension and
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hypokalemia, thus lipHSD-2 is often found to be co-localised with MR (Hirasawa et
al., 2000). MR expression in human endometrium or first trimester decidua has not
been previously reported.
Cortisol has a high affinity for MR and can act as a potent mineralocortocoid when it
binds to MR. Excess binding of Cortisol to MR can cause a number of disorders, in
particular apparent mineralocorticoid excess and hypertension (Wilson et al., 1995,
cited by Smith et al., 1997). In order to prevent this, ll(3HSD-2 has been found to be
co-localised with MR in a number of tissues including kidney (Edwards et al., 1988),
colon (Funder et al., 1988), eye (Suzuki et al., 2001) and placenta (Hirasawa et al.,
2000).
1.2.4.2 Sex Steroid Receptors
The receptors for the products of the reactions catalysed by the 3PHSD and AKR1C
enzymes are predominantly the androgen receptor (AR), estrogen receptors (ERa and
ERP) and the progesterone receptor (PR). The expression of all these receptors in the
endometrium has been well characterised.
There are two PR isoforms, PRA and PRB (Tung et al., 1993). Both are active, with
PRB thought to be the more transcriptionally active form (Wen et al., 1994). PRA is
thought to act as a repressor of PRB function. Studies have been conducted on these
receptor isoforms using knockout mice. PR knockout (PRKO) mice are unable to
support implantation (Lydon et al., 1995). Unopposed estrogen action causes
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epithelial cells to become hyperplastic (Conneely et al., 2001). Specific PR-A and
PR-B knockouts have shown that the two isoforms have distinct uterine functions
(Mulac-Jericevic et ah, 2000, 2003). PR-A knockout mice show inhibition of
endometrial stromal cell decidualisation and it has been proposed that PR-A has a
crucial role in the process of decidualisation. PR-B knockout mice display normal
antiproliferative and implantation-associated responses to progesterone, thus PR-A is
necessary and sufficient to mediate these responses (Mulac-Jericevic et ah, 2000).
PR-B activation in PR-A knockout mice surprisingly led to abnormal progesterone-
dependent induction of epithelial cell proliferation, thus PR-A is required to inhibit
potentially adverse effects of PR-B such as this abnormal proliferation. Aberrant
ratios of PR-A to PR-B have been associated with endometrial cancers (Arnett-
Mansfield et ah, 2001; DeVivo et ah, 2002).
PR expression in the endometrium is induced by estrogen in the proliferative phase.
Both PR isoforms have been identified in the stromal and epithelial cells in this
phase. Progesterone secretion increases following ovulation, and causes PR
expression to be down-regulated, particularly in the glandular epithelium
(Chauchereau et ah, 1992). PR has been reported in the stromal, perivascular and
endothelial cells in first trimester decidua (Perrot-Applanat et ah, 1994; Wang et ah,
1992). Wang et ah (1998) studied the PR-A and PR-B isoforms in human
endometrium and found both subtypes to be present in glands and stroma in the
proliferative phase, and both were dramatically reduced in the glands during the
secretory phase. PR-B was in fact not detectable at all in the secretory phase (Wang
et al, 1998).
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There are two distinct forms of ER, ERa and ERP, encoded by separate genes. ERa
is highly expressed in both the glands and stroma of the endometrium in the
proliferative phase of the menstrual cycle (Lessey et al., 1988; Snijders et al., 1992;
Garcia et al., 1988). ERa expression is down-regulated in the secretory phase in
response to elevated progesterone levels. Both ERa and PR have been reported to be
expressed in perivascular cells (Perrot-Applanat, 1988; Critchley et al., 2001a).
Narvekar et al. (2006) have shown PR expression to be reduced in the endometrial
surface epithelium following treatment with the antiprogestogen mifipristone. PR
expression was greatly increased following mifepristone administration, however the
treatment had no effect on ER expression.
ERP is expressed in the glandular epithelium and stromal cells, and also in
endothelial cells, unlike ERa (Critchley et al., 2001a). ERP has also been shown to
be expressed at greatest levels in the proliferative phase and down-regulated in the
secretory phase (Taylor & Al-Azzawi, 2000; Critchley et al., 2001a). Two ERP
splice variants have been identified. ERpi and ERPcx/p2 are both expressed in the
human endometrium, with expression of ERPcx/p2 being less intense than that of the
full length variant ERpl (Critchley et al., 2002). ERpl expression does not differ
across the menstrual cycle, however a reduction in ERPcx/p2 levels was observed in
the glands of the functional layer of the endometrium in the mid-secretory phase.
ERa levels are very low in first trimester decidua (Lessey et al., 1988); however ERP
can be detected in decidual stromal cells (Milne et al., 2005).
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AR expression has been studied in human endometrium; however reports of its
expression pattern have varied. Horie et al. (1992) and Ito et al. (2002) found AR to
be expressed in both glandular and stromal cells, whereas other authors have reported
stromal localisation of AR (Maia et al., 2001; Mertens et al., 2001; Slayden et al.,
2001; Burton et al, 2003). Slayden et al. (2001) have also reported AR to be
expressed in a similar manner in the endometrium to ER and PR, greatest expression
in the estrogen-dominated proliferative phase and down-regulated in the secretory
phase. AR is expressed in decidual stromal cells and endothelial cells (Milne et al.,
2005). The role of androgens and the AR in the endometrium is not yet well
understood, however AR has been shown to be upregulated following
antiprogestogen treatment (Brenner et al., 2003), and this upregulation is thought to
have an antiproliferative effect potentially by suppressing estrogen-dependent growth
factors (Brenner et al., 2003).
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1.3 Exogenous steroid manipulation of the endometrium
A number of synthetic steroids are commonly used clinically in the management of
sub-fertility, contraception and treatment of menstrual disorders. These take a variety
of forms, including synthetic progestins and estrogens, and substances that act as
agonists or antagonists of endogenous steroids. These steroid treatments often alter
the morphology and gene and protein expression profile of the endometrium,
however there is still much to learn about these effects.
Of particular interest in this thesis are the effects on the endometrium of the
Levonorgestrel-releasing Intra-Uterine System (LNG-IUS) and GnRH antagonists.
The LNG-IUS is an intrauterine contraceptive device that releases a steady flow of
levonorgestrel (20fig daily), a synthetic progestin. The LNG-IUS also has a number
of clinical uses other than contraception, such as management of dysmenorrhoea,
suppression of menstruation and endometrial protection for women using estrogen
replacement therapy (Luukkainen, 2000; Guttinger & Critchley, 2007).
The GnRH antagonist, Cetrorelix, is widely used in in vitro fertilisation (IVF)
procedures and causes rapid suppression of LH levels as well as preventing
premature LH surges as part of controlled ovarian hyperstimulation (Albano et al.,
2000).
Endometrial effects of both of these therapeutic interventions are described in further
detail in the following sections.
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1.3.1 The Levonorgestrel Intra-Uterine System (LNG-IUS)
Levonorgestrel (LNG) is a potent synthetic progestogen used in a number of
contraceptive systems including the Levonorgestrel-releasing Intra-Uterine System
(LNG-IUS). Levonorgestrel also has substantial androgenic activity (Kloosterboer et
al., 1988) and is an androgenic progestogen. The LNG-IUS is a highly effective
contraceptive system that is also used in the management of heavy menstrual
bleeding (menorrhagia), as it has been shown to reduce menstrual blood loss
(Andersson et al., 1992) and menstrual pain (dysmennorhoea) (Luukkainnen et al.,
1990). The LNG-IUS is a small plastic intra-uterine system that is inserted into the
uterine cavity and steadily releases levonorgestrel for up to 5 years at a rate of 20|Jg
per 24 hours (Luukkainen, 2000). The LNG is absorbed from the uterus into the
systemic circulation; maximum serum levels are achieved within a few hours
(Luukkainen, 2000). Following LNG administration proliferation is reduced. Figure
1.12 shows a LNG-IUS.
r
Figure 1.12 A LNG-IUS
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1.3.1.1 Effects of the LNG-IUS on the Endometrium
LNG-IUS usage causes a number ofmorphological alterations to the endometrium,
primarily changes characteristic of decidualisation (Critchley 2003; Guttinger &
Critchley 2007). There is a reduction in thickness of the functional layer and the
glands become narrow and atrophic. Stromal cells take on the swollen appearance of
decidualised stromal cells. Thus, endometrium exposed to constant levonorgestrel
delivery is described as pseudo-decidualised endometrium.
These changes can be seen within one month of insertion of the LNG-IUS, but
further changes are rare with continued useage. Within 1-3 months of removal of the
LNG-IUS, endometrial morphology returns to normal and users return to complete
fertility (Andersson et al., 1992; Silverberg et al., 1986).
In addition, an influx of uNK cells, similar to that seen in first trimester decidua, can
be observed in LNG-exposed endometrium (Critchley et al., 1998; Critchley, 2003).
Increased expression of a number of decidualisation markers such as IGFBP-1,
prolactin and prolactin receptor occurs in the endometrium of users of the LNG-IUS
(Jones & Critchley, 2000).
Long-term usage of the LNG-IUS is also associated with alterations in sex steroid
receptor expression in comparison to normal endometrium. In particular, the
progesterone receptor is down-regulated in both the epithelial and stromal cells
(Critchley et al., 1998; Critchley, 2003). Estrogen receptor is also down-regulated in
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pseudo-decidualised endometrium for at least the first 12 months of LNG-IUS use
(Critchley et al., 1998). Expression of the androgen receptor has also been shown to
be down-regulated in the endometrium following usage of the LNG-IUS (Burton et
al., 2003). The effects of the LNG-IUS on glucocorticoid or mineralocorticoid
receptor expression have not previously been reported.
Levonorgestrel can be metabolised by the same enzymes responsible for
progesterone and androgen metabolism (primarily 3PHSD, 17PHSD-2, 17PHSD-5
and AKRs; Lemus et al., 1992). The effects of this metabolism may control the
availability of LNG for binding to AR and PR (Lemus et al., 1992).
1.3.1.2 Drawbacks of the LNG-IUS
Although the LNG-IUS is a very effective contraceptive and it is also associated with
reduced menstrual blood loss and reduced pain, many users report problems with
breakthrough bleeding (BTB), i.e. unscheduled bleeding between menstrual periods.
This is the most common reason for women to discontinue use of this contraceptive
method. Breakthrough bleeding is most common in the first six months of use and
often improves with time (Zalel et al., 2003). The mechanisms underlying this
breakthrough bleeding have not yet been fully established. There is evidence for
increased fragility of blood vesssels, alterations in steroid responsiveness and
angiogenic factors playing a role (Milling-Smith & Critchley, 2005; Guttinger &
Critchley, 2007). The factors that are altered in the endometrium following LNG-IUS
treatment are summarised in Table 1.3.
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Table 1.3 Effects of intrauterine LNG on the endometrium.
Morphology Sex steroid
receptors
























(Adapted from Guttinger & Critch ey, 2007)
Burton et al. (2003) found 17PHSD-2 to be up-regulated in the endometrium in the
first three months of LNG-IUS usage, but levels then returned to normal. This would
lead to reduced local intracellular estrogen availability, which may contribute to
breakthrough bleeding in the first months of use and account for the cessation of
breakthrough bleeding after 6 months in the majority of cases. Studies have not,
however, been carried out on a number of other steroid metabolising hormones that
may work in conjunction with 17PHSD-2 and may be altered in LNG-exposed
endometrium.
1.3.2 GnRH antagonists in fertility treatments
A number of technologies are now widely used for the treatment of sub-fertility,
including in-vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI).
Both these protocols require ovarian stimulation, carried out using recombinant FSH.
Following recombinant FSH administration, premature LH surges are possible, and
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ovarian hyperstimulation syndrome can occur. In order to prevent this, it is necessary
to modulate gonadotrophin production.
1.3.2.1 GnRH Agonists and Antagonists
Modulation of gonadotrophin production may be achieved with the use of either
GnRH agonists or antagonists. GnRH agonists act by facilitating release of large
amounts of LH and FSH from the pituitary and causing an up-regulation of GnRH
receptor expression, if administered in a pulsatile manner (Lemay et al., 1984). If
continuous GnRH agonist is administered, the effect is opposite, the agonist/receptor
complex is internalised and receptor expression down-regulated. Thus,
gonadotrophin synthesis and release are suppressed, leading to arrest of follicular
development and reduction of circulating sex steroid levels. This effect is completely
reversible when treatment is stopped. This continuous administration is known in
fertility management as a GnRH agonist "long" protocol and it is this which is most
commonly used in IVF and considered to be the most effective (Akagbosu, 1999, in
Brindsen [ed., 1999]).
GnRH antagonists act by competitively binding GnRH receptors in the pituitary to
prevent GnRH action, also leading to the arrest of follicular development. GnRH
antagonist protocols allow a shorter treatment cycle and overall reduction in amount
of gonadotrophins required (Albano et al., 2000).
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Until relatively recently, GnRH agonists were used as the most common method of
gonadotrophin suppression in IVF cycles. The "long" protocol however, requires a
lengthy treatment period, and additional luteal phase support is required to allow
recovery. This is usually achieved with progesterone or human chorionic
gonadotrophin (hCG) (Akagbosu, 1999, in Brindsen [ed., 1999]).
The development of GnRH antagonists appeared to have many advantages in
overcoming these drawbacks. However, there is much debate about the effect this
treatment has on pregnancy rates. Ludwig et al. (2001) found similar rates of
pregnancy using GnRH agonist and antagonist protocols, whereas Al-Inany et al.
(2006) reported a reduction in pregnancy rates following GnRH antagonist treatment.
1.3.2.2 Effect of treatment on pregnancy rates
Rates of implantation and pregnancy following assisted reproduction techniques
remain low despite advances. The reasons for this have not yet been fully elucidated,
but there have been reports of an altered steroid receptor expression profile in the
early luteal phase (Papanikolau et al., 2005), and also of endometrial advancement
following use of GnRH antagonists (Kolibianakis et al., 2002). The window of
implantation can be defined as days 5-10 after the LH surge (Sharkey & Smith,
2005). There are currently limited data available on the endometrium during this
window, however it is likely to play a major role in determining the success of
assisted reproduction techniques. There may be a correlation between endometrial
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thickness and success of implantation, although no agreement has been reached on
the importance of this factor (Devroey et al., 2004).
Sex steroid hormones are thought to have a vital role in the development of the
endometrium prior to implantation (Norwitz et al., 2001; Ma et al., 2003; Lessey,
2002; Apparao et al., 2002). However the precise role these hormones play has not
yet been fully defined.
42
1.4 Aims and Hypotheses
The aims of the studies in this thesis were:
• To investigate steroid metabolism and pre-receptor signalling in human
endometrium by studying expression patterns of steroid metabolising
enzymes across the menstrual cycle and in the first trimester of pregnancy.
• To investigate the 11(3HSD system further by studying the regulation of these
enzymes and the receptors by which their products act in endometrial cells in
vitro.
• To investigate the effects of exogenous steroid administration on steroid
metabolism and pre-receptor signalling by studying expression patterns of
enzymes in endometrium following clinical treatments.
Thus, the hypotheses were:
• That both glucocorticoid and sex steroid metabolising enzymes are vital in
the regulation of the menstrual cycle, and thus expression of these will vary
across the menstrual cycle.
• That IL-la is a regulator of glucocorticoid action and that epithelial cells in
the female reproductive tract behave similarly regardless of location.
• That exogenous steroid manipulation causes expression of steroid
metabolising enzymes to be perturbed.
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Chapter 2:
General Materials and Methods
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2.1 Patient Recruitment and Sample Collection
2.1.1 Endometrial samples
Endometrial biopsies were collected from women undergoing surgery or
investigation for benign gynaecological conditions. All patients were of reproductive
age, had not received exogenous hormones or used an intrauterine contraceptive
device in the three months prior to sample collection. All patients, excluding those
who gave samples for use in Chapter 4 of this thesis, had regular menstrual cycles of
25-35 days. Cycle length and regularity of the patients studied in Chapter 4 varied,
some did not have a discernable cycle at all.
Biopsies were collected in the two ways that follow. Full thickness endometrial
biopsies, including both myometrium and basal and functional endometrium were
taken after the uterus had been removed by hysterectomy. Endometrium-only
(predominantly functional layer) biopsies were sampled vaginally by pipelle suction
curette (Laboritoire CCD, Paris, France). All subjects had a blood sample taken at
the time of sample collection to determine circulating serum estradiol and
progesterone levels by radioimmunoassay (RIA) by Mr Ian Swanston and colleagues,
MRC HRSU, Centre for Reproductive Biology, University of Edinburgh.
Histological dating was also performed on all samples by Dr. A. Williams,
Department of Pathology, Royal Infirmary of Edinburgh according to the criteria of
Noyes et al. (1950). In all samples used the circulating serum hormone levels at time
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of biopsy collection, histological dating, and patient's reported last menstrual period
(LMP) were consistent and used to determine cycle stage.
Two or more biopsies were taken from the same site in the uterus of each patient; or
a single biopsy was split into two or more pieces wherever possible to use for both
RNA work and immunohistochemistry. Full-thickness biopsies were collected in 4%
neutral buffered formalin (NBF; Sigma, Poole, UK) for histology. Endometrium-
only biopsies (collected both by pipelle and surgically) were taken in RNAlater
storage solution (Ambion, Warrington, UK) and used for RNA extraction, or
collected in Dutch-Modification Roswell Park Memorial Institute (RPMI) 1640
medium (Sigma) and used in tissue culture.
2.1.2 Decidua samples
Decidual tissue samples were obtained from women undergoing surgical termination
of pregnancy by vacuum aspiration during the first trimester of pregnancy. All
procedures were carried out under general anaesthetic. Prior to surgery, patients had
an ultrasound scan to confirm viability of the pregnancy and gestational age. All
material from the aspiration was collected, and decidual tissue identified by
microscopic inspection. Sterile gauze was held over a waste collection vessel and the
contents of the tissue collection vessel poured over the gauze. Excess blood and
saline were removed by gentle compression, then sterile forceps were used to extract
the decidua parietalis. Decidual biopsies were split between NBF and RNAlater
solutions as described in 2.1.1.
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2.1.3 Informed consent and ethical approval
Written, informed consent was obtained from all patients. Local ethical committee




2.2.1 Tissue Processing for RNA Extraction
Tissue for RNA extraction was collected in RNAlater (Ambion) storage solution and
transferred to the laboratory. The sample was stored in RNAlater for 24 hours at 4°C,
then transferred to a cryotube (Nunc, Roskilde, Denmark) and frozen at -70°C until
required for RNA extraction. Samples may be stored in this way for extended periods
of time.
2.2.2 Tissue Processing for Histology
Tissue samples for histology were collected in NBF (Sigma) and transferred to the
laboratory. Samples were kept at 4°C for 24 hours, then transferred to 70% ethanol
and stored at room temperature prior to wax embedding. Processing and wax
embedding was carried out in the MRC Human Reproductive Sciences Unit (HRSU)
Histology facility. Samples were placed in labelled cassettes in 70% ethanol for
automatic processing. In a Leica TP1050 automatic processor, samples underwent
dehydration in graded alcohols for 1.5 hours in each alcohol, 2x2 hours in absolute
alcohol, then 3x3 hours in xylene, before going through three chambers of molten
wax for 1,1, and 1.5 hours respectively. Following processing, samples were aligned
correctly in metal moulds (particularly important for full-thickness biopsies), and
molten paraffin wax poured into each mould. The cassette was placed on top of the
molten wax and the mould placed on a cooling block to set. When set, the mould
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could be gently eased off. Embedded tissue sections were stored at room
temperature. When tissue sections were required, the blocks were cooled on ice to
make the blocks easier to cut. 5pm sections were cut using a hand-operated
microtome (Leica Microsystems, Milton Keynes, UK). Sections were floated on
distilled water at 37°C in a heated waterbath and gently picked up by charged coated
slides. Sections were dried overnight at 50°C in a drying oven (Lamb RA, East
Sussex, UK, model E28.5) then stored at room temperature until required.
2.2.3 Tissue Processing for Tissue Culture
Tissue samples for culture were collected in RPMI medium and stored as close to
37°C as possible prior to transfer to the laboratory. As soon as samples were received
in the laboratory the cell separation procedure described in 2.8 was commenced.
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2.3 RNA Extraction
RNA was extracted using different methods depending on the type of sample (large
and small tissue samples, cells). All RNA samples were treated with DNase to
prevent contamination.
2.3.1 RNEasy Midi Kit Extraction
RNA was extracted from tissue samples using the RNEasy Midi Kit (Qiagen,
Crawley, UK). Samples were removed from storage and transferred into a large
centrifuge tube. P-mercaptoethanol (P-ME; Sigma) was added to the supplied lysis
buffer prior to use. lOpl p-ME was added per 1ml lysis buffer to be used. 2ml lysis
buffer was added to the tissue and the tissue homogenised using a rotor-stator hand¬
held homogeniser (Sartorius, London). The tissue lysate was centrifuged at 2300g for
10 minutes in a Thermo IEC CLIO centrifuge and the supernatant transferred to a
new centrifuge tube. The pellet was discarded. 70% ethanol (4ml) was added to the
lysate and mixed by shaking. The sample was applied to an RNEasy midi column,
placed inside a centrifuge tube, then centrifuged at 2300g for 5min. The flow-
through was discarded. This stage was performed inside a Class II microbiological
safety cabinet.
The procedure was transferred to a fume cupboard. On-column DNase digestion was
performed as suggested by the manufacturers as follows. 2ml wash buffer was added
to the column and the tube centrifuged for 5 min at 2300g. The flow-through was
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discarded. 20pl DNase 1 stock solution (Qiagen) was added to 140pl DNase buffer
(Qiagen) per sample and mixed by flicking the tube. The DNase 1 mix was pipetted
directly on to the membrane of the RNEasy column and left at room temperature for
15 minutes. A further 2ml wash buffer was added and the column left at room
temperature for 5 minutes, then centrifuged for 5 minutes at 2300g. The flow-
through was discarded.
2.5ml elution buffer was added to the column, which was then centrifuged for
2minutes at 3000xg and flow-through discarded. A further 2.5ml elution buffer was
added to the column, centrifuged for 5 minutes at 2300g and flow-through discarded.
The column was transferred to a new tube and 250pl RNase-free water was pipetted
directly onto the membrane. The tube was allowed to stand for one minute then
centrifuged for 3 minutes at 2300g. The eluate was removed from the tube and
passed through the column once more as described to obtain a higher RNA
concentration. RNA was then stored at -70°C.
2.3.2 RNEasv Mini Kit Extraction
RNA was extracted from cultured cells using the RNEasy Mini Kit (Qiagen).
Culture medium was removed from the cells. Two methods of removing cells from
the culture plates were used. In the first method, 1% Trypsin/EDTA (Sigma) was
applied as described in 4.2.3, and then the cells were scraped with a pipette tip and
transferred to a 2ml tube. These cell suspensions were centrifuged at 2000rpm for 5
minutes, supernatant removed and the pellet re-suspended in lysis buffer+fl-
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mercaptoethanol from the Qiagen RNeasy mini-kit. Cells were then passed through a
19-gauge needle to homogenise them and frozen at -70°C for later RNA extraction.
After the initial experiments it was clear that the yield of RNA was not as great as
would be expected, so an alternative method of cell harvesting was sought. This
involved washing the cells in PBS and pipetting lysis buffer containing (3-
mercaptoethanol directly onto the culture plates, before scraping the cells and
pipetting them up and down repeatedly. The suspension was transferred to a 2ml
tube, passed through a 19-guage needle and frozen at -70°C as before. A greater
yield of RNA was obtained using this method. Cell lysates were removed from
storage and thawed in a waterbath at 37°C for 20 minutes prior to beginning
extraction.
70% ethanol (700pl) was added to the lysate and mixed by pipetting. The sample
was applied to an RNEasy midi column, placed inside a centrifuge tube then
centrifuged at 10,000rpm in a microcentrifuge for 15 seconds. The flow-through was
discarded.
On-column DNase digestion was performed. 350pl lysis buffer was added to the
column and the tube centrifuged for 5 minutes at 3000xg. The flow-through was
discarded. lOpl DNase I stock solution (Qiagen) was added to 70pl DNase buffer
(Qiagen) per sample and mixed by flicking the tube. The DNase 1 mix was pipetted
directly onto the membrane of the RNEasy column and left at room temperature for
15 minutes. A further 350pl wash buffer was added then centrifuged for 15 seconds
at lOOOOrpm. The flow-through was discarded.
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500(0,1 elution buffer was added to the column, centrifuged for 15 seconds at lOOOrpm
and flow-through discarded. A further 500(0.1 elution buffer was added to the column,
centrifuged for 2 minutes at lOOOOrpm, and flow-through discarded. The column was
transferred to a new tube and centrifuged for a minute at full speed to dry the
column. The column was once again transferred to a new tube and 250pl RNase-free
water was pipetted directly onto the membrane. The tube was centrifuged for 1
minute at lOOOOrpm. The eluate was removed from the tube and passed through the
column once more as described to obtain a higher RNA concentration. RNA was
stored at -70°C.
2.3.3 Trizol Extraction
Some archival RNA samples had been extracted using Trizol (Invitrogen, Paisley,
UK) extraction reagent prior to my joining the laboratory. Samples were
homogenised in 1ml Trizol RNA extraction reagent (per lOOmg tissue) using a hand¬
held homogeniser and incubated for 5 minutes at room temperature. Homogenates
were transferred to a phase lock gel tube (Eppendorf, Cambridge, UK) and 200pl
chloroform added. Tubes were shaken for 15 minutes. The aqueous phase was
transferred into a clean 2ml tube and 500pl isopropanol added. Samples were
incubated for 10 minutes at room temperature, and then centrifuged at 13,000rpm for
10 minutes at 4°C in a Sigma 1-15K centrifuge. The supernatant was removed and
the pellet washed in 70% ethanol, and vortexed, then centrifuged at 9000rpm for 10
minutes at 4°C. Supernatant was again removed. The pellet was dried on ice for 5
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minutes and re-suspended in 50pl RNA storage buffer. Samples were left on ice for 1
hour to disperse in storage buffer, then stored at -70°C.
When this method was used it was necessary to DNase-treat RNA samples separately
prior to use for PCR. This was done using an Ambion DNase treatment kit
(Ambion). The volume of RNA required to give a final concentration of lOOng/ql
was calculated, and the correct volume of water to make lOpl added, lpl of buffer
and lpl of DNase were added and the mixes incubated at 37°C in a Hybaid Omn-E
PCR machine for 20 minutes. 0.5pi DNase Inactivation Reagent was then added and
incubated for 2 minutes at room temperature. Samples were centrifuged for 1 minute
at 12,500rpm, then frozen at -70°C.
2.3.4 Measuring RNA concentration and quality
RNA concentration and quality were measured using an Agilent 2100 Bioanalyzer
and RNA 6000 Nano Kit (Agilent Technologies, Stockport, UK).
The Agilent 2100 bioanalyzer instrument detects biomolecules by laser-induced
fluorescence. During chip preparation a dye concentrate is mixed with a gel. The
priming station allows the channels of the chip to be filled with the gel-dye mix.
During the chip run the dye intercalates directly with the RNA to be analysed and
outputs data in the form of an electropherogram.
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Cleaning chips were used to clean the electrodes with both RNase Zap (Ambion) and
nuclease-free water (Sigma) prior to use. Reagents were removed from the fridge 30
minutes before use.
Gel was prepared by spinning the RNA 600 Nano gel matrix at 4000rpm for 10
minutes in a spin filter. The gel was stored at 4°C for later use. Prior to use, dye
containing DMSO was added to the gel to allow it to bind to nucleic acids. An RNA
Nano chip was placed in the priming station and gel-dye mix pipetted into the
appropriate well. The chip priming station was closed and the plunger pressed down
for 30 seconds to pressurise the gel. RNA 6000 Nano marker was pipetted into the
ladder well and each of the sample wells. Any wells which were not to be used
received 6pl of dye instead of 5pi. The RNA 6000 ladder was denatured at 70°C for
2 minutes and pipetted into the ladder well, lpl of each sample was loaded into each
sample well on the chip. The chip was vortexed for 1 minute and inserted into the
Agilent 21000 bioanalyser and the run started. Results were presented in
electropherograms. An example of the ladder electropherogram is shown in Figure
















Figure 2.1 Ladder Electropherogram from RNA 6000 Nano analysis.Taken
from Agilent 2100 Bioanalyzer brochure, Agilent Technologies.
Figure 2.2 Examples of an electropherogram produced from a good (A) and
poor (B) quality RNA samples. The good quality sample has two distinct 18S
and 28S peaks, however in the poor quality sample the peaks are less
distinct. Taken from Agilent 2100 Bioanalyzer brochure, Agilent
Technologies.
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RNA quality was further tested by the determination of an RNA Integrity Number
(RIN) by the 2100 Expert software (Agilent Technologies). Intact RNA gives a RIN
of 10, a RIN below 7 suggests there is degradation of the RNA. For QRT-PCR, all
samples had a RIN of 8.5 or above. When RNA concentration was determined, if it
was greater than lOOng/pl, the RNA was diluted in nuclease-free water tolOOng/pl
and stored in aliquots at -70°C.
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2.4 Reverse-Transcriptase PCR
RNA was reverse-transcribed using a Multiscribe reverse transcriptase (1.25IU/pl),
random hexamers (2.5 pmol/1), magnesium chloride (5.5 mmol/1), dNTPs (lmmol/1)
and an RNase inhibitor (0.4 IU/pl) (all PE Applied Biosystems, Warrington, UK).
Reactions consisted of 8pi of reaction mix and 2pl RNA (lOOng/pl) or multiples
thereof. Reaction mixes were thoroughly vortexed and briefly centrifuged in a
microcentrifuge to ensure all contents were in the bottom of the tube. Tubes were
then put in a thermal cycler (Omn-E, Hybaid, UK) and samples were incubated for
25°C for 20 minutes, 42°C for 60 minutes, then 95°C for 5 minutes. Two negative
controls were also included, an "RT-negative" containing no Multiscribe RTase and
an "RT-water" containing nuclease-free water in place of RNA. The resulting cDNA
was stored at -20°C.
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2.5 Quantitative Real-Time PCR (Taqman)
Quantitative Real-Time PCR (QRT-PCR) measures levels of a gene-specific
sequence of cDNA generated in a reverse-transcriptase PCR reaction, and thus
provides a measure of RNA expression in a tissue. QRT-PCR was carried out using
the Taqman system and ABI Prism 7900HT sequence detection system (both PE
Applied Biosystems). This works by producing a fluorescent signal during the
amplification of the PCR product. Forward and reverse primers are designed for a
target DNA sequence and the probe to anneal to this target sequence between the
primers. The probe has two labels, a reporter label at the 5' end (FAM; 6-
carboxyfluoresceine) and a quencher at the 3' end (TAMRA; 6-
carboxytetramethylrhodamine). The probe is designed to have a higher melting point
than the primers. When intact, the quencher suppresses the fluorescence of the
reporter. The probe anneals to the cDNA during the polymerisation step then
amplification occurs. The probe is cleaved during this step by AmpliTaq Gold
(within Taqman Universal PCR Master Mix, PE Applied Biosystems) and the
reporter and quencher are separated. Fluorescence can now be detected. The amount
of fluorescence is directly proportional to the amount of PCR product, and non¬
specific amplification does not cause fluorescence. This is represented
diagrammatically in Figure 2.3.18S ribosomal RNA detection is used as an internal
control in this system. The 18S probe also has a reporter (VIC) which emits
fluorescence at a different wavelength to the FAM reporter on the gene of interest
probe. Quantification is relative to 18S as levels remain relatively constant in cells.
Data are acquired when PCR amplification is in the exponential phase. The data are
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in the form of the cycle number where the fluorescence of the reporter dye rises



























Figure 2.3 Diagrammatic representation of Taqman QRT-PCR. Adapted
from Taqman PCR Reagent Kit Protocol.
2.5.1 QRT-PCR
Taqman primers and probes were either designed in-house using Primer Express
software, or purchased from Assay on Demand (PE Applied Biosystems). Details of
primers and probes used are given in the relevant chapters. Primers designed in-
house were manufactured by Biosource (Nivelles, Belgium) or Eurogentec
(Southampton, LUC) and diluted to 250nM and probes to 50nM in nuclease-free water
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(Sigma). Assay on Demand primer/probe sets were used neat as they are provided
pre-optimised at a final concentration of 900nM primer and 250pM probe. Reaction
mixtures containing TaqMan Universal PCR Master Mix (PE Applied Biosystems;
consists of AmpliTaq Gold® DNA Polymerase, AmpErase® UNG, dNTPs with
dUTP, Passive Reference 1, and optimized buffer components) and specific forward
and reverse primers and probe were made in a final volume of 25pi per well.
Ribosomal 18S primers and probe (PE Applied Biosystems) were added at a final
concentration of 50nM. Samples were run in triplicate on an ABI Prism 7900
sequence detection system (PE Applied Biosystems). For each sample, a tube
containing 72pl of the reaction mixture and 3pi cDNA was prepared. 24pl of this
was pipetted into three separate wells on a 96-well plate. The RT-negative and RT-
water controls were included, alongside a "no template" control, where nuclease-free
water was included instead of cDNA.
2.5.2 Analysis of output
Data were output in the form of "CT" values; the number of PCR cycles required
before there is sufficient cDNA amplification to be detected. A CT value was given
for both the gene of interest and 18S. These data were transferred to a Microsoft
Excel spreadsheet for analysis. A number of calculations were performed on the data.
The first was calculation of the ACT value, by subtracting the 18S CT value from the
CT of the gene of interest. Then the average ACT was calculated as the mean of the 3
CT values for each sample. To calculate AACT, a comparator sample had to be
chosen. For experiments looking at samples across the menstrual cycle, this was a
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proliferative phase sample; the same sample was used in each experiment wherever
possible to ensure all experiments were comparable. For other experiments, the
comparator was an untreated control sample. The AACT was calculated by
subtracting the ACT of the comparator from the ACT of each sample. The final
calculation was to find (2A- AACT) for each sample, to give a fold increase in
expression over comparator. The mean fold increase for each sample group was then
calculated. An example spreadsheet is shown in Figure 2.4.
I I
average of the 3
triplicates for each
sample.
mple)-CT(18S \ |' 1 average-comparator average I
Sample CT (18S) CT(sample DCT AVERAGE DDCT 2A-DDCT =2A(-DDCT) |
1 11.3966 29.13059 17.73399 17.74 -0.03 1.02346
1 11.10005 29.08031 17.98026
1 11.83673 29.33213 17.4954
2 11.28214 28.79379 17.51166 17.61 -0.16 1.1204
2 11.42452 28.96353 17.53901
2 11.00313 28.77044 17.7673
3 11.63524 27.03788 15.40265 14.92 -2.85 7.20317
3 11.88735 26.58823 14.70089
3 11.71255 26.37313 14.66058
4 11.30327 25.67604 14.37276 14.21 -3.56 11.7859
4 11.31162 25.58229 14.27068
4 11.16155 25.15116 13.98961
Figure 2.4 Example Microsoft Excel Spreadsheet showing Taqman data
analysis
2.5.3 Statistical analysis
Statistical analysis of QRT-PCR data was performed using one-way analysis of
variance and Dunn's post-hoc test, using GraphPad InStat software. The significance
criterion was set at p<0.05.
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2.6 Immunohistochemistry
Expression patterns and localisation of proteins in the endometrium were
investigated by immunohistochemistry using a number of specific primary
antibodies. A standard avidin-biotin horseradish peroxidase (ABC-HRP) method was
employed. Briefly, the primary antibody binds specifically to the protein of interest,
and the biotinylated secondary recognises and binds to antigenic sites on the primary
antibody. An avidin-biotin-HRP complex binds to the biotin on the secondary
antibody and DAB binds the HRP and is oxidised. This causes a visible colour
change which results in the brown staining of tissue sections where the antibody has
bound. Figure 2.5 shows this in diagrammatic form.
cell
Figure 2.5 Diagrammatic representation of ABC-HRP immunohistochemistry
method. Adapted from Dako UK Ltd. Handbook of Immunochemical staining
methods 3rd edition, Boenisch et al., 2001)
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2.6.1 Slide Preparation
Cut tissue sections were appropriately labelled, dewaxed for 10 minutes in xylene,
then dehydrated in graded alcohols for 2 minutes each, all in a fume cupboard. Slides
were washed in distilled water for 10 minutes.
2.6.2 Antigen Retrieval
To break the bonds created by fixation and allow antibodies to bind, antigen retrieval
was required for use of some antibodies. This was done by pressure cooking in
0.01M citrate buffer (pH6). 21 of buffer was placed inside a pressure cooker on a hot
plate and allowed to heat. When the buffer was almost boiling, the slides were gently
placed inside the pressure cooker, ensuring they were completely immersed in buffer
and the lid sealed. When full pressure was reached, the slides were heated for 5
minutes, then the pressure released. When all the pressure was released, the lid was
removed and the pressure cooker allowed to cool for 20 minutes to prevent the
sections coming off the slides when they were removed from the buffer. Following
cooling, sections were washed in PBS (Sigma) for 10 minutes.
2.6.3 Endogenous Peroxidase Block
Endogenous peroxidases have to be blocked to prevent excess background staining.
A 3% hydrogen peroxide solution (VWR, Leicestershire, UK) was made by diluting
stock hydrogen peroxidase (VWR) in distilled water. Slides were immersed in the
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solution for 10 minutes at room temperature, then washed twice for 5 minutes in PBS
whilst being gently agitated.
2.6.4 Avidin/Biotin Block
Endogenous avidin and biotin also need to be blocked to prevent excess background
staining. An avidin-biotin blocking kit (Vector, Peterborough, UK) was used. Slides
were placed in a humidified chamber and avidin applied, then slides were incubated
for 15 minutes. Concentrations of avidin and biotin solutions are not available. Slides
were briefly washed in PBS while agitated for 2 minutes and returned to the
humidified chamber where biotin was applied. Slides were incubated at room
temperature for a further 15 minutes, then washed again in PBS.
2.6.5 Non-immune block
Background staining was further prevented by the inclusion of a non-immune block
to prevent non-specific binding of the secondary antibody. A solution of serum was
prepared by diluting the serum of the species the secondary antibody was raised in
1:5 in PBS and adding 5% BSA (Sigma). This solution was applied to slides in a
humidified chamber and incubated for 20 minutes at room temperature. Sections
were not washed following this procedure.
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2.6.6 Primary antibodies
Primary antibodies were diluted to the appropriate concentration determined by
titration in the serum used for blocking. The primary antibodies used and the
working dilutions are shown in the relevant chapters. Where possible, the primary
antibody was pre-absorbed against a blocking peptide for use as a negative control.
Alternatively, pre-immune serum or generic immunoglobulins from the same species
at the same concentration as the primary antibody was used. Positive controls were
tissue sections known to express high levels of the protein of interest. Details of
specific positive and negative controls are given in the appropriate chapters. Primary
antibodies and negative controls were applied to sections in a humidified chamber
and covered with coverslips to prevent drying. Sections were incubated overnight
(approx. 18 hours) at 4°C. Following incubations, sections were dipped in PBS to
gently remove coverslips, then washed in PBS containing 0.05% Tween-20 (PBST;
Sigma) with gentle agitation.
2.6.7 Secondary antibodies
Biotinylated secondary antibodies raised against the immunoglobulins of the species
in which the primary antibody was raised were diluted as described in the appropriate
chapters in the serum solutions used for the non-immune block. The antibody was
applied to sections in a humidified chamber and incubated for 1 hour at room
temperature. Following incubation slides were washed in PBST for 10 minutes with
gentle agitation.
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2.6.8 Tertiary antibody: ABC-Elite
The ABC-Elite detection system (Vector) was used to amplify the signal from the
biotinylated secondary antibody. The ABC-Elite was prepared by adding 1 drop of
solution A and 1 drop of solution B from the kit to 2.5ml PBS, 30 minutes prior to
use and kept at room temperature. The solution was added to the slides in a
humidified chamber and they were incubated for 1 hour at room temperature, then
washed for 10 minutes in PBST with gentle agitation.
2.6.9 Developing and counterstaininq
Slides were developed and staining visualised using 3,3'-diaminobenzidine (DAB;
Dako, Cambridge, UK). 1 drop of chromagen (concentration of DAB stock
unavailable) was added to each ml of buffer solution required and DAB dropped onto
sections in a humidified chamber, with care taken that all sections were incubated for
equivalent time. When brown staining was visualised, DAB was washed off with
plenty of distilled water and slides washed for at least 10 minutes in distilled water
with gentle agitation. Sections were then counterstained in Harris' haemotoxylin
(Pioneer Research Chemicals Ltd, Colchester, UK) for 30 seconds and nuclear
staining developed in Scott's tap water (Pioneer Research Chemicals Ltd.) for 10
seconds. Slides were then dehydrated in graded alcohols and cleared in histoclear
(Pioneer Research Chemicals) and xylene for 10 minutes each before mounting
under a borosilicate glass coverslip (VWR) using Pertex mounting medium (Cellpath
pic, Hemel Hempstead, UK).
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2.6.10 Visual analysis
Staining was analysed semi-quantitatively and blindly by two observers, myself and
another member of the lab team, using a 4-point scoring system where 0=no staining,
l=mild staining, 2=moderate staining and 3=intense staining. Both layers of the
endometrium were analysed separately where possible and glands, surface
epithelium, stroma and vessels were analysed over the whole section. Where
relevant, notes were made as to the location of vascular staining. Scores from each
observer were compared, areas of disagreement were re-analysed and a final score
reached. Generally the two observers' scored had a good degree of correlation. Mean
scores were then calculated for each group of tissue sections.
2.6.11 Statistical analysis
Basic statistical analysis was performed using InStat GraphPad software, by the non-
parametric Kruskall-Wallis test, followed by Dunn's post-hoc multiple comparison
test. The criterion for significance was set at p<0.05.
2.6.12 Photomicroscopy
Tissue sections were photographed using an Olympus Provis microscope (Olympus
Optical Co., London, UK) and Kodak DCs330 camera (Eastman Kodak Co., Hemel
Hempsted, UK). All images were photographed at 20x magnification unless
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otherwise stated. Images were re-sized and compiled using Photoshop computer
software (Adobe Systems, San Jose, California, USA).
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2.7 Western Blotting
Specificity and quality of previously untested antibodies was confirmed using
standard western blotting techniques. Briefly, homogenised tissue samples were
mixed with a bromophenol blue dye and run on a gel using electrophoresis. The
proteins in the gel were then transferred to a polyvinylidene difluoride (PVDF)
membrane (Immobilon, Millipore, Watford, UK) using electrotransfer, then probed
with primary antibody, to which antibodies on an HRP-conjugated secondary
antibody bind. Protein expression was visualised using chemiluminescent substrate,
which reacts with HRP to emit light.
2.7.1 Sample preparation
Tissue samples were homogenised in a buffer consisting of lOmM Tris, 0.3M
sucrose and ImM EDTA at pH7.4 using a hand-held electric homogeniser.
Homogenates were centrifuged at 1500rpm in Beckmann centrifuge. Sample
concentration was measured by Bradford Assay and samples were mixed 2:1 with
loading buffer consisting of SDS, glycerol, (i-mercaptoethanol and bromophenol blue
for visualisation purposes.
2.7.2 Electrophoresis
A 10% resolving gel was prepared consisting of water, acrylamide, 1.5M Tris pH8.8,
10% SDS solution, 10% ammonium persulphate solution (AMPS) and TEMED. The
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gel was poured into gel apparatus and allowed to set. A 10% stacking gel was then
prepared and poured on top of the resolving gel, combs inserted to create wells and
allowed to set. Gels were not denatured. The gels were then transferred to an
electrophoresis tank containing electrode running buffer (Tris, glycine, SDS) and
samples loaded. 20pg of each protein sample was loaded. Alongside the samples
Precision Plus Protein Standards, all blue, (Bio-Rad, Hemel Hempstead, UK) were
run for identification purposes. The electrophoresis tank was connected to a power
supply and run at 200V, 50mA, 10W until the dye had reached the end of the gel,
and then removed. The gel was washed in transfer buffer (Tris, glycine) before
electrotransfer.
2.7.3 Electrotransfer
The protein was transferred from the gels onto PVDF membranes which had been
previously washed in methanol. The gel and membrane were assembled in
electrotransfer apparatus and connected to a power pack. The transfer was performed
at 400V, 250mA, 100W for approximately 90 minutes (longer for larger proteins).
2.7.4 Western Blot
The membranes were then blocked for 2 hours in a 3% powdered milk solution in
PBS containing 0.05% Tween-20 (Sigma; PBST) at 4°C. A solution of primary
antibody was made up in the milk solution; dilutions are detailed in the appropriate
chapters. Following blocking, the membranes were washed 3 times for 10 minutes in
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PBST and incubated with primary antibody at dilutions given in the appropriate
chapters overnight at 4°C. Membranes were again washed 3 times for 10 minutes in
PBST and the secondary antibody applied. This was HRP-conjugated and directed
against immunoglobulins of the species in which the primary antibody was raised,
made up in milk solution. The membranes were incubated for 1 hour at room
temperature in secondary antibody then washed 6 times for 10 minutes in PBST. The
blots were developed by chemiluminescence (ECL plus kit, Amersham Life
Sciences, Amersham, UK). The chemiluminescent substrate reacts with the HRP
bound to the secondary antibody the protein is detected by light emission. The ECL
reagent was applied for 5 minutes at room temperature, then the blots developed
using a Typhoon 9400 phosphorimager (Amersham Life Sciences). Molecular size of
the bands was determined by comparison with the protein standards.
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2.8 Cell Separation and Culture
Samples were collected in Dutch Modification RPMI culture medium (Sigma). These
biopsies were then washed in Dulbecco's PBS (Sigma) and finely diced using a
sterile scalpel. When tissue was diced, 2ml PBS was added, with 200ul collagenase
(lOng/pl; Sigma) and 20pi DNase (lOOng/pl; Sigma). The tissue was then transferred
in this suspension to a sterile 15ml tube and incubated at 37°C for 2 hours and 15
minutes. Following this incubation, 2ml culture medium (F medium) consisting of
Dutch modification RPMI 1640 supplemented with 10% fetal calf serum, penicillin
(50pg/ml), streptomycin (50pg/ml), L-glutamine (2mmol/l) and gentamycin
(5pg/ml) (all Sigma) was added to stop the digestion reaction. The solution
containing the digested tissue was transferred to a sterile Petri dish. It was then
passed repeatedly through a 19G needle (at least 6 times, until no large lumps
remain), then filtered through a 70pm filter, then again through a 40pm filter. Each
filter was washed into a clean Petri dish with Dulbecco's PBS (Sigma) when the
filtrate had passed through. The filtrate was then centrifuged at 1700rpm for 3
minutes (Thermo IEC CLIO centrifuge) and the supernatant discarded. The pellet
was re-suspended in 10ml serum-containing "F" media and transferred to a 75cm3
culture flask. These cells were the stromal component and were cultured at 37°C
until confluent (1-2 weeks, 1.2xl06 cells), with media changed every 7 days.
The fragments of tissue that were washed out of the filters were transferred to a
sterile 15ml tube with 400pl lOx collagenase and 40pl lOOx DNase and incubated at
37°C for a further 2 hours. Following this incubation, 4ml culturemedium (HOSE 1)
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consisting of Medium199:MCDB105 (1:1 vol/vol) supplemented with fetal calf
serum (15% vol/vol), streptomycin (50 pg/ml), penicillin (50 IU/ml) and L-glutamine
(2 mmol/litre) (all Invitrogen) was added to stop the reaction. The suspension was
passed repeatedly through a 19G needle as before, then centrifuged at 1700rpm for 3
minutes. The supernatant was discarded and the pellet re-suspended in 10ml HOSE 1
medium (as used routinely in the laboratory for ovarian surface epithelial cells),
before being transferred to a 75cm culture flask. These cells were epithelially
enriched, and were cultured until confluent (3-4 weeks; 1.2xl06 cells) in the same
manner as the stromal cells. The presence of epithelial cells in the cultures was
confirmed visually. Figure 2.6 shows typical endometrial epithelial cells in culture,
and Figure 2.7 shows stromal cells.
Figure 2.6 Representative sample of endometrial epithelial cells in culture.
Images taken at 20x magnification.
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Figure 2.7 Representative sample of endometrial stromal cells in culture.
Images taken at x20 magnification.
Additional samples of cells from the surface of the endometrium were collected (N=
7) using a "Tao" brush (Cook, Limerick, Ireland) which had been inserted into the
uterine cavity via the cervix/endocervical canal and rotated to sweep the endometrial
surface. The brush was then shaken into a tube ofHOSE 1 media to remove the
scrapings, which were transferred to a 75cm3 culture flask and cultured as for the
other cell types. These cells were noted to be a mix of stromal and epithelial cells.
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Chapter 3:
Glucocorticoid metabolism and pre-receptor
signalling in the human endometrium
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3.1 Introduction
Ovulation, implantation and menstruation are pivotal reproductive events, all of
which involve extensive tissue remodelling and subsequent repair. A number of
factors mediate this remodelling and these factors are themselves regulated by
steroids and other locally produced mediators including cytokines. Steroids involved
in the reproductive system include androgens, estrogens, progestins and
glucocorticoids. Pre-receptor signalling events and metabolism associated with these
steroids are likely to play important roles in the regulation of tissue remodelling.
Glucocorticoids are proposed to have multiple roles in the human endometrium
across the menstrual cycle, in events involving tissue remodelling such as
menstruation and implantation. It is now accepted that menstruation is an
inflammatory process as first proposed by Finn (1986), and that glucocorticoids are
likely involved in modulating this response (Henderson et al., 2003).
Glucocorticoid action is regulated at a local, tissue-specific level by the 1 lpHSD
enzymes. 1 lpHSD-1 predominantly converts cortisone to active Cortisol in intact
cells, whereas 11 |3HSD-2 is a unidirectional enzyme that converts Cortisol to
cortisone. Cortisol acts by binding to its cognate receptor, the glucocorticoid receptor
(GR) and activating an anti-inflammatory response. Cortisol also binds with high
affinity to the mineralocorticoid receptor (MR); however, activation of the
mineralocorticoid receptor can lead to clinical disorders such as apparent
mineralocorticoid excess (AME). Thus the balance of 1 ipHSD-1 and -2 is important
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to regulate Cortisol metabolism and action. Consequently, 1 ipHSD-1 tends to be the
predominant enzyme found in Cortisol target tissues expressing GR, while 11 PHSD-2
can be found co-localised with MR in mineralocorticoid target tissues (Driver et al.,
2001; Hirasawa et al., 2000).
11PHSD expression in the endometrium has been studied previously by Smith et al.
(1997), who found that both enzymes were active across the cycle. Only 11 PHSD-2
protein has been studied in the endometrium due to the lack of a suitable antibody for
localisation of 1 ipHSD-1. GR expression has been studied across the cycle by
Bamberger et al. (2001) and Henderson et al. (2003), who found it to be expressed
across the menstrual cycle and localised to stromal and endothelial cells of
endometrium and additionally in glandular epithelia of first trimester decidua
(Henderson et al., 2003). There are no reports currently ofMR expression patterns in
human endometrium.
Uterine natural killer (uNK) cells have been shown to express GR (Henderson et al.,
2003), and earlier reports have shown glucocorticoids to act on these cells. However
there is little known about the expression of 1 ipHSD-1 and -2, and MR in this
phenotypically unique group of cells.
The aims of this chapter are to study the expression patterns of 1 ipHSD-1, -2, GR
and MR in human endometrium across the menstrual cycle, in first trimester decidua
and in uNK cells at both mRNA and protein levels.
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3.2 Materials and Methods
3.2.1 Tissue Collection and Subjects
Local ethical approval and informed consent were provided by patients for all
endometrial tissue collected. Tissue samples were collected as described in 2.1.1.
Briefly, 18 biopsies consisting primarily of the functional layer of the endometrium
were collected at hysterectomy or by pipelle sampling device and used for RNA
extraction. Five first trimester decidua biopsies were collected at elective surgical
termination of pregnancy and used for RNA extraction.
34 full-thickness endometrial biopsies were collected at hysterectomy and wax-
embedded for use in immunohistochemistry. Five first trimester decidua biopsies
were collected at elective surgical termination of pregnancy and also wax embedded
for immunohistochemistry.
All subjects were of reproductive age, with regular menstrual cycles of 25-35 days
and had no exogenous hormone treatment in the previous 3 months. Tissue samples
were consistent across three parameters: date of reported last menstrual period,
histological stage and ovarian stage of cycle as determined by serum estradiol and
progesterone concentrations at the time of biopsy, measured by RIA, to allow for
variation from the classic 28 day cycle.
Details of these samples are shown in Tables 3.1 and 3.2.
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Table 3.1 Endometrial samples used for QRT-PCR (functional layer only)
Sample E2 level at time of
biopsy
(pmol/1)




1 118 2.9 Menstrual
2 151 4.3 Menstrual
3 291 2.9 Menstrual
4 167 1.6 Menstrual
5 423 5.2 Proliferative
6 534 3.4 Late proliferative
7 842 7.1 Mid proliferative
8 544 2.3 Mid proliferative
9 604 42.5 Early secretory
10 368 12.9 Early secretory
11 574 14.4 Early secretory
12 534 39.2 Early secretory
13 276 42.1 Mid secretory
14 552 78.9 Mid secretory
15 680 106.2 Early secretory
16 129 5.7 Late secretory
17 602 14.7 Late secretory
18 490 22.9 Mid-late
secretory
Note: A sub-set of these samples were used for each experiment, n=4 or 5 for each
stage. Some archival samples were used up in the course of the experiments so had to
be substituted with newer samples.
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Table 3.2 Endometrial samples used for immunohistochemistry (full
thickness biopsies)
Sample E2 level at time P4 level at time Histological date
of biopsy of biopsy
(pmol/1) (nmol/1)
1 371 7.5 Menstrual
2 223 3.0 Menstrual
3 * * Menstrual
4 * * Menstrual
5 169 2.8 Proliferative
6 1233 2.6 Late proliferative
7 642 1.6 Late proliferative
8 43 4.0 Early proliferative
9 234 1.2 Early proliferative
10 762 1.1 Mid proliferative
11 681 3.8 Late proliferative
12 694 2.3 Early proliferative
13 808 3.7 Mid proliferative
14 847 5.3 Late proliferative
15 207 12.2 Early secretory
16 124 19.1 Early secretory
17 282 23 Early secretory
18 534 39 Early secretory
19 202 17 Early secretory
21 853 101 Mid secretory
22 265 39.4 Mid secretory
23 404 65 Mid secretory
24 496 31.1 Mid secretory
25 218 42.3 Secretory
26 120 71.3 Secretory
27 369 12.2 Late secretory
28 492 2.6 Late secretory
29 189 4.1 Late secretory
30 191 8.6 Late secretory
31 129 5.7 Late secretory
32 819 6.4 Late secretory
33 275 5.3 Late secretory
34 176 11.3 Late secretory
* archival samples, data not available.
Note: A sub-set of these samples were used for each experiment, n=4 or 5 for each
stage. Some archival samples were used up in the course of the experiments so had to
be substituted with newer samples.
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The following samples of first trimester decidua were used for both QRT-PCR and
immunohistochemistry.







Uterine natural killer cells were isolated by Dr Ashley Moffett, as previously
described (Henderson et al., 2003). Briefly, lx 108 decidual cells were suspended in
300 pi buffer (PBS/2 mM EDTA/1% human serum). After the addition of 0.5%
human y-globulins in PBS and 100 pi CD56 magnetic cell sorting microbeads
(Miltenyl Biotech, Bergisch Gladbach, Germany), the suspension was incubated at 4
C for 20 min. The cells were washed, resuspended in buffer, and applied to a
VarioMACS magnet (Miltenyl Biotech). The column was washed, and the CD56+
cells were eluted and resuspended in RPMI/10% fetal calf serum. The purity of the
decidual NK cells was greater than 97%, as confirmed by flow cytometry.
3.2.2 RNA extraction and reverse-transcriptase PCR
RNA extraction and reverse-transcriptase PCR were performed as described in
sections 2.3 and 2.4.
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3.2.3 Taqman Quantitative Real-Time PCR
QRT-PCR was performed using standard methods as described in Chapter 2.
Oligonucleotide forward and reverse primers and oligonucleotide Taqman probes
were used to detect the sequences of interest. The probes used were designed using
Primer Express software as previously described (11(3HSD-1, -2, GR) (Rae et al.,
2004a, Henderson et al., 2003), or commercially available from PE Applied
Biosystems Assay on Demand service (MR). The following specific primers and
probes were used:
Table 3.4 Taqman Primers and Probes
11PHSD-1 forward AAG ATG TTC CTG CAT GGA TTT C
lipHSD-1 reverse AGC TCT GCG CCA AGA AGA AGT
11PHSD-1 probe TGA CAG CTC ACT CTG GAC CAC TCT TCT GA
llpHSD-2 forward GGC CAA GGT TTC CCA GTG A
lipHSD-2 reverse GTT GTG CCA GGA GGG TGT TT
llpHSD-2 probe CTC TGC GCC TCT CCA CTG TTT CAT GA
GR forward GCG ATG GTC TCA GAA ACC AAA C
GR reverse GCA GAG GAT AAC TTC CTC TGT AAT CTC
GR probe TCA GAG CCT CAG CAA CCT TCA CTG CA
MR primer/probes from Assay on Demand; reference Hs00230908_ml. Sequences
unavailable but pre-validated by ABI.
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Analysis of data was carried out by one-way analysis of variance, as described in
section 2.5.
3.2.4 Immunohistochemistrv
11PHSD-1, lipHSD-2 and GR immunohistochemistry was performed by standard
methods as described in 2.6 using biotin-conjugated secondary antibodies and ABC-
Elite avidin biotin peroxidase complex (Vector, Milton Keynes, UK).
Immunoreactivity was detected using the chromagen, 3,3'-diaminobenzidine (DAB).
Semi-quantitative visual analysis and statistics were performed as described in
2.6.10.
MR immunostaining was carried out using a BOND-X automatic immunostaining
robot (Vision Biosystems), with "define polymer with counterstain" reagent kit as
described in section 2.6. This automated immunostaining process involves a
peroxidase block prior to application of primary antibody, biotinylated secondary
antibody (consisting of goat anti-mouse IgM, horse anti-mouse IgG and horse anti-
rabbit IgG), followed by streptavidin-HRP conjugate, 3,3-diaminobenzidine
detection and haemotoxylin counterstain. Prior to loading into the immunostaining
robot, sections were dewaxed in xylene, rehydrated through graded alcohols and
antigen retrieval performed as described in 2.6.2.
The lipHSD-1 antibody was a sheep polyclonal obtained from Dr Karen Chapman,
Centre for Cardiovascular Science, University of Edinburgh. The antibody was
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raised in sheep against recombinant mouse 11(3HSD-1. Commercial primary
antibodies were used against lipHSD-2 (PC545, The Binding Site, Birmingham,
UK) and GR (NCL-GCR, NovoCastra, Newcastle-upon-Tyne, UK). The MR
monoclonal antibody (MRN2-2D6) was one of a series produced by Celso Gomez-
Sanchez (University of Mississippi) by immunizing mice with a peptide
corresponding to amino acids 64-82 of the rat mineralocorticoid receptor
(SKEKHELLPYIQQDNSRSG-C) conjugated to keyhole limpet hemocyanin.
Resulting lymphocytes were fused with SP-2-mIL6 myeloma cells. This antibody is
an IgG2b isotype and cross-reacts with the human mineralocorticoid receptor.
The conditions used for each antibody are shown in Table 3.5.
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llpHSD-1 1:1500 Rabbit anti- No antigen -i-ve: human
sheep retrieval liver; -ve
matched IgG




























Note: Performing antigen retrieva had no effect on the pattern of staining but
increased the intensity. In the case of lipHSD-1, some background staining occurred
when antigen retrieval was performed.
3.2.5 Western Blotting
Western blotting was carried out to determine specificity of previously untested
antibodies (against 1 ipHSD-1 and MR). The procedure was carried out using the
standard technique described in 2.5. Antibody dilutions and control tissues are listed
in Table 3.6.
86

















3.3.1 Confirmation ofAntibody Specificity
Specificity of the 11J3HSD-1 and MR antibodies was confirmed using western
blotting as they had not been previously validated. Both antibodies showed a clear,
single band at the appropriate molecular weight in control tissues. Pre-adsorption
with the appropriate peptide as these peptides were not available. Figure 3.1 shows
1 ipHSD-1 and Figure 3.2 shows MR on western blots.
kDa Liver
Figure 3.1 Western immunoblot of 11pHSD-1 in human liver, molecular
weight 33kDa, as shown by western blotting.
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Figure 3.2 Western immunoblot of MR in human endometrium and placenta,
molecular weight 102kDa, as shown by western blotting
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3.3.2 Expression of 11BHSD-1mRNA in human endometrium
Levels of 1 ipHSD-1 mRNA were measured and validated using specific Taqman
primers and probes as described. There were very low levels of 1 ipHSD-1 mRNA in
normal endometrium, and this did not differ significantly between proliferative and
secretory phases. The levels of 1 ipHSD-1 mRNA in menstrual endometrium were
significantly increased in comparison to the rest of the menstrual cycle (p<0.05).
Levels ofmRNA were also significantly increased in first trimester decidua
(P<0.05). There was also some increase in 1 ipHSD-1 mRNA levels in uterine
natural killer (uNK) cells, a group of phenotypically unique cells that increase in
number prior to pregnancy, in comparison to non-pregnant endometrium. These data




Figure 3.3 Expression of HpHSD-1 mRNA across the menstrual cycle, in
first-trimester decidua, and uNK cells, mean ± SEM. M = menstrual, P =
proliferative, ES = early secretory, MS = mid secretory, LS = late secretory, D
= decidua, uNK = uNK cells. The comparator was a proliferative

































3.3.3 Expression of 1ipHSD-1 protein in human endometrium
lipHSD-1 protein was expressed at low levels throughout the menstrual cycle.
Expression was localised to the glandular and surface epithelia, with very low
expression seen in the endothelial and stromal cells. There was no significant
difference in expression patterns between the functional and basal layers. Intensity of
expression did not differ significantly across the menstrual cycle, but there was a
trend towards increased expression in menstrual endometrium.
11PHSD-1 protein was localised to the same cell types in first trimester decidua as in
non-pregnant endometrium, the glandular and surface epithelium. Expression levels
of the protein were seen to be slightly greater in first trimester decidua than
endometrium, however this was not statistically significant.
These data are shown in Figures 3.4 and 3.5. Charts showing immunoscores are
included in Figure A1 in Appendix 1.
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Figure 3.4 Immunolocalisation of 11(3HSD-1 protein in the functional layer of
the endometrium and decidua. M=menstrual, P=proliferative, ES=early
secretory, MS=mid secretory, LS=late secretory, D=decidua, +ve= positive
control, human liver, -ve=negative control, primary antibody substituted for
matched IgG. Scale bar=10 microns.
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Figure 3.5 Immunohistochemical localisation of 11(3HSD-1 in the basal layer
of the endometrium. M=menstrual, P=proliferative, ES=early secretory,
MS=mid secretory, LS=late secretory. Scale bar=10 microns.
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3.3.4 Expression of 11BHSD-2 mRNA in human endometrium
1 ipHSD-2 mRNA was moderately expressed in normal endometrium throughout the
menstrual cycle. There was no increase in 11 PHSD-2 mRNA levels in menstrual
phase endometrium. Levels of 11PHSD-2 mRNA in first trimester decidua did not
differ significantly from those in normal endometrium. 11PHSD-2 mRNA was not
detectable in uNK cells. These data are shown in Figure 3.6
M P ES MS LS D uNK
Stage of Cycle
n= 4 4 4 4 4 5 1
Figure 3.6 Expression of 11 pHSD-2 mRNA across the menstrual cycle, in
first-trimester decidua, and uNK cells, mean ± SEM. M = menstrual, P =
proliferative, ES = early secretory, MS = mid secretory, LS = late secretory, D
= decidua, uNK = uNKr cells. The comparator was proliferative endometrium.
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3.3.5 Expression of 113HSD-2 protein in human endometrium
lipHSD-2 protein expression and localisation was studied across the menstrual
cycle and in first trimester decidua. lipHSD-2 protein was expressed in the
cytoplasm. llpHSD-2 protein was localised in the glandular epithelium in both the
functional and basal layer of the endometrium across the cycle, and at a greater level
in first trimester decidua. Low levels of the protein were seen in the stroma of the
functional layer, with an increase in first trimester decidua compared to normal
endometrium. lipHSD-2 protein was not present in the stroma of the basal layer.
There was negligible expression in the endothelial cells of blood vessels of the both
layers across the cycle, but some expression was seen in these cells in the functional
layer of first trimester decidua. There was moderate expression of llpHSD-2 protein
in the surface epithelium of normal endometrium, and higher levels in first trimester
decidua. Expression did not vary significantly in any part of the endometrium across
the normal menstrual cycle. Figures 3.7 and 3.8 illustrate llpHSD-2







Figure 3.7 Immunolocalisation of 11(3HSD-2 protein in the functional layer of
the endometrium and decidua. M=menstrual, P=proliferative, ES=early
secretory, MS=mid secretory, LS=late secretory, D=decidua, +ve= positive
control, human kidney, -ve=negative control, primary antibody substituted for
matched IgG. Scale bar= 10 microns.
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Figure 3.8 Immunohistochemical localisation of 11(3HSD-2 in the basal layer
of the endometrium. M=menstrual, P=proliferative, ES=early secretory,
MS=mid secretory, LS=late secretory.Scale bar=10 microns.
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3.3.6 Expression of GR mRNA in human endometrium
Expression ofGR mRNA was also assessed by Taqman QRT-PCR. It was found that
the mRNA was present in normal endometrium at low levels across the cycle and in
first trimester decidua, with no significant difference in expression between stages of
the cycle. However, expression levels were higher in menstrual endometrium. Figure
3.9 illustrates the expression pattern ofGR immunoreactivity in endometrium across





































Fig. 3.9 Expression of GR mRNA across the menstrual cycle, in first-
trimester decidua, and uNK cells, mean ± SEM. M = menstrual, P =
proliferative, ES = early secretory, MS = mid secretory, LS = late secretory, D
= decidua, uNK = uNK cells. The comparator was a proliferative
endometrium sample. *P<0.05 compared to all other stages of the cycle.
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3.3.7 Expression of the glucocorticoid receptor (GR) protein in human
endometrium
GR protein was expressed in the nuclei of stromal cells at fairly high levels. There
was no significant difference in expression across the cycle or in first trimester
decidua. Expression of GR was low in glandular epithelium in both the functional
and basal layers across the cycle. There was a significant increase in expression in
decidual glands (p<0.001 by Kruskall-Wallis test as described in 2.6.11). There was
high expression of GR in the endothelial cells of the vasculature in both functional
and basal layers of the endometrium, and in first trimester decidua, with no
significant difference across the cycle. Expression of GR protein increased across the
cycle in the surface epithelium, from negligible expression in the proliferative and
early secretory phases to weak expression in the late secretory phase. There was high
expression of the protein in all cell types of first trimester decidua. Figures 3.10 and
3.11 illustrate patterns of immunoreactivity in the functional layer of the




. •' • ' - -i-v„ A;
•
a-.- " • =~--.! . •,-=•"
• .' •' • .




-r-ir " *vv-v '* • - ■
ifvi ' ■ : ■»■•'-: •■ .
'■" ' . S .-;■ *» £c X#I i| M • ?«."* j•-»•'«
•' Jf, W--3Z \ . J. /•"' s'*' # • - '■ ''**& ' ">.•*•
•- ' - i %h > * j *• ; »■ ' '
,.**C ' *' '%&''* ? • ' ' ■' ' •'*?
ES MS
'
I,'*'- . ' .- " '• •" •• ' " •
*5...
'
■ cu.(:.v '\ VP' W--V X "' ?.>:• •'• v;^--;vV':">.vCvt-;i-
v.; V V ' •• :• {f/.'V"-:^T % •-•"•V
»'■'■■■ ' • J met
"t; V.1--
. v., •'. ''■■■•--ir' 1 ■ v:
Figure 3.10 Immunolocalisation of GR protein in the functional layer of the
endometrium and decidua. M=menstrual, P=proliferative, ES=early secretory,
MS=mid secretory, LS=late secretory, D=deciduas, -ve=negative control,
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Figure 3.11 Immunohistochemical localisation of GR in the basal layer of the
endometrium. M=menstrual, P=proliferative, ES=early secretory, MS=mid
secretory, LS=late secretory. Scale bar=10 microns.
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3.3.8 Expression of the mineralocorticoid receptor (MR) mRNA in human
endometrium
MR mRNA was expressed throughout the menstrual cycle in non-pregnant
endometrium. It was also expressed in first-trimester decidua and in an isolated
population of uNK cells, although expression was very low in the latter. Expression
levels are significantly higher in mid-secretory phase endometrium than in the
proliferative phase. MR mRNA levels then fell significantly in the late secretory
phase. There was an increase in the level ofMR mRNA expression in first trimester
decidua, but this result was not found to be statistically significant. These data are









































Fig. 3.12 Expression of MR mRNA across the menstrual cycle, in first-
trimester decidua, and uNK cells, mean ± SEM. M = menstrual, P =
proliferative, ES = early secretory, MS = mid secretory, LS = late secretory,
D = decidua, uNK = uNK cells. The comparator was a proliferative
endometrium sample. *P<0.05 compared to all other stages of the cycle.
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3.3.9 Expression of the mineralocorticoid receptor (MR) protein in human
endometrium
MR protein was found to be most strongly expressed in the glandular epithelia. There
was variable, mild immunoreactivity seen in endometrial stromal cells and
endothelial cells. Mild-moderate expression ofMR protein was observed in the
surface epithelium.
The expression pattern ofMR protein in the basal layer of the endometrium was
similar to that in the functional layer, although there was a trend towards reduced
expression. There was very little expression ofMR protein in the stromal cells or
vasculature of the basal layer.
Expression of MR protein in first trimester decidua closely mirrored that of non¬
pregnant endometrium, with expression in the glandular epithelia, and some
expression in stromal and endothelial cells. MR protein expression did not differ
significantly between first trimester decidua and normal endometrium across the
menstrual cycle.
MR protein was expressed variably in both the nucleus and cytoplasm in different
tissues. In human kidney (positive control tissue) there was MR expression in the
cytoplasm and punctate nuclear staining was also seen. In human endometrium there
seemed to be predominantly cytoplasmic staining in the non-pregnant endometrium;
however, nuclear staining was seen in first trimester decidua. These observations are
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Figure 3.13 Immunolocalisation of MR protein in the functional layer of the
endometrium and decidua. M=menstrual, P=proliferative, ES=early secretory,
MS=mid secretory, LS=late secretory, D=decidua, +ve= positive control,
human kidney, -ve=negative control, primary antibody preabsorbed against








Figure 3.14 Immunohistochemical localisation of MR in the basal layer of the
endometrium. M=menstrual, P=proliferative, ES=early secretory, MS=mid
secretory, LS=late secretory. Scale bar=10 microns.
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3.4 Discussion
These studies have shown for the first time the expression and localisation of
11 pHSD-1 and MR protein in human endometrium across the menstrual cycle, and
demonstrated the expression of 11PHSD-1 and -2, GR and MR mRNA and protein
expression across the menstrual cycle in greater detail than has been previously
reported. It has been shown that 11 PHSD-1 expression is upregulated at menstruation
and in first trimester decidua, whereas 11PHSD-2 expression does not vary across the
cycle. GR is expressed throughout the menstrual cycle and levels of mRNA are
increased at menstruation. MR is also expressed throughout the menstrual cycle and
mRNA expression peaks in mid-secretory endometrium.
There was a large increase in 11PHSD-1 mRNA levels in endometrium at the time of
menstruation in comparison to endometrium at other stages of the menstrual cycle.
This may reflect an anti-inflammatory response, as both decidualisation and
menstruation involve extensive remodelling of tissue. Correspondingly, levels of GR
mRNA are also increased at menstruation.
MMPs are enzymes involved in the degradation of extracellular matrix proteins.
Given the degree of injury and repair involved in menstruation, MMPs are likely to
play a role. There may also be a link between lipHSD-1 activity and MMP action,
as proposed by Arcuri et al. (1996). It has also been shown that MMP levels are
modulated by activation of the hypothalamic-pituitary-adrenal axis, of which Cortisol
is a product (Yang et al., 2001). Glucocorticoids are potent regulators of extracellular
matrix degrading enzymes, of which MMPs are a large group.
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lipHSD-1 mRNA levels were also greatly increased in uNK cells. These are a
phenotypically unique cell type that increase in number with increasing circulating
levels of progesterone in the non-pregnant secretory phase. The uNK cell population
further increases in number in the first trimester of pregnancy. The increase in
llpHSD-1 mRNA expression in first trimester decidua may be a reflection of
increased uNK cell numbers, a major component of the leukocyte population in first
trimester decidua.
lipHSD-1 protein has been shown to be predominantly localised to the glandular
epithelium of the endometrium and first trimester decidua. Expression is greatest in
first trimester decidua, with a trend towards increased expression in menstrual
endometrium. This pattern of protein expression is consistent with the mRNA data
shown here, and lends further support to the suggestion that lipHSD-1 plays a vital
role in the injury and repair of the human endometrium at the time of menses. This
also implies that the processes of implantation and menstruation are indeed of an
inflammatory nature as suggested by Finn (1986). This is the first time lipHSD-1
protein expression and localisation have been studied in such detail in human
endometrium and it corroborates the novel aspects of the mRNA data shown here,
namely the dramatic upregulation of lipHSD-1 expression at menstruation and in
first trimester decidua.
11PHSD-2 mRNA was expressed in human endometrium at all stages of the
menstrual cycle and in first trimester decidua; expression did not differ significantly
across the menstrual cycle.
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It has been shown here that 1 ipHSD-2 protein is expressed in the cytoplasm of the
glands in both the functional and basal layers of normal human endometrium, and
also at low levels in the stroma of the functional layer. The level of expression
remains constant across the menstrual cycle. Levels of lipHSD-2 protein are
increased in first trimester decidua, suggestive that lipHSD-2 may well be involved
in trophoblast invasion at the onset of pregnancy, by preventing cortisol-mediated
inhibition of MMPs. Alternatively, the increase of lipHSD-2 expression in first
trimester decidua may be in balance with the dramatic upregulation of 1 ipHSD-1
mRNA.This may perhaps be to deliver protection to the fetus from excess circulating
maternal glucocorticoids, which could be harmful. This response would not be
crucial in the absence of pregnancy, thus there is no corresponding increase of
11PHSD-2 at menstruation.
lipHSDs may also be involved in the local regulation of various cellular events, by
modulating glucocorticoid availability in a site-specific manner, including
proliferation (Bigsby and Young, 1993), apoptosis (Terada et al., 1991; Jo et al.,
1993), and biosynthesis of hormones, growth factors and enzymes such as MMPs
(Makrigiannakis et al., 1992; Salamonsen, 1994). Hoffman et al. (1984) also
suggested glucocorticoids may be involved in inhibition of implantation. This could
explain the increase in llpHSD-2 seen in first trimester decidua, to increase the
synthesis of cortisone and thus decrease local Cortisol levels, removing the local
inhibitory effect.
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GR mRNA was expressed in endometrium across the menstrual cycle, and mRNA
levels did not differ significantly between the proliferative and secretory phases. This
confirms data previously published by Bamberger et al. (2001) and Henderson et al.
(2003). In menstrual endometrium, however, GR mRNA was upregulated compared
to the rest of the menstrual cycle. This corresponds to the increase in expression of
the enzyme that makes active ligand available (llpHSD-1), further suggesting a role
for local glucocorticoid action in the inflammatory process ofmenstruation.
GR protein was expressed in endometrial stromal cells across the menstrual cycle
and in decidualised endometrium. Levels of GR protein in the endometrial glands
were up-regulated in first trimester decidua. This confirms data previously published
(Henderson et al., 2003). GR is predicted to be co-localised with 11(3HSD-1, and in
the endometrium this is indeed the case in terms of temporal expression. However,
GR is expressed only in the stroma of human endometrium, whereas lipHSD-1 is
largely confined to the glands. This suggests that the Cortisol made available by
11PHSD-1 must be transported to the stroma in order to act on GR in a paracrine
signalling manner. In first trimester decidua however, GR protein was also expressed
in the glandular epithelia, the same location as the lipHSD-1 enzyme. This would
allow intracrine signalling to occur, which may elicit a faster glucocorticoid response
than the paracrine signalling in non-pregnant endometrium.
A number of studies have shown that increased Cortisol levels can lead to
downregulation of GR in a number of cell types, including myoblasts (Whorwood et
al., 2001), HeLa cells (Cidlowski et al., 1981; Shimojo et al., 1999), AtT-20 cells
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(Svec et al., 1981) and COS-1 cells transfected with human GR (Burnstein et al.,
1990). The studies in this thesis show an increase in expression of endometrial GR at
the time Cortisol levels would be expected to be greatest (due to increased 1 ipHSD-1
expression) - the menstrual phase. This may, however, be due to signals in the late
secretory phase if pregnancy is not detected, to increase GR transcription. This
increase would then be observed in the following stage of the cycle.
Correspondingly, GR levels fall in the proliferative phase, following exposure to the
expected high Cortisol levels of the menstrual phase.
Cortisol has a greater affinity for MR than for GR and can act as a potent
mineralocortocoid when it binds to MR. Excess binding of Cortisol to MR can cause
a number of disorders, in particular apparent mineralocorticoid excess and
hypertension (Wilson et al., 1995). In order to prevent this, lipHSD-2 is normally
co-localised with MR. MR mRNA studies have shown that this indeed seems to be
the case in a number of tissues including kidney (Edwards et al., 1988), colon
(Funder et al., 1988), eye (Suzuki et al., 2001) and placenta (Hirasawa et al., 2000).
Immunohistochemical localisation has confirmed this by showing both lipHSD-2
and MR to be predominantly expressed in endometrial epithelial cells.
There have also been reports of GR and MR, or GR alone being co-expressed with
11PHSD-2, in particular in fetal tissues (Condon et al., 1998). It has been proposed
that during pregnancy the role of lipHSD-2 is to protect the fetus from relative
maternal hypercortisolaemia (Driver et al., 2001). This suggests that glucocorticoid
excess is more harmful to the fetus than mineralocorticoid excess.
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MR is expressed across the normal menstrual cycle and in first trimester decidua,
with an increase at the time of increased post-ovulatory progesterone concentrations,
and a decrease in expression when progesterone is withdrawn, suggesting MR is
directly regulated by progesterone. It has also been demonstrated that progesterone is
able to bind to MR, however, it cannot elicit a mineralocorticoid response
(Rupprecht et al., 1993; Quinkler et al., 2003). Progesterone thus appears to be acting
as an antagonist ofMR function. McDonnell et al. (1994) proposed a mechanism
whereby MR transcriptional activity is repressed by ligand-activated PR-A via cross¬
talk ofMR with this potent transdominant inhibitor competing for a common
transcriptional factor or adaptor.
In the excretory systems, this process happens across the epithelia lining the distal
parts of these systems (Horisberger & Rossier, 1992). It is therefore sensible to
propose a similar mechanism in the endometrial epithelia, and correspondingly MR
was found to be primarily expressed in glandular and surface epithelia.
Immunohistochemical data herein shows that MR expression in human endometrium
is primarily cytoplasmic; however in first trimester decidua expression is both
cytoplasmic and nuclear. This corresponds with the pattern of 11(3HSD-1 expression,
regulating the availability of ligand to bind MR. When lipHSD-1 levels and thus
Cortisol levels are low, MR expression is predominantly cytoplasmic. In first
trimester decidua, when lipHSD-1 levels (and thus Cortisol levels) are elevated, MR
is observed in nuclei also. This suggests that MR translocates to the nucleus when
ligand is bound, as previously reported (Sartorato et al., 2004).
Ill
The main function of the mineralocorticoid response is to regulate the balance of
water and salts in tissues, in particular the balance of sodium and potassium. This is
achieved by adjusting the transport rate of these salts. This would be a particularly
cmcial factor in the human endometrium at the time of pregnancy in order for the
fetus to grow and develop normally. This could explain the increase seen in MR
expression in the mid-secretory phase - the time when the endometrium receives
signals to prepare for implantation. There was also a lesser, non-significant increase
in MR mRNA in first trimester decidua which could be explained in a similar
manner.
Interestingly, mRNA studies in uterine natural killer cells have shown that these cells
express lipHSD-1 and GR. These uNK cells however have negligible lipHSD-2 or
MR expression. There is currently little known about the precise role of uNK cells;
however, it appears that glucocorticoid function is required whereas
mineralocorticoid action is not. As there is very little MR present, llpHSD-2 is not
required to protect from excess Cortisol binding. Previous studies have shown
llpHSD-1 mRNA and protein to be expressed in murine splenic lymphocytes
(Zhang et al., 2005), and in human monocytes upon differentiation to macrophages
(Thierenger et al., 2001). lipHSD-2 was not seen to be present in either cell type.
MR protein expression in human endometrium across the menstmal cycle has not
previously been reported. Here it has been demonstrated that MR is expressed across
the menstrual cycle, however there are no significant differences in expression
during the key events in the endometrium, menstruation and implantation.
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As uNK cells are immune cells that increase greatly in number in the late secretory
phase of the menstrual cycle, and further in first trimester decidua, it is possible they
play a role in the inflammatory processes in the human endometrium here. A number
of factors have been identified in the uNK cell population that implicate them in
menstrual breakdown and endometrial regeneration, such as vascular endothelial
growth factors (VEGF) and angiopoietin-2 (Li et al., 2001; reviewed by Moffett-
King, 2002).
In order to further determine the expression patterns and roles of 1 ipHSD-1 and -2 in
the endometrium, activity assays could be carried out. These studies would allow an
accurate measurement of both the dehydrogenase and reductase activities of
1 ipHSD-1 and -2 by assaying their ability to metabolise substrates in the presence of
different cofactors. This would also allow a comparative measure of 1 ipHSD-1 and -
2 in the endometrium and thus give an accurate picture of the fine balance between
the two enzymes.
Concluding Remarks
These data show that glucocorticoid expression and action are likely to have a key
role in human endometrium. 11 pHSD-1 has been shown to be expressed at greatest
levels at times of extensive tissue remodelling, ie menstruation and early pregnancy,
thus we can infer that there is a role for local modulation of Cortisol expression in the













Figure 3.15 Schematic diagram summarising expression patterns of
11 (3HSD-1 and -2 enzymes, GR and MR across the menstrual cycle.
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Chapter 4:
Cytokine control of glucocorticoid metabolism
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4.1 Introduction
Cytokines are small glycoproteins that can have pro- and anti-inflammatory effects.
They are produced by virtually all cells and can be split into two groups, T-helper 1
(TH1) and T-helper 2 (TH2) cytokines. TH1 cytokines generally have a pro¬
inflammatory action whereas TH2 cytokines are anti-inflammatory. Cytokines are
expressed in the human endometrium by the lymphoid, stromal and epithelial cells
(Hunt & Pollard, 1992; Tabibzadeh & Sun, 1992). A number of investigators have
contributed to the hypothesis that a TH1 response is detrimental to pregnancy and
TH2 response is beneficial (Wegmann et al., 1993; Lim et al., 1998; Hill & Choi,
2000).
11 (IHSD-l and -2 act as a glucocorticoid "shuttle" interconverting the active and
inactive glucocorticoids, Cortisol and cortisone respectively in humans. Cortisol acts
as an anti-inflammatory agent via the glucocorticoid receptor (GR), but also binds
with high affinity to the mineralocorticoid receptor (MR). Consistent with Cortisol's
anti-inflammatory action, it is predicted that during periods of inflammation,
1 ipHSD-1 expression will predominate, as shown in section 3.3 of this thesis. The
regulation and mechanism of action of 1 lpHSDs and the receptors for
glucocorticoids, are consequently of interest.
Studies on the regulation of glucocorticoid-metabolising enzymes have shown that a
number of factors including cytokines can modulate the expression of lipHSD-1 and
-2. Of these cytokines, a number of studies have focussed on the actions of
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interleukins, in particular interleukin 1 (IL-1). This is a pro-inflammatory TH1
cytokine. There are two forms of IL-1, IL-1 a and IL-1 p. Both forms have similar
action and act through the same receptor. IL-1 p is not expressed in proliferative and
early secretory endometrium; however, IL-1a is expressed throughout the cycle
(Tabibzadeh & Sun, 1992). Studies in our laboratory have investigated the effects of
IL-1 a and a number of other cytokines on 1 ipHSD-1 mRNA expression. Rae et al.
(2004a) and Yong et al. (2002) have found 1 IpHSD-1 to be upregulated by IL-1 a in
human ovarian surface epithelium cultures. They also found that the co-incubation
with Cortisol amplified this response.
A number of studies have shown a similar response in different cells for example
glomerular mesangial cells (Escher et al., 1997) and cells of the airway (Feinstein &
Schleimer, 1999). Thus it could be proposed that epithelial cells behave similarly
regardless of the tissue type. Against this background, it would be expected that both
the surface and glandular epithelia of the endometrium may behave in a similar
manner to the ovarian surface epithelium. The endometrium, however, is a
heterogeneous tissue, consisting of a large stromal component as well as epithelia
and other cell types. The predominant cell type in the stromal compartment is a
fibroblast-like cell. Thus, when investigating the effects of cytokines on
glucocorticoid metabolism and action, it is desirable to study both stromal and
epithelial cells.
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The hypothesis is that endometrial epithelial cells are regulated in a similar manner
to those in the ovarian surface epithelia, in that expression of lipHSD-1 was
increased in response to IL-la and attenuated by Cortisol.
Hence the aims of this study were:
To treat endometrial epithelial and stromal cells with increasing doses of IL-la and
measure response using the following end-points:
1 ipHSD-1 and -2, GR and MR mRNA expression.
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4.2 Materials and Methods
4.2.1 Subjects and Tissue Collection
Ethical approval and informed consent was obtained from all women who agreed to
participate in these studies. Endometrial biopsies were collected from 14 women
attending the out-patient clinic for investigation of benign gynaecological complaints
or for surgical management ie hysterectomy, as described in 2.1. Subjects were all
healthy women of reproductive age, and taking no steroidal medication, however not
all had regular menstrual cycles. Details of the samples are given in Table 4.1.
Table 4.1 Endometrium samples used in this chapter
Sample E2 level at
time of biopsy
(pmol/1)
P4 level at time of
biopsy (nmol/1)
Histological dating
1 59 1 Late secretory
2 504 72 Early secretory
3 479 20 Unclear
4 229 16.8 Proliferative
5 245 1.7 Unclear
6 150 3.1 Menstrual
7 266 58 Unclear
8 153 2.2 Inactive
9 356 118.9 Mid secretory
10 98 2. Late secretory
11 479 4.2 Proliferative
12 856 18.5 Early secretory
13 255 24 Unclear
14 396 36.6 Mid secretory
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4.2.2 Cell culture
Samples were collected in Dutch Modification RPMI culture medium (Sigma). The
biopsies were then washed in Dulbecco's PBS (Sigma), and a cell separation
protocol carried out as described in 2.8. Isolated stromal cells were then cultured in
Dutch Modification RPMI medium (Sigma) containing fetal calf serum, penicillin,
streptomycin, L-glutamine and gentamycin (all Sigma), known as "F" medium.
Epithelially enriched cells and cells collected from the surface of the endometrium
with a brush were cultured in "HOSE 1" medium as described in section 2.8. (1:1
vol/vol 199 medium:MCDB105, fetal calf serum, streptomycin, penicillin and L-
glutamine; all Life Technologies). This collection and separation method is described
in detail in 2.8.
4.2.3 Incubation of cells with IL-1a
When the cultured stromal, epithelially enriched and surface cells (as described in
2.8) were fully confluent, they were removed from culture flasks using lx
Trypsin/EDTA treatment (5 minutes at 37°C; reaction stopped with serum-
containing medium), centrifuged at 2000rpm for 3 minutes and the supernatant
discarded. The pellet was resuspended in the appropriate medium and cell counts
performed on a small aliquot using a haematocytometer. Cells were diluted to a
concentration of 200,000 cells/ml medium and transferred to 6-well 35mm plates
(1ml/well). The volume in each well was adjusted to 3ml with serum-containing
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medium. Cells were incubated overnight at 37°C, then transferred to serum-free
medium. The cells were again cultured overnight at 37°C.
Cells were then treated with either 50, 500 or lOOOpg/pl IL-la in the presence or
absence of lpM Cortisol in serum-free medium and cultured for 48 hours at 37°C.
All concentrations used were based on those used by Rae et al. (2004a) in their
investigation of the effects of cytokines on glucocorticoid metabolism in ovarian
•3
surface epithelial cells. Where Cortisol was added to the reaction mix, 10" M stock
was added (usually 3pi) to give a final concentration of lpM. Cells were treated with
these reaction mixes at 37°C for 48 hours, then harvested. Cultures with no added
Cortisol had 3pl ethanol vehicle added instead.
4.2.4 Cell harvesting
Culture medium was removed from the cells. Two methods of removing cells from
the culture plates were used. In the first method, 1% Trypsin/EDTA was applied as
described in 4.2.3, then the cells were scraped with a pipette tip and transferred to a
2ml tube. These cell suspensions were centrifuged at 2000rpm for 5 minutes,
supernatant removed and the pellet resuspended in lysis buffer from the Qiagen
RNeasy mini-kit. Cells were then passed through a 19-gauge needle to break them
and then frozen at -70°C for later RNA extraction.
After the initial experiments it was clear that the yield of RNA was not as great as
would be expected, so an alternative method of cell harvesting was sought. This .
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involved washing the cells in PBS and pipetting lysis buffer directly onto the culture
plates, before scraping the cells and repeatedly pipetting. The suspension was
transferred to a 2ml tube, passed through a 19-guage needle and frozen at -70°C as
before. A greater yield of RNA was obtained using this method.
4.2.5 Confirmation of cell type using cvtokeratin staining
Epithelial cells were identified using immunocytochemistry with an antibody that
detects cytokeratins 5, 6, 8 and 17 (Dako). This was done using standard
immunohistochemical technique as described in 2.6, with the following
modifications.
When cells were plated for culture, a small drop of each sample was placed in a well
of a 6-well chamberslide (Nunc) and cultured at 37°C for 48 hours. Medium was
then removed and the cells washed with PBS. Cells were then fixed for 10 minutes at
-20°C in cold methanol and washed in PBS. Normal goat serum was then applied for
30 minutes and the primary antibody applied and incubated overnight at 4°C. The
following day the cells were washed in PBS and the secondary antibody (biotinylated
goat anti-mouse, Vector) applied for 30 minutes at room temperature. The cells were
again washed in PBS and ABC-HRP solution applied (Dako) for 30 minutes.
Following a wash with PBS, the plastic casing was removed and cells stained with
DAB, counterstained with haemotoxylin and mounted in Pertex (Cellpath, Hemel
Hempstead, UK).
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4.2.6 RNA extraction and reverse transcriptase-PCR
RNA was extracted using an RNeasy Mini Kit (Qiagen) as described in 2.3.2, with
the modification as described in the manufacturer's handbook and in 2.3.2 of this
thesis. After freezing cell homogenates in lysis buffer, they were heated to 37°C in a
water bath for 20 minutes before beginning the extraction with the addition of 70%
ethanol. RNA was then stored at -70°C, and 1pi used to measure RNA concentration
and quality using an Agilent 2000 Nano Bioanalyser as described in section 2.5.
There was found to be no difference in RNA quality between the two cell harvesting
methods.
Reverse transcriptase-PCR was performed using standard conditions as described in
section 2.6.
4.2.7 Quantitative Real-Time PCR (QRT-PCR)
Oligonucleotide forward and reverse primers, and oligonucleotide Taqman probes
were used to detect the sequences of interest. The probes used were designed using
Primer Express software as previously described (11 (fHSD-l, -2, GR) (Rae et al.,
2004a; Henderson et al., 2003) or commercially available from Applied Biosystems
Assay on Demand service (MR). The sequences of the primer/probe sets have been
shown previously in Table 3.4. Quantitative Real-time PCR was performed using a
7900 sequence detection system and analysed as described in section 2.7.
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4.3 Results
4.3.1 Expression of 11BHSD-1 in response to treatment with IL-1a and
Cortisol
Expression of 11 (3HSD-1 was increased significantly in endometrial fibroblasts
following treatment with IL-la, however addition of Cortisol had no effect. Maximal
upregulation of lipHSD-1 mRNA was seen with 500pg/ml IL-la, with a 10-fold
increase over untreated control. In an epithelially enriched population of cells, a
similar trend was seen, with IL-la causing an upregulation of lipHSD-1 expression
maximally at a dose of 500pg/ml, however addition of Cortisol in this case showed a
further increase. Cells taken from the surface of the endometrium exhibited a small
increase in lipHSD-1 expression with IL-la treatment, although this increase did
not become significant until the dose of IL-la was lOOOpg/ml. When lpM Cortisol
was added however, a significant increase in expression of lipHSD-1 was seen with
only 50pg/ml IL-la, and a highly significant increase at 500pg/ml. Cortisol alone had
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IL-1a dose (pg/ml)
Figure 4.1 Expression of 11PHSD-1 mRNA in response to increasing doses
of IL-1 a in the presence and absence of Cortisol, mean ± SEM. RNA levels
are measured as a fold change relative to untreated control. A: endometrial
stromal cells (n=5), B=epithelially enriched cells (n=4), C= mixed cells
brushed from endometrial surface (n=5). The comparator was the untreated
control for each sample.*p<0.05; **p<0.01, ***p<0.001 compared to
untreated control. Note the differing scales on the vertical axis between the
cell types. Stage of cycle had no significant bearing on response.
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4.3.2 Expression of 11BHSD-2 in response to IL-1a and Cortisol treatment.
No significant difference in lipHSD-2 expression was seen in endometrial stromal
cells when treated with increasing doses of IL-la in the presence or absence of
Cortisol. In epithelially enriched cultures, there was a small increase in lipHSD-2
expression with treatment with 50-500pg/ml IL-la, however this was not statistically
significant. Cortisol had no effect on 1 ipHSD-2 mRNA levels in these cells.
11PHSD-2 was not detectable by QRT-PCR in cells from the surface of the
endometrium before or after treatment with IL-la and/or Cortisol. These data are
shown in the charts in Figure 4.2.
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IL-1a dose (pg/ml)
Figure 4.2 Expression of 11(BHSD-2 mRNA in response to increasing doses
of IL-1 a in the presence and absence of Cortisol, mean ± SEM. RNA levels
are measured as a fold change relative to untreated control. A: endometrial
stromal cells (n=5), B=epithelially enriched cells (n=4). The comparator was
the untreated control for each sample. 1 ipHSD-2 was not detectable in cells
from the endometrial surface.
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4.3.3 Expression of GR in response to IL-1a and Cortisol
GR mRNA was expressed in all cell types studied, but expression was not
significantly changed in endometrial stromal cells in response to either IL-la or
Cortisol treatment. In an epithelially enriched population of cells, there was a trend
towards increasing GR mRNA expression after treatment with 50pg/ml IL-la;
however, this was not statistically significant. There was no further increase seen
with increasing doses of IL-la, or with the addition of Cortisol. GR expression in
cells from the surface of the endometrium did not change in response to IL-la or
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Figure 4.3 Expression of GR mRNA in response to increasing doses of IL-1a
in the presence and absence of Cortisol, mean ± SEM. RNA levels are
measured as a fold change relative to untreated control. . A: endometrial
stromal cells (n=5), B=epithelially enriched cells (n=4), C= mixed cells
brushed from endometrial surface (n=5). The comparator was the untreated
control for each sample.
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4.4.4 Expression of MR in response to IL-1a and Cortisol.
There was no significant change in expression of MR mRNA in response to IL-la or
Cortisol treatment in either endometrial stromal, epithelial, or surface cells. MR


























































Figure 4.4 Expression of MR mRNA in response to increasing doses of IL-1a
in the presence and absence of Cortisol, mean ± SEM. RNA levels are
measured as a fold change relative to untreated control. . A: endometrial
stromal cells (n=5), B=epithelially enriched cells (n=4), C= mixed cells
brushed from endometrial surface (n=5).
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4.4 Discussion
There was a clear increase in lipHSD-1 expression in endometrial stromal cells with
IL-la treatment. lipHSD-1 expression was observed to increase steadily at doses up
to 500pg/ml IL-la, and did not increase significantly further with lOOOpg/ml. Thus
500pg/ml IL-la was found to be the optimal dose to induce lipHSD-1 expression in
agreement with studies on ovarian surface epithelial cells (OSE) by Yong et al.
(2002), who found the same dose of IL-la to be sufficient to induce 11PHSD-1
expression in human ovarian surface epithelial cells.
This increase in expression would lead to an increase in local Cortisol availability in
endometrial stromal cells. Cortisol could act on stromal cells in a paracrine manner
to mediate inflammation in other cell types within the stroma, such as immune cells
or component cells of the vasculature (endothelial and perivascular smooth muscle
cells). Immune cells are often active at the same time as inflammatory molecules to
fight infection or stress. Menstruation is a highly inflammatory process (Critchley et
al., 2001b; Jabbour et al., 2006), and one in which the vasculature has a major role in
the control of bleeding and restriction of blood loss. When progesterone is withdrawn
and the endometrium receives the signal to prepare for menstruation, cytokine
signalling induces increased vascular permeability (Kelly et al., 2002). During the
first 24 hours ofmenstruation, arterioles undergo periods of vasoconstriction, as first
demonstrated by Markee (1940). This in turn leads to hypoxia, which induces the
release of a number of factors associated with inflammation such as prostaglandins.
These factors are the signal for menstruation to begin (Sugino et al., 2004; Jabbour et
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al., 2006). There is an association between activation of pro-inflammatory cytokines
and release of MMPs in menstruation, however it is currently unclear whether this
occurs before or after the vasoconstriction. It has been proposed that IL-1 has a role
in the initiation of menstruation via the stimulation of MMPs and prostaglandins,
(Cole et al., 1995; Kawano et al., 2001; Rossi et al., 2005). Thus it would be
important to modulate the inflammatory process in these cells.
A similar pattern of expression of llpHSD-1 mRNA was seen in epithelially
enriched endometrial cultures following IL-1a and Cortisol treatment. The increase in
11PHSD-1 was much greater in these epithelially enriched cells, a more than 50-fold
increase over control following treatment with 500pg/ml IL-la. The maximal
responsive dose of IL-la was again seen to be 500pg/ml. These data show that IL-la
appears to upregulate lipHSD-1 mRNA expression in endometrial epithelial cells.
Glands are secretory structures in the endometrium responsible for the proteins
secreted by this tissue. Inflammation results in increased secretion of a number of
growth factors, prostaglandins and other factors (Modugno et al., 2005). The glands
are the site of endometrial secretion thus it follows that these secretory cell types
may also be expected to express increased lipHSD-1 leading to increased Cortisol
production. 1 ipHSD-1 protein has also been found to be predominantly expressed in
the glands of the menstrual human endometrium as shown in 3.3.1 of this thesis. At
key times of inflammation in the endometrium, for example implantation and
menstruation, the glands undergo morphological changes and remodelling. In the
process of decidualisation, the glands become atrophic and the cells lose their
columnar shape. At menstruation the entire functional layer of the endometrium is
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shed, the glands first elongating and then commencing to break up. Thus these cells
undergo a large amount of stress in the course of the menstrual cycle. The anti¬
inflammatory action of Cortisol is known to mediate the stress caused by an
inflammatory response, thus it is important that a capacity to produce extra Cortisol is
available. The hypothesis that intracrine formation of Cortisol in OSE cells limits
inflammation and associated tissue injury at the time of ovulation (Yong et al., 2002;
Hillier & Tetsuka, 1998) also applies to the human endometrium, lending weight to
the proposal that epithelial cells behave similarly regardless of the tissue they are in,
and in particular the tissues of the female reproductive tract undergo similar
processes.
In a mixed population of cells containing both surface epithelial cells and stromal
cells, with potentially some contaminating glandular epithelia also, there was once
again an increase in the expression of lipHSD-1 in response to increasing IL-la
dose. There was also an amplification of the response with the addition of Cortisol. In
these cells there was a small further increase in lipHSD-1 expression with lOOOpg
IL-la that was not seen in the other cell populations; however the increase seen with
the addition of Cortisol was not any greater at this dose of IL-la than at 500pg/ml.
Due to the monolayer nature of the surface epithelium it is extremely difficult with
the methods available to get a population of solely surface epithelial cells, thus there
is a great degree of variation between cultures that is reflected in the data. The
surface epithelium is the site of inflammatory reactions. It is the first part of the
functional endometrium to be sloughed off at menstruation and must be penetrated to
allow implantation and embedding of a fertilised embryo. Thus it must also be the
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site of increased local Cortisol production resulting from increased lipHSD-1
expression. There is also evidence of the feed-forward effect of Cortisol discussed
earlier at the surface of the endometrium. These data also mirror those of Rae et al.
(2004), showing that similar processes are mediated in a similar manner at the
surface of both the endometrium and the ovary.
All three cell types (epithelially enriched, stromal, and mixed cells from the
endometrial surface) studied show a broadly similar trend in expression of lipHSD-
1 in response to IL-la plus Cortisol. As reported in other tissues, including the OSE
(Escher et al., 1997; Feinstein & Schlcimcr, 1999; Yong et al., 2002; Rae et al.,
2004a), IL-la upregulates the expression of lipHSD-1 and this effect is amplified
by the addition of Cortisol. As also reported by Rae et al. (2004a) in ovarian surface
epithelium, the maximal dose of IL-la to elicit a maximal response is 500pg/ml.
Despite the failure of cytokeratin staining procedures to identify epithelial cells, the
huge scale difference in lipHSD-1 expression in epithelia compared to fibroblast
cultures is suggestive the IL-la response occurs in the epithelia, and not fibroblasts.
The effect seen in surface cells is at a much smaller scale than that in glandular
epithelia, suggesting that the response is related to the location near the surface of the
tissue rather than the cell composition of the samples.
No significant effect was seen on expression of lipHSD-2 in response to IL-la,
Cortisol, or IL-la plus Cortisol in either endometrial stromal cells or epithelia.
Expression of lipHSD-2 was relatively constant in these cells regardless of
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treatment. There was also no effect of stage of the menstrual cycle as reported earlier
in this thesis (3.3.2), and also in McDonald et al., (2006). Thus it appears that
11PHSD-2 in endometrium is maintained at stable levels and is not influenced by
internal or external factors. Rae et al. (2004a) also found IL-la in the presence or
absence of Cortisol to have no measurable effect on 11PHSD-2 expression in the
OSE, following the hypothesis that epithelial cells of the female reproductive tract
behave similarly regardless of tissue type.
11 PHSD-2 protein has been studied across the menstrual cycle by Smith et al. (1997)
and in 3.3.2 of this thesis (also McDonald et al., 2006). It was found to be
predominantly expressed in the glandular and surface epithelial cells, with no
significant variation across the menstrual cycle. It seems that 11 PHSD-2 is not
affected by fluctuating steroid hormone levels, or by regulatory factors such as
cytokines which have been tested.
11PHSD-2 was not detectable by QRT-PCR in cells taken from the surface of the
endometrium. This is the site that will experience the primary inflammatory response
during tissue remodelling and thus there may be a requirement for the anti¬
inflammatory action of Cortisol, but not for cortisone production. This corresponds to
the findings of Yong et al. (2002) and Rae et al. (2004a) who discovered negligible
expression of 11PHSD-2 in OSE cultures.
GR mRNA was expressed in all cell types studied, although there was no significant
change in GR mRNA expression in the presence of IL-la, Cortisol or the
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combination of the two, compared to untreated cells in endometrial stromal cultures.
There was a trend towards increased GR mRNA in endometrial epithelial cells
following treatment with 50pg/ml IL-la. Addition of Cortisol had no further effect,
nor did increased doses of IL-la. Although this result is not statistically significant, it
is of interest when compared to the findings of Rae et al. (2004a) in studies in
ovarian surface epithelium, who discovered a small but significant increase in GR
mRNA expression in response to IL-la treatment. This trend in expression was not
replicated in cells from the endometrial surface, where no effect of either IL-la,
Cortisol, or IL-la plus Cortisol was seen.
However studies in a number of other cells, such as T cells (Kam et al., 1993), liver
cells (Falus and Beres, 1995; Stith and McCallum 1983; Hill et al., 1988) and lung
cells (Liu et al., 1993; Verheggen et al., 1996) have shown treatment with cytokines
including IL-la to reduce GR expression and function. This seems to be a tissue-
specific response, and Pariante et al. (2006) proposed that it provides a putative
pathway for the immune system to influence the HPA axis and disease expression. In
the female reproductive tract this reduction does not occur, in fact we see a trend
towards increased GR expression following IL-la treatment. This corresponds with
the increased 1 ipHSD-1 expression seen in the same cells, increased GR expression
may further sensitise the cells to the Cortisol regenerated by 1 ipHSD-1. Perhaps GR
in the female reproductive tract behaves differently in response to IL-la to cells in
other tissues due to the repetitive tissue injury and repair that occurs throughout the
cycle, and the need for glucocorticoids to respond and modulate this response.
However in endometrial cells there was only a small change in GR expression in
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response to cytokine treatment, suggesting perhaps that regulation of the anti¬
inflammatory response of glucocorticoids by cytokines occurs at the pre-receptor
level, in the form of modulation of llpHSD-1 expression levels.
There is a correlation between repeated inflammatory events and diseases such as
cancer in the female reproductive tract. It has been proposed by Gubbay et al. (2004;
2005) that the tissue injury and repair that occurs in the ovarian surface epithelium at
each ovulation may contribute to the incidence of ovarian cancer. Gubbay et al.
(2004) also found that ovarian cancer cell lines expressed higher levels of 11 (311SD-2
than those taken from normal ovarian surface epithelium. Thus they proposed a
correlation between increased 11 (3HSD-2 and subsequent reduction of local Cortisol
levels, and incidence of ovarian cancer (Gubbay et al., 2004). It may be postulated
then that increased 11(3HSD-1 at times of inflammation confers some protection to
the tissue against cancer. A similar link between inflammatory processes and
endometrial cancer was postulated by Modugno et al. (2005), and it follows from this
that the increase in 1 ipHSD-1 and GR but not 1 ipHSD-2 seen in endometrial cells
offers some protection to a tissue repeatedly exposed to inflammation.
MR mRNA expression did not differ significantly in the presence of IL-la with or
without the addition of Cortisol in all 3 of the endometrial cell types studied
(epithelially enriched, stroma, and cells from the surface of the endometrium).
Although Cortisol is a glucocorticoid, it binds with high affinity to the
mineralocorticoid receptor also, making MR expression a relevant end-point for this
study. As it was not affected by IL-la or Cortisol, it is suggested that the
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mineralocorticoid pathway is regulated in a different manner to the glucocorticoid
pathway in human endometrium.
There was a large degree of variation between samples in all of these studies. There
is natural variation in levels of gene expression between patients; in this case this
may be increased due to the fact the samples were collected opportunistically from
patients at all stages of the menstrual cycle and some of the patients did not have
regular cycles. Rae et al., (2004b), utilising microarray, found that after 3 weeks in
culture in the presence of serum, any effect of circulating steroids at the time of
collection was nullified, and this also appeared to be the case with the endometrial
cells (based on results shown here and visual observations) however, the stage of the
cycle when the sample was taken would still impact on the relative proportions of
cell types. In epithelially enriched cell populations stromal cells had a tendency to
become more dominant over time so care had to be taken to utilse cells before the
epithelial cells were overgrown. Due to the opportunistic nature of sampling, both
full-thickness endometrial biopsies and pipelle sampling were used, thus the size of
samples varied. Care was taken to minimise this variation, but it was impossible to
remove this effect completely.
Concluding remarks
These studies add weight to the hypothesis advanced by Yong et al. (2001) and Rae
et al. (2004a) that Cortisol operates a feed-forward regulatory mechanism, whereby it
synergistically with IL-la, upregulates its own production via 1 ipHSD-1 expression,
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allowing Cortisol regeneration at the local site of action in the current context in
endometrial epithelial and stromal cells.
Overall, it has been shown that IL-la promotes lipHSD-1 expression in human
endometrium, predominantly in the glandular epithelia, and has a small effect on GR
expression in these cells. llf3HSD-2 and MR expression are not affected by this
cytokine. These data are consistent with the report by Yong et al. (2002) and Rae et
al. (2004a) in the ovarian surface epithelium, suggesting similarities between the two
reproductive tissues, and lending weight to the theory that epithelial cells behave
similarly regardless of tissue type.
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Chapter 5:




Sex steroid hormones are vitally important in the regulation of events in the female
reproductive tract. Both estradiol and progesterone are key, along with a number of
androgens including testosterone and DHEA. Sex steroids are secreted by the ovary and
adrenal gland and transported to target sites in the blood. In addition to these steroids
however, there is tight regulation of sex steroid availability and action at a local, pre-
receptor level. A number of metabolic enzymes are involved in this local regulation of
sex steroids, including the related 3PHSD, 3aHSD (AKR1C) and 17PHSD
dehydrogenase subfamilies.
3pHSDs are involved in the conversion of pregnenolone to progesterone, a key step in
the synthesis of estrogens, androgens, mineralocorticoids and glucocorticoids (Readhead
et al., 1993; Rhee et al., 2003). They are also involved in the metabolism of a number of
androgens. The reactions catalysed by 3pHSD are given in Table 5.1, and illustrated in
the pathway diagram in section 1.2. 3PHSD expression in the endometrium has been
studied by Tang et al. (1993) who found the enzyme to be active in endometrium, and by
Rhee et al. (2003) who found 3PHSD to be expressed throughout the menstrual cycle,
with expression levels increasing in the secretory phase.
The AKR1C and 17PHSD enzymes are involved in the regulation and metabolism of sex
steroids. The reactions performed by the four AKR1C enzymes are shown in Table 5.1.
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The expression of AKR1C enzymes in endometrium has been investigated, but not in
detail. All four AKR1C enzymes were found to be expressed in the uterus at low levels
(Penning et al., 2000), and AKR1C3 (17|3HSD-5) has been shown to be expressed in
both the proliferative and secretory phases (Ito et al., 2006). 17PHSD-2 protein is
expressed in the glandular epithelia in the secretory endometrium, and at negligible
levels in the proliferative phase (Casey et al.; 1994, Burton et al., 2003). 17PHSD-2
mRNA expression however shows the opposite pattern, with expression greatest in the
proliferative phase (Casey et al.; 1994, Mustonen et al.; 1998, Burton et al., 2003). A
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possible explanation for this was given by Burton et al. (2003) of enhanced stability of
mRNA, resulting mRNA persisting for extended periods without being translated.
Expression of the sex steroid receptors in the endometrium has been well characterised
and reviewed earlier in section 1.2.4 of this thesis. PR and AR are expressed at low
levels in the proliferative phase of the cycle and upregulated in the secretory phase
(Slayden et al., 2001; Lessey et al., 1988). ERa and ER(3 on the other hand, are both
found at higher levels in proliferative endometrium (Lessey et al., 1988; Critchley et al.,
2001a). AR is localised to the stromal cells, whereas ERa and PR are predominantly
glandular. ER(3 is also found in the endothelial cells, where ERa is not (Critchley et al.,
2001a).
The aims of this chapter were to study the expression patterns of 3PHSD and AKR1C1-4
in endometrium across the menstrual cycle and in first trimester decidua, using both
mRNA and protein detection techniques.
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5.2 Materials and Methods
5.2.1 Tissue Collection and Subjects
Local ethical approval and informed patient consent were provided for all samples
collected. Samples were collected as described in section 2.1. Briefly, 18 endometrium-
only biopsies were collected at hysterectomy or by pipelle sampling device and used for
the extraction of RNA. Five first trimester decidua biopsies were collected at elective
surgical termination of pregnancy and used for RNA extraction.
34 full-thickness endometrial biopsies were collected at hysterectomy and wax
embedded for use in immunohistochemistry. Five first trimester decidua biopsies were
collected at elective surgical termination of pregnancy and also wax embedded for
immunohistochemistry.
All subjects providing samples were of reproductive age, with regular menstrual cycles
of 25-35 days and had no exogenous hormone treatment in the previous 3 months.
Tissue samples were consistent across three parameters: date of reported last menstrual
period, histological stage and ovarian stage of cycle as determined by serum estradiol
and progesterone concentrations at the time of biopsy, measured by RLA
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The human tissue samples used in this chapter have been previously detailed in Tables
3.1 and 3.2.
5.2.2 RNA extraction and reverse-transcriptase PCR
RNA was extracted using methods described in 2.3.2. lpl was used to measure RNA
concentration and quality using an Agilent 2000 Nano Bioanalyser as described in
section 2.3, and the remaining RNA was stored at -70°C.
Reverse transcriptase-PCR was performed using standard conditions as described in
section 2.4.
5.2.3 Quantitative Real-Time PCR (QRT-PCR)
Oligonucleotide forward and reverse primers and oligonucleotide Taqman probes were
used to detect the sequences of interest. The probes used were commercially available
pre-validated from Applied Biosystems Assay on Demand. The reference numbers of
the primer/probe sets are shown in Table 5.2.2. Quantitative Real-time PCR was
performed using a 7900 sequence detection system and analysed as described in section
2.5.
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Sequences are not available but primer/pro re sets were pre-validated by ABI.
Analysis of data and statistical analysis was performed as described in section 2.7.
5.2.4 Immunohistochemistrv
Immunohistochemistry was performed using antibodies specific to 3PHSD and
AKR1C3 by standard methods as described in Chapter 2 using biotin-conjugated
secondary antibodies and ABC-Elite avidin biotin peroxidase complex (Vector).
Immunoreactivity was detected using the chromagen 3,3'-diaminobenzidine (DAB).
The 3J3HSD antibody was a rabbit polyclonal raised against human recombinant
3PHSD-2 previously in the laboratory. Due to the high similarity between the two
3pHSD isoforms, it detects both 3PHSD-1 and 3PHSD-2. The AKR1C3 mouse
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monoclonal antibody was kindly provided by Prof. Trevor Penning, University of
Pennsylvania (Iin et al., 2004). Semi-quantitative visual analysis and statistics were
performed as described in Chapter 2. The individual conditions for each antibody as
determined by titration are shown in Table 5.3.








3J3HSD 1:500 Goat anti-rabbit,
1:200

















5.3.1 3BHSD-1 mRNA expression in human endometrium
3[3HSD-1 mRNA was not detectable by QRT-PCR in human endometrium at any stage
of the menstrual cycle. The transcript was however expressed in first trimester decidua.
These data are shown in Figure 5.1.
5.3.2 3BHSD-2 mRNA expression in human endometrium
3PHSD-2 mRNA was not detectable after 40 cycles of QRT-PCR in non-pregnant




M P ES MS LS D
Stage of Cycle
n= 4 4 5 4 4 5
Figure 5.1 Expression of 3pHSD-1 mRNA across the menstrual cycle and in
first-trimester decidua, mean ± SEM M = menstrual, P = proliferative, ES = early
secretory, MS = mid secretory, LS = late secretory, D = decidua. As no mRNA
was detectable in any samples other than first trimester decidua it was not
possible to compare samples, so data are represented as mean "ACT" values
(CT for 3PHSD1-CT for 18S) as described in 2.5.2. Statistical analysis was not
possible as 3PHSD-1 was not detectable in any samples other than decidua.
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5.3.3 33HSD protein expression in human endometrium
3(3HSD protein was detected using an antibody raised against recombinant human
3[3HSD2 as described in 5.2.4; however this antibody similarly detects both 3PHSD-1
and -2.
3pHSD protein was localised predominantly to the glandular and surface epithelia, with
some expression in the endothelial cells of the vasculature. Expression of 3PHSD protein
was very low at all stages of the menstrual cycle in non-pregnant endometrium and did
not differ significantly between the functional and basal layers of the endometrium.
In first trimester decidua, immunostaining was stronger than that observed in non¬
pregnant endometrium. Localisation was again primarily located to the glandular and
surface epithelia and vasculature; however there were also low levels of 3PHSD protein
expressed in the stroma.
These data are illustrated in Figures 5.2 and 5.3. Charts showing immunoscores are
included in Figure A5 of Appendix 1.
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Figure 5.2 Immunolocalisation of 3(3HSD protein in the functional layer of the
endometrium and decidua. M = menstrual, P = proliferative, ES = early
secretory, MS = mid secretory, LS = late secretory, D=decidua, +ve= positive






Figure 5.3 Immunohistochemical localisation of 3pHSD in the basal layer of the
endometrium. M = menstrual, P = proliferative, ES = early secretory, MS = mid
secretory, LS = late secretory. Scale bar=10 microns.
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5.3.4 AKR1C mRNA expression in human endometrium
AKR1C1 mRNA was expressed in human endometrium at all stages of the menstrual
cycle, with the apparent greatest expression in the secretory phase, but this difference
was not found to be statistically significant. AKR1C1 mRNA was also expressed in first
trimester decidua at a low level, although not significantly lower than that in non¬
pregnant endometrium.
AKR1C2 mRNA was also expressed in normal endometrium at all stages of the
menstrual cycle. Greatest expression was seen in the mid secretory phase, with very low
levels of expression in the late secretory stage. Again, these differences in expression
were not found to be statistically significant. AKR1C2 mRNA was expressed at low
levels in first trimester decidua.
AKR1C3 mRNA was expressed at all stages of the menstrual cycle. Expression was
significantly greater in the early secretory stage of the cycle than at any other stage.
Expression levels decreased from early to late secretory phases. AKR1C3 mRNA was
expressed at very low levels in first trimester decidua.
AKR1C4 mRNA was not detectable at any stage of the menstrual cycle or in first
trimester decidua after 40 cycles of QRT-PCR.














M P ES MS LS D
Stage of Cycle
n= 4 5 54 4 5
Figure 5.4 Expression of AKR1C1-1C3 mRNA across the menstrual cycle and
in first-trimester decidua, mean ± SEM. M = menstrual, P = proliferative, ES =
early secretory, MS = mid secretory, LS = late secretory, D = decidua).
A=AKR1C1, B=AKR1C2, C=AKR1C3. The comparator was a proliferative
endometrium sample. *p<0.05 compared to other stages of the menstrual cycle.
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5.3.5 AKR1C3 protein expression in human endometrium
AKR1C3 protein was strongly expressed across the menstrual cycle. The protein was
localised to the glands, surface epithelia and was strongly expressed in the endothelial
cells of the vasculature. Expression was similar in both the functional and basal layers of
the endometrium and did not differ significantly across the menstrual cycle. A similar
intensity and pattern of immunostaining was observed in first trimester decidua.
These data are shown in Figure 5.5 and 5.6. Charts showing immunoscores are included
in Figure A6 of Appendix 1.
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Figure 5.5 Immunolocalisation of AKR1C3 (17(3HSD-5) protein in the functional
layer of the endometrium and decidua. Endothelial cells of the vasculature are
indicated with an arrow). M=menstrual, P=proliferative, ES=early secretory,
MS=mid-secretory, LS=late secretory, D=first trimester decidua, +ve= positive
control, human kidney, -ve=negative control, primary antibody substituted for





















Figure 5.6 Immunohistochemical localisation of AKR1C3 (17pHSD-5) in the
basal layer of the endometrium. M = menstrual, P = proliferative, ES = early
secretory, MS = mid secretory, LS = late secretory. Scale bar=10 microns.
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5.3.6 Summary of Protein Expression Data



























++ intense immunostaining +/- mild immunostaining
+ moderate immunostaining - no immunostaining
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5.4 Discussion
Neither 3PHSD-1 nor -2 mRNA was detectable in human endometrium. However
3(3HSD-1 mRNA was found to be present in first trimester decidua.
Immunohistochemical studies showed 3PHSD protein to be predominantly localised to
the epithelial cells, expressed at very low levels in normal human endometrium and
increased in first trimester decidua. These data are consistent with data published by
Rhee et al. (2003) who found 3PHSD to be expressed at low levels in proliferative
endometrium, with a small increase in the secretory phase and a greater upregulation in
first trimester decidua. In the present study, expression patterns have been investigated
across the menstrual cycle differentiating between early, mid and late secretory stages. It
has also been shown here for the first time that 3PHSD protein is expressed at low levels
in menstrual endometrium.
Rhee et al. (2003) also performed RT-PCR to suggest that the 3PHSD isoform present
was 3PHSD-1. The results of the quantitative real-time PCR shown here suggest this is
the case, as 3PHSD-1 mRNA is the only transcript to be expressed in first trimester
decidua, where the most substantial protein expression is observed.
3PHSD expression was seen to be greatest in the early stages ofpregnancy. Ifpregnancy
is detected, progesterone levels are maintained at the increased levels seen in the
secretory phase. As 3PHSD is responsible for progesterone synthesis, this suggests there
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is perhaps a feed-forward mechanism in action whereby progesterone upregulates its
own formation.
Rhee et al. (2003) also proposed that endometrial progesterone may be derived from two
sources. As well as circulating progesterone secreted in the "classical" manner by the
ovary, their report of the presence of P450scc enzyme involved in pregnenolone
formation in human endometrium suggests an alternative local source of progesterone
from local 3pHSD action. This additional source of progesterone becoming available in
early pregnancy may account for the maintenance of elevated progesterone levels
required for pregnancy. Additionally, local progesterone may be necessary to ensure
progesterone-dependent genes are appropriately expressed.
3(3HSD has additional activities besides progesterone formation, including the
metabolism of androgens, in particular of 5aDHT, 5a-androstanediol and DHEA. The
activation or inactivation of androgens, depending on available cofactors, affects the
local steroid balance. The presence of 3[!HSD, as well as other steroidogenic enzymes
could facilitate the endometrium to produce its own steroids, with 3PHSD acting both
early (conversion of pregnenolone to progesterone is a key step in formation of almost
all steroid hormones) and later in the pathway of androgen synthesis.
AKR1C1 mRNA was expressed throughout the menstrual cycle, with greatest
expression in the early and mid secretory phases. The predominant activity of this
enzyme in intact cells is the reduction of progesterone to 20a-hydroxyprogesterone
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(20aOHP), thus deactivating progesterone. Low levels of AKR1C1 would thus be
expected in first trimester decidua, to maintain the elevated progesterone levels required
for successful establishment of pregnancy. Levels of AKR1C1 mRNA were indeed
lower in first trimester decidua than in the secretory endometrium. Lowest mRNA levels
were seen in menstrual and proliferative endometrium. This is also as would be
expected, since estrogen induces glandular proliferation and progesterone has an
inhibitory action (Rizner et al., 2006). This is the stage of the menstrual cycle in which
the functional layer of the endometrium is regenerated following shedding at
menstruation.
AKR1C1 levels have been shown to be elevated in endometrial cancer (Rizner et al.,
2006), thereby keeping local progesterone levels low and removing the inhibitory effect
of progesterone on cell proliferation.
Highest levels of AKR1C1 were seen in the early and mid secretory stages of the cycle,
the time when progesterone expression is greatest. AKR1C1 could be acting here to
modulate progesterone formation and ensure low levels of this steroid are maintained.
AKR1C2 mRNA was expressed across the menstrual cycle; levels were low at all stages
of the cycle, with reduced expression in late secretory endometrium and first trimester
decidua and greatest expression in the proliferative and mid secretory phases. The
predominant activity of this enzyme in intact cells is the inactivation ofDHT to
androstanediol, a potent androgen converted a less potent form of the steroid. Thus, this
162
enzyme has been described as an "off switch" for the androgen receptor (Penning et al.,
2004). The androgen receptor is expressed in greatest levels in the proliferative phase
and a significant decline is seen in the late secretory phase, corresponding with the
decrease in the enzyme that makes available active ligand.
AKR1C3 (17(BHSD-5) mRNA was expressed at all stages of the menstrual cycle.
Expression was significantly upregulated in the early secretory stage of the cycle in
comparison with other stages, thereafter levels decline in the mid and late secretory
stages of the menstrual cycle respectively, before dropping to its lowest levels in first
trimester decidua.
The availability of a specific AKR1C3 (17(3HSD-5) antibody allowed protein
localisation to be studied in the endometrium. Intensity of immunostaining did not vary
across the menstrual cycle. AKR1C3 (17pHSD-5) protein was strongly expressed in the
glandular and surface epithelia, and endothelial cells of the vasculature. Estrogen
receptor |3 (ERfl), but not estrogen receptor a (ERa) has been shown to be expressed in
these cells (Critchley et al., 2001a). This co-localisation suggests the potential prominent
role for this enzyme in the endometrium is in estrogen metabolism, forming estradiol
from inactive estrone.
The localisation of this enzyme to the vasculature also implicates a role in the regulation
of endometrial bleeding. AKR1C3 (17pHSD-5) can also act to reduce progesterone to
20aOHP and thus may be implicated as a contributory factor in the progesterone
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withdrawal associated with the late secretory stage of the cycle leading to menstruation,
alongside the predominant source of progesterone withdrawal, luteal regression.
Both androgen and estrogen metabolism could be implicated in the low levels of
AKR1C3 (17(3HSD-5) mRNA seen in first trimester decidua - high progesterone levels
must be maintained so conversion to 20aOHP is minimised. Additionally, progesterone
must not be opposed by estrogen, thus estradiol synthesis via AKR1C3 (17(3HSD-5) will
also be restricted.
This is the first time AKR1C3 (17PHSD-5) has been studied in any depth in the human
endometrium. A previous report b Pelletier et al. (1999) localised the enzyme to the
glandular and surface epithelium but did not consider the expression of this enzyme
across the different stages of the menstrual cycle, nor did they report any details of
expression in endometrial vasculature.
AKR1C4 mRNA was not detectable in either human endometrium or first trimester
decidua. This confirms previous reports (Penning et al., 2003) that this enzyme is largely
liver-specific and acts to protect the liver from excess circulating hormones.
Previous studies (Burton et al., 2003) showed 17PHSD-2 mRNA to be expressed at
greatest levels in the proliferative phase and downregulated in early secretory
endometrium in a pattern reciprocal to that shown here for AKR1C3 (17PHSD-5). This
suggested the possibility of a "switch" in operation in human endometrium, controlling
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the expression of active androgens and estrogens via 17|3HSD action. This trend was
however not observed at a protein level. Burton et al. (2003) reported 17PHSD-2 protein
expression only in the secretory endometrium; and it has been shown here that AKR1C3
(17PHSD-5) protein is expressed at all stages of the cycle. Additionally, a recent gene
array study showed 17PHSD-2 to be highest in the mid secretory phase (Talbi et al.,
2006).
Previous observations of expression have reported opposing results, with low levels of
17PHSD-2 in proliferative endometrium (Casey et al., 1994). From this we cannot
clearly state that there is a distinct "on-off" switch between active and inactive estrogens
and androgens operated by 17PHSD-2 and AKR1C3 (17pHSD-5), but a variable one.
Control of these steroid hormones is likely to be more complicated and involve a
number of other regulatory factors.
The metabolising enzymes discussed thus far regulate the availability of ligands for the
sex steroid receptors. 3PHSD acts to create progesterone, the ligand for the progesterone
receptor. 3PHSD is expressed in first trimester decidua, mainly in the glandular
epithelia. PR is also expressed in first trimester decidua, but is localised to the stroma. In
order for progesterone locally produced by 3PHSD to act via PR, it must first be
transported to the stromal cells and thus acts in a paracrine signalling manner.
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3[3HSD is also able to act to metabolise androgens and AR is also expressed in the
stromal compartment of first trimester decidua (Milne et al., 2005). Thus, the cognate
receptors for the products of both types of 3PHSD action are present.
AKR1C1 acts to inactivate progesterone by converting it to 20a-hydroxyprogesterone. It
is expressed at greatest levels in the secretory endometrium. Levels of circulating
progesterone are greatest at this stage; PR is also expressed in endometrial stromal cells
in the secretory phase of the cycle. This could further support the suggestion that
AKR1C1 is acting to protect the endometrium from excessive progesterone action.
On the other hand, AKR1C2 is involved in androgen metabolism; producing the potent
androgen DHT. Its expression is also greatest in the mid secretory endometrium, with a
decline in the late secretory phase.
AKR1C3 (17(3HSD-5) is perhaps the most "promiscuous" of the AKR1C enzymes, with
the ability to activate estrogen, activate and inactivate androgens, and inactivate
progesterone. Its expression peaks in early secretory endometrium. At this stage in the
cycle, all three sex steroid receptors are expressed and levels of all three decline as the
cycle progresses, a trend mirrored by AKR1C3 (17PHSD-5). This indicates that
AKR1C3 (17pHSD-5) does indeed have the potential to modulate the expression of all
three types of sex steroid in the human endometrium and indeed may perform more than
one function in this tissue. Furthermore, AKR1C3 (17PHSD-5) very effectively converts
deoxycortisol (DOC) to 20aDOC, ie inactivating the potent mineralocorticoid. This may




In this chapter it has been shown that 3PHSD expression is very low (undetectable by
QRT-PCR and very mild immunoreactivity) in non-pregnant endometrium and
expressed in first trimester decidua. AKR1C1-3 were all found to be expressed across
the menstrual cycle, with AKR1C3 (17PHSD-5) mRNA significantly upregulated in the
early secretory phase. This enzyme showed strong immunoreactivity in glandular and
surface epithelia and endothelial cells. The expression profiles of these enzymes suggest
an ability of the endometrium to produce and regulate the balance of local steroids,
which in conjunction with the cyclical modulation of sex steroid receptors allow careful
local control of sex steroid action
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Chapter 6:
Effects of exogenous steroid administration




Both natural and synthetic steroids have a number of applications in many clinical
situations, including contraception, hormone replacements and management of
menstrual complaints. Levonorgestrel (LNG) is a widely used synthetic progestogen in
contraceptives and is often administered through use of the levonorgestrel intrauterine
system (LNG-IUS).
Levonorgestrel is a potent synthetic progestogen which also has significant androgenic
activity. It is a widely used and highly effective contraceptive when used in the LNG-
IUS. This intra-uterine system is also often used for management ofmenstrual disorders
such as heavy menstrual bleeding (menorrhagia) (Critchley, 2003; Guttinger &
Critchley, 2007).
A common side effect of many progestogen-only contraceptives is that of breakthrough
bleeding; that is unscheduled bleeding between menstrual periods (Milling-Smith &
Critchley, 2005). Breakthrough bleeding is a major reason for discontinued usage of the
LNG-IUS by many women (Findlay, 1996; cited Milling Smith & Critchley, 2005).
However, the exact mechanism of breakthrough bleeding is as yet unknown. A great
deal of the available evidence points to increased fragility of endometrial blood vessels,
changes in local steroid responses and local angiogenesis mediators being some of the
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factors involved (Milling-Smith & Critchley, 2005). Suggestions are that breakthrough
bleeding occurs from a different vascular source to normal menstrual bleeding; from
superficial dilated vessels (Hickey et al., 1996). Vascular fragility may also be increased
(Song et al., 1995). The mechanism leading to aberrant angiogenesis and vascular
fragility is not yet known.
Continuous exposure to an exogenous source of progestogen brings about a number of
morphological changes in the endometrium. The endometrium takes on the appearance
of first trimester decidua and is often described as pseudo-decidualised. In particular, the
stromal cells become enlarged and oedematous and the glandular epithelia lose their
cuboidal shape, flatten, and become atrophic (Phillips et al., 2003). These changes can
be seen within one month of insertion of the LNG-IUS, but further changes are rare with
continued usage. Within 1-3 months of removal of the LNG-IUS, endometrial
morphology returns to normal and users return to complete fertility (Andersson et al.,
1992; Silverberg et al., 1986). Pseudo-decidualised endometrium also expresses a
number ofmarkers of decidualisation such as insulin-like growth factor binding protein-
1 (IGFBP-1) and prolactin (Critchley, 2003).
There are also reports that long-term use of the LNG-IUS can lead to altered patterns of
sex steroid receptor expression, which are discussed further in section 1.3.1 of this
thesis. Levonorgestrel can be metabolised by the same enzymes responsible for
progesterone and androgen metabolism (Lemus et al., 1992). The effects of this
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metabolism may control the binding affinity for LNG to AR and PR (Lemus et al.,
1992).
The aim of this study was to investigate the expression patterns of a number of steroid
metabolising enzymes and receptors in the endometrium of women using the LNG-IUS.
The following end-points were studied at both mRNA and protein levels.
• lipHSD-1 and -2
• GR and MR
• 3pHSD-l and -2
• AKR1C1,1C2 (mRNA only) and 1C3 (17HSD-5)
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6.2 Methods
6.2.1 Subjects and endometrial tissue resource.
Local ethical approval and informed consent was obtained from all subjects.
Biopsies were collected by pipelle sampling device from seven women as described in
section 2.1. These women had regular menstrual cycles of 25-35 days and had a LNG-
IUS in situ, with no other hormonal intervention in the preceding 6 months. These
samples were used for RNA extraction and QRT-PCR.
Biopsies were collected in a similar manner from a group of women attending clinic to
have a LNG-IUS fitted. These women also had regular cycles of 25-35 days and no
hormonal intervention for the preceding 6 months. Biopsies were taken in the
proliferative (n=5) and secretory (n=5) stages of their cycles prior to insertion of the
LNG-IUS, then follow up endometrial biopsies were collected at 1, 3, 6 and 12 months
following insertion (n=5 at each point). These biopsies were fixed in NBF and used for
immunohistochemistry.
These samples were collected for a previous study (Burton et al., 2003) and as there was
insufficient material in this archival resource to complete all the studies required here, a
further group of samples were used. These samples were collected from 5 women as
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described above (samples for RNA extraction). A single biopsy was collected from each
subject, who had a LNG-IUS in situ for varying periods of time. These samples were
fixed in NBF and used in immunohistochemistry.
6.2.2 RNA extraction and reverse-transcriptase PCR
RNA extraction and reverse-transcriptase PCR were performed as described in sections
2.3 and 2.4.
6.2.3 Taqman Quantitative Real-Time PCR
QRT-PCR was performed using standard methods as described in section 2.5.
Oligonucleotide forward and reverse primers, and oligonucleotide Taqman probes were
used to detect sequences of interest. The probes were commercially available from
Applied Biosystems' Assay on Demand service or designed as previously described in
sections 3.2 and 5.2. Details of all primer/probe sets are given in these preceding
chapters. Analysis of data and statistical analysis was performed as described in section
2.5, using one-way analysis of variance. LNG-IUS samples were run alongside the
samples described in section 3.2 (normal endometrium from across the menstrual cycle)
and analysed relative to the same comparator, a proliferative endometrial sample.
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6.2.4 Immunohistochemistrv
Immunohistochemistry was performed with specific antibodies against 11 (3HSD-1 and -
2, GR, MR, 3(3HSD and AKR1C3 (17PHSD-5) and standard methods as described in
section 2.6 using biotin-conjugated secondary antibodies and ABC-Elite avidin biotin
peroxidase complex (Vector). Immunoreactivity was detected using DAB (Dako).
MR immunostaining was performed using a Bond-X automated immunostaining robot
as described in section 2.6.
All the antibodies used, specific conditions and controls were described previously in
sections 3.2 and 5.2. Semi-quantitative visual analysis and statistics were performed as
described in section 2.6 using the Kruskall-Wallis test.
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6.3 Results
6.3.1 11BHSD mRNA expression
llpHSD-1 mRNA was expressed in pseudo-decidualised endometrium at greater levels
than in proliferative and secretory endometrium, but lower than menstrual endometrium.
The level of mRNA expression in pseudo-decidualised endometrium was similar to that
in first trimester decidua. These data were not found to be statistically significant.
lipHSD-2 mRNA was expressed in pseudo-decidualised endometrium. Levels did not
differ significantly from any stage of the normal menstrual cycle. Expression was greater
than in first trimester decidua, although again this increase in expression was not
statistically significant.
These data are shown in Figure 6.1.
6.3.2 113HSD-1 protein expression
Expression of llpHSD-1 protein was very low in LNG-exposed endometrium, this
observation did not differ significantly compared to normal endometrium or first
trimester decidua. lipHSD-1 was mainly expressed in the cytoplasm of the glandular
and surface epithelia. Immunoreactivity was not seen in all samples. These data are
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shown in Figure 6.2. Charts showing immunoscores are included in Figure A7 of
Appendix 1.
6.3.3 11BHSD-2 protein expression
lipHSD-2 protein was localised predominantly to the cytoplasm of the epithelia and
stroma of pseudo-decidualised endometrium. There was an upregulation of expression in
the stromal compartment after 3 months LNG-IUS usage and no further increase over
time, although this was not found to be statistically significant. There was no significant
difference in expression in either the surface or glandular epithelia. Expression in the
vasculature was very low, and variable. It did not differ significantly over time. These







































Figure 6.1 Expression of 11PHSD-1 and -2 mRNA across the menstrual cycle,
in first-trimester decidua, and pseudo-decidualised endometrium, mean ± SEM.
A=11pHSD-1; B=1ipHSD-2. M = menstrual, P = proliferative, ES = early
secretory, MS = mid secretory, LS = late secretory, D = decidua, LNG=LNG
exposed (>1 year). The comparator was a proliferative endometrium sample.
*p<0.05 compared to all other stages of the menstrual cycle.
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Figure 6.2 Immunolocalisation of 11 (BHSD-1 protein in normal and pseudo-
decidualised endometrium (>1 year post-insertion of LNG-IUS). P=Proliferative
endometrium, S=secretory endometrium, D=first trimester decidua,
LNG=pseudo-decidualised endometrium, +ve= positive control, human liver, -
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Figure 6.3 Immunolocalisation of 11PHSD-2 protein expression in normal and
pseudo-decidualised endometrium over a period of 12 months. P=proliferative
endometrium prior to insertion, S=secretory endometrium prior to insertion
(samples collected depending on stage of cycle at time of insertion), 1=1 month
post insertion, 3=3 months post insertion, 6=6 months post insertion, 12=12
months post insertion, +ve= positive control, human kidney, -ve=negative
control, primary antibody substituted for matched IgG.. Sections shown are
representative of each group and did not necessarily come from the same
patient. Bottom right inset shows negative control, primary antibody replaced
with matched IgG. Scale bar=10 microns.
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6.3.4 GR and MR mRNA expression
GR mRNA was expressed in pseudo-decidualised endometrium. Levels did not differ
significantly from any stage of the normal cycle. Expression in pseudo-decidualised
endometrium was greater than in first trimester decidua although this was not
statistically significant.
MR mRNA was expressed in pseudo-decidualised endometrium at broadly similar levels
to all stages of the normal menstrual cycle and first trimester decidua.
These data are shown in Figure 6.4
6.3.5 GR protein expression
GR protein was also expressed in the nuclei of all cellular compartments of pseudo-
decidualised endometrium. There was no significant difference in expression between
pre- and post-insertion samples, or over time in the stroma, vessels, or surface epithelia.
Expression was greatest in the glandular epithelia and was upregulated one month after
insertion of LNG-IUS compared to pre-insertion (proliferative and secretory phase).
There was a small decline in expression after 3 months and thereafter expression was
constant. Again these data were not found to be statistically significant, and are
illustrated in Figure 6.5. Charts showing immunoscores are included in Figure A9 of
Appendix 1.
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6.3.6 MR protein expression
MR protein was expressed most strongly in the glandular and surface epithelia of LNG-
exposed endometrium. There was some expression in the stroma and little in the
vasculature. Expression did not differ significantly from normal endometrium at any
stage of the cycle or first trimester decidua. Expression was predominantly stromal.
These data are shown in Figure 6.6. Charts showing immunoscores are included in
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Figure 6.4 Expression of GR and MR mRNA across the menstrual cycle, in first-
trimester decidua, and pseudo-decidualised endometrium, mean ± SEM. A=GR,
B=MR. M = menstrual, P = proliferative, ES = early secretory, MS = mid
secretory, LS = late secretory, D = decidua, LNG=LNG exposed (>1 year). The
comparator was a proliferative endometrium sample. *p<0.05 compared to all
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Figure 6.5 Immunolocalisation of GR protein expression in endometrium
exposed to LNG over a period of 12 months. P=proliferative endometrium prior
to insertion, S=secretory endometrium prior to insertion, 1=1 month post
insertion, 3=3 months post insertion, 6=6 months post insertion, 12=12 months
post insertion, -ve=negative control, primary antibody substituted for matched
IgG.. Scale bar=10 microns.
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Figure 6.6 Immunolocalisation of MR protein in normal and pseudo-
decidualised endometrium. P=Proliferative endometrium, S=secretory
endometrium, D=first trimester decidua, LNG=pseudo-decidualised
endometrium (>1 year post-insertion), +ve= positive control, human kidney,
-ve=negative control, primary antibody substituted for matched IgG. Scale
bar=10 microns
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6.3.7 33HSD mRNA expression
3(3HSD-1 was expressed in pseudo-decidualised endometrium at greater levels than in
first trimester decidua. There was no detectable expression in normal endometrium.
These data are shown in Figure 6.7.
3PHSD-2 mRNA was not detectable in pseudo-decidualised endometrium, as was also
the case in normal endometrium and first trimester decidua.
6.3.8 33HSD protein expression
3pHSD protein was expressed in the stroma at low levels in all cellular compartments.
There was no difference in expression between pre- and post-insertion samples, or in
any of the timed post-insertion biopsies in the stroma, surface epithelia and vessels.
Greatest expression was seen in the glandular epithelia,with a non-significant increase 1
month after LNG-IUS insertion although expression was still at low levels. There was a
small decline in expression after 3 months post LNG-IUS insertion, although again this
was a non-significant observation. These data are shown in Figure 6.8. Charts showing




























Figure 6.7 Expression of 3(3HSD-1 mRNA across the menstrual cycle, in first-
trimester decidua and pseudo-decidualised endometrium, mean ± SEM. M =
menstrual, P = proliferative, ES = early secretory, MS = mid secretory, LS = late
secretory, D = decidua, LNG=LNG exposed (>12 months). The comparator was
a first trimester decidua sample, used as this group was the only "normal" group
to show any 3(3HSD-1 expression . *p<0.05 compared to first trimester decidua.
Statistical analysis was not possible against normal endometrial samples as
3(3HSD-1 was not detectable. Axis is split to allow both bars to be shown on the
same chart.
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Figure 6.8 Immunolocalisation of 3(BHSD protein expression in normal and
pseudo-decidualised endometrium over a period of 12 months. P=proliferative
endometrium prior to insertion, S=secretory endometrium prior to insertion, 1=1
month post insertion, 3=3 months post insertion, 6=6 months post insertion,
12=12 months post insertion, +ve= positive control, human placenta, -
ve=negative control, pre-immune serum. Scale bar=10 microns
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6.3.9 AKR1C1 -1C4 mRNA expression
AKR1C1 mRNA was expressed in pseudo-decidualised endometrium. Expression was
greater than that seen at any stage of the cycle in normal endometrium, or in first
trimester decidua.
AKR1C2 mRNA expression in LNG-exposed endometrium was at similar levels to first
trimester decidua. Expression did not differ significantly from any stage of the normal
cycle.
Expression of AKR1C3 (17PHSD-5) mRNA in LNG-exposed endometrium was
significantly lower than that in early secretory endometrium. Expression was not
significantly different to any other stage of the menstrual cycle, or first trimester
decidua.
Data are shown in Figure 6.9.
AKR1C4 mRNA was not expressed in pseudo-decidualised endometrium.
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6.3.10 AKR1C3 (17BHSD-5) protein
AKR1C3 (17|3HSD-5) protein was localised to the cytoplasm of the glandular and
surface epithelia and the endothelial cells of the vasculature of pseudo-decidualised
endometrium. Expression was high although there was a small decline in expression in
first trimester decidua and pseudo-decidualised endometrium in comparison to normal
endometrium, but this was not statistically significant. These data are illustrated in


























Figure 6.9 Expression of AKR1C1-1C3 mRNA across the menstrual cycle, in
first-trimester decidua and pseudo-decidualised endometrium, mean ± SEM M =
menstrual, P = proliferative, ES = early secretory, MS = mid secretory, LS = late
secretory, D = decidua, LNG=LNG exposed. A=AKR1C1, B=AKR1C2,
C=AKR1C3 (17HSD-5). The comparator was a proliferative endometrium
sample.*p<0.05 compared to all other stages of the menstrual cycle.
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Figure 6.10 Immunolocalisation of AKR1C3 (17PHSD-5) protein expression in
normal pseudo-decidualised endometrium. P=Proliferative endometrium,
S=secretory endometrium, D=first trimester decidua, LNG=pseudo-decidualised
endometrium, +ve= positive control, kidney, -ve=negative control, primary
antibody substituted for matched IgG. Scale bar=10 microns.
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6.4 Discussion
The 11(3HSD enzymes create a cortisol-cortisone "shuttle" whereby 11 [3HSD-1 converts
inactive cortisone to the active glucocorticoid Cortisol and 11PHSD-2 performs the
reverse reaction in vivo.
11PHSD-1 mRNA was upregulated in LNG-exposed endometrium compared with
proliferative and secretory endometrium. Expression levels were similar to those in first-
trimester decidua, suggesting a similar role for 11PHSD-1 in LNG-exposed
endometrium as in first trimester decidua. Further investigation may allow 11 PHSD-1 to
be defined as a marker of both decidualisation and pseudo-decidualisation. However
11PHSD-1 protein was only expressed at low levels in pseudo-decidualised
endometrium and was not seen in all samples. It seems that the mRNA may not be
translated. As most of the subjects in this group attended clinic due to bleeding problems
while using the LNG-IUS, the precise aetiology of erratic and unsubstantiated bleeding
patterns in these patients is not known although lots of evidence strongly point to
problems of vascular integrity. The upregulation of the mRNA suggests there is some
inflammatory response occurring in pseudo-decidualised endometrium, as is seen in first
trimester decidua. Perhaps patients who did not experience breakthrough bleeding would
have been appropriate controls for this study, however these patients did not return to
clinic for follow-up biopsies other than in the timed study. As there were insufficient
192
samples in this set to conduct all the analyses it was decided to use pre-insertion
endometrium as controls in all experiments.
llpHSD-2 mRNA expression was greater in pseudo-decidualised endometrium than in
first trimester decidua, although this was not statistically significant. Expression did not
differ significantly when compared to any stage of the normal cycle either. This small
increase compared to first trimester decidua could be in order to balance the increase in
11PHSD-1 expression and thus modulate the potential prolonged inflammatory
response. lipHSD-2 protein was studied at timed intervals after insertion of an LNG-
IUS. A small upregulation was seen in expression in the stroma after 6 months of usage.
This is also observed in the first trimester of pregnancy where expression is seen in the
stroma as well as the epithelia. There was no further change in expression over time.
This corresponds with the mRNA data.
The ratio of 11PHSD-1 and -2 expression is also important in modulating the local
availability of Cortisol. In the present study, the increase in expression of 11 PHSD-1
mRNA is greater than the non-significant upregulation of 11PHSD-2 mRNA, thus
favouring 11 PHSD-1 action, leading to the potential for increased Cortisol production.
Small et al. (2005) showed 11 PHSD-1 to amplify the angiostatic effect of
glucocorticoids in a rodent model, and studies in our laboratory have followed up these
observations in human endometrium, and found Cortisol to also inhibit angiogenesis in
the human endometrium.
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Previous studies have shown 11 [3HSD-1 and -2 to be expressed in the blood vessel wall
in humans (Hadoke et al., 2001; Cai et al., 2001; Christy et al., 2003). Expression of
both 11PHSD-1 and -2 was detected in the vasculature in the present study, although at
low and variable levels in both non-pregnant and pseudo-decidualised endometrium.
However there was no significant difference between normal and LNG-exposed
endometrium, thus we cannot draw any firm conclusions as to the role of 11 [3HSD-1 and
-2 in the aberrant bleeding often experienced by users of the LNG-IUS.
It has been proposed that breakthrough bleeding may be a result ofMMP activation
(Hickey and Fraser, 2000), and glucocorticoids are thought to be regulators ofMMPs.
Thus alterations in lipHSD expression, and consequently glucocorticoid availability,
could have an indirect effect in pseudo-decidualised endometrium and contribute to
breakthrough bleeding.
The corresponding cognate receptors for Cortisol, GR and MR, were also studied. GR
mRNA expression in LNG-treated endometrium was not significantly different to
normal endometrium or first trimester decidua, although there was a small increase in
comparison to the first trimester decidua. This corresponds to the slightly increased
11PHSD-1 mRNA, which can allow increased Cortisol availability and elicit a
glucocorticoid response via the GR. GR protein was also studied in timed biopsies after
insertion of LNG-IUS. Expression was seen in both glandular and stromal
compartments, as is the case in first trimester decidua. There was a small non-significant
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increase in glandular epithelia one month after insertion, which again corresponds to the
small increase seen at the mRNA level.
GR protein was also expressed consistently in the nuclei of endothelial cells of both non¬
pregnant and pregnant endometrium and pseudo-decidualised endometrium following
LNG-IUS use. GR has been previously reported to be expressed in the endothelial cells
of both endometrium and decidua (Bamberger et al., 2001; Henderson et al., 2003). This
suggests that breakthrough bleeding associated with LNG-IUS useage is unlikely to be
due to altered GR expression in the endothelium. However, this study did not take into
account expression levels at different tissue locations. It has been previously reported
that breakthrough bleeding occurs from more superficial, dilated vessels (Hickey et al.,
1996) so perhaps an alteration would be seen in GR or 1 ipHSD-1 expression if these
superficial vessels were compared to those deeper into the tissue.
MR mRNA was expressed in LNG-exposed endometrium and levels did not
significantly differ from any stage of the cycle or first trimester decidua. This was
mirrored by the protein expression which was localised to the epithelia. This suggests
any effect of Cortisol on LNG-exposed endometrium is likely acting through the
increased levels of GR. The small increase in ll(5HSD-2 seen will add further protection
to MR and direct Cortisol to bind to the GR. This also suggests there is no additional
requirement for mineralocorticoid action in response to continual exposure to
progestogen.
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3(3HSD-1 and -2 are isoforms of an enzyme that produces progesterone from
pregnenolone and also has the ability to metabolise a number of androgens.
3(3HSD-1 mRNA was upregulated in both pseudo-decidualised endometrium and first
trimester decidua compared to normal endometrium. There was a further significant
increase in expression in pseudo-decidualised endometrium compared to first trimester
decidua, although expression levels remained very low. This could be due to
progestogen (LNG) acting in a feed-forward manner to further increase the level of
progesterone available. It has been shown that that Cortisol acts on 11(3HSD-1 in this
manner (Yong et al., 2002; Rae et al., 2004a). 3PHSD-2 mRNA was not detectable in
pseudo-decidualised endometrium. 3PHSD protein (studied using an antibody that
detects both isoforms, as described in section 5.2) was expressed in the glands and some
expression was seen in the vasculature of LNG-exposed endometrium. This suggests
3PHSD and perhaps the corresponding progesterone increase has a role in the regulation
of bleeding. However, as progesterone is withdrawn in the absence of pregnancy and
induces bleeding, it may be that 3PHSD is acting on androgens to cause irregular
bleeding, The precise role of androgens in the endometrium has not yet been well
defined, however they have been proposed to have an inhibitory effect on the female
reproductive tract, including endometrial atrophy (Miller et al., 1986; Futterweit &
Deligdisch, 1986; Slayden et al., 2001). Okon et al. (1998) showed exogenous androgen
to block estrogen action in the endometrium of ovariectomised macaques. Androgens act
via the AR, the expression patterns of which are the subject of some conflict between
researchers, perhaps due to differences in immunohistochemical methods. Horie et al.
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(1992) and Ito et al. (2002) have found AR to be expressed in both glandular and stromal
cells of the endometrium, whereas other authors have reported stromal localisation of
AR (Maia et al., 2001; Mertens et al., 2001; Slayden et al., 2001). Slayden et al. (2001)
have also reported AR to be expressed in the endometrium in a similar manner to ER
and PR; greatest expression in the estrogen-dominated proliferative phase and
downregulated in the secretory phase. AR is also expressed in decidual stromal cells and
endothelial cells (Milne et al., 2005). In endometrium exposed to levonorgestrel, there is
a significant decrease in AR expression in the stroma, to levels similar to those seen in
the secretory phase (Burton et al., 2003). It has been shown previously that PR is
downregulated in pseudo-decidualised endometrium (Critchley et al., 1998), and
consequently the endometrium is less responsive to progesterone-mediated events. This
may be a response to counter the continual exposure of the endometrium to progestogen
and thus lends weight to the theory that 3PHSD is acting on androgen metabolism in this
tissue, rather than progesterone formation.
The predominant activity ofAKR1C1 is to reduce progesterone to 20a-
hydroxyprogesterone, a less potent ligand. AKR1C1 mRNA expression was upregulated
in relation to normal endometrium and first trimester decidua. Thus AKR1C1 may act in
balance with 3[3HSD to modulate the availability of active progesterone. AKR1C1 may
also be responsible for bringing about a progesterone withdrawal response and inducing
bleeding in users of the LNG-IUS. Unfortunately it was not possible to study this
enzyme in timed biopsies following insertion, to investigate whether AKR1C1
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expression is downregulated after a period of LNG-IUS use, corresponding to the
reduction in bleeding experienced in many users in time.
AKR1C2 acts to reduce potent androgens to less potent forms. AKR1C2 mRNA
expression in pseudo-decidualised endometrium was similar to that in both normal
endometrium and first trimester decidua. As there is no difference in AKR1C2
expression in pseudo-decidualised endometrium, it is unlikely that AKR1C2 plays a
major role in the problem of breakthrough bleeding.
AKR1C3 (17PHSD-5) acts to produce active androgens and estrogens from less potent
forms. AKR1C3 (17PHSD-5) mRNA was significantly reduced in pseudo-decidualised
endometrium compared to early secretory endometrium, but did not differ significantly
from the other stages of the cycle. Expression was low in both first trimester decidua and
LNG-exposed endometrium. In first trimester decidua, estrogen levels are low, as would
be expected in pseudo-decidualised endometrium. Thus, low expression of AKR1C3
will help to maintain these low estrogen levels. However AKR1C3 protein was highly
expressed in LNG-exposed endometrium at levels not significantly different to those in
normal endometrium or first trimester decidua, although there was a small non¬
significant decline in both first trimester decidua and pseudo-decidualised endometrium.
Protein expression was localised to the epithelia and endothelial cells of the vessels.
Strong expression in the vasculature implies a role for AKR1C3 in the regulation of
bleeding. Reduced levels ofAKRlC3 (17PHSD-5) would lead to reduced local amounts
of both estrogen and testosterone. The cognate receptors for these steroids, ER and AR
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have also been shown to be downregulated in pseudo-decidualised endometrium
(Critchley et al., 1998; Burton et al., 2003).
AKR1C4 controls the expression of 5a/5tetrahydrosteroid. It was not expected to
detect AKR1C4 in pseudo-decidualised endometrium, as this enzyme has been
previously reported to be liver specific, and was also shown in section 5.3 of this thesis
not to be detectable in normal human endometrium, and this was indeed shown to be the
case. AKR1C4 expression is not induced by continued exposure to progestogen.
Concluding remarks
Table 6.1 summarises the expression patterns of the enzymes studied in endometrium
exposed to LNG, and the effect on steroid hormone activity.
Table 6.1 Summary of enzyme expression.
Enzyme mRNA Protein Predominant Product Activity
expression Expression
llpHSD-1 T 1 Cortisol T
1 ipHSD-2 T <—> Cortisone 1
3(3HSD-1 T n/a Progesterone, testosterone t
3PHSD-2 - t Progesterone, testosterone t
AKR1C1 r n/a 20aOHP 1
AKR1C2 <—> n/a Androstendiol/testosterone <—»
AKR1C3 i <—> Androstenedione, estrone 1
Many of the steroid metabolising enzymes and receptors studied here are expressed in
similar patterns in LNG-exposed endometrium and first trimester decidua, consistent
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with observations that LNG induces morphological pseudo-decidualisation. There are,
however, some differences, notably in 3PHSD expression. It would be desirable to
further understand the mechanisms relating to breakthrough bleeding, and a possible
method for this would be to study these and other enzymes and receptors in users of the
LNG-IUS who have had breakthrough bleeding, in comparison with those who have not.
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Chapter 7:
Effect of exogenous steroid manipulation (GnRH




Gonadotrophin-releasing hormone (GnRH) antagonists, of which Cetrorelix is an
example, have recently become widely used in treatment of sub-fertility. During in-vitro
fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI), treatment protocols, it is
desirable to prevent a premature luteinising hormone (LH) surge (Olivennes et al., 2000;
Albano et al., 2000). GnRH antagonists suppress LH and consequently eliminate the
possibility of a premature LH surge (Albano et al., 2000). An advantage of using GnRH
antagonists for this purpose instead of the previously used GnRH agonists is that there
are no menopausal side effects caused by the estrogen deprivation associated with
GnRH agonist treatment. The amount of gonadotrophs required is also reduced with
GnRH antagonist treatment.
There are concerns however about a potential reduction in pregnancy rates when GnRH
antagonists are used in IVF/ICSI treatments, compared with the use of GnRH agonists
(Al-Inany et al., 2002). This area is controversial as some studies have shown both
methods to produce similar pregnancy rates (Ludwig et al., 2001). It is however
currently unclear how these treatments affect the reproductive system. In particular,
effects of GnRH antagonists on the endometrium are not well described. There is
however evidence of premature advancement of the endometrium at the time of oocyte
retrieval following use of GnRH antagonists and recombinant follicle stimulating
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hormone (recFSH) (Kolibianakis et al., 2002; 2003). This has been associated with
failure of implantation.
The mechanisms involved in implantation have received considerable attention, however
they have not yet been fully elucidated. Implantation involves an interaction between the
endometrium and embryo, mediated by a number of factors including growth factors
(Bausero et al., 1998), hormones, adhesion molecules (Home et al., 2000; Lessey, 2002),
extracellular matrix molecules (Jokimaa et al., 2000), cytokines and prostaglandins
(Kelly et al., 2001). Sex steroids, in particular estrogens and progestogens are thought to
play vital roles in endometrial development. These steroid ligands act via their cognate
receptors (PR, ER, AR). The expression of these sex steroids and their cognate receptors
is reviewed in section 1.2.4 of this thesis.
The ovarian stimulation that occurs during IVF and ICSI causes the levels of
gonadotrophins to rise beyond physiological levels and this consequently has an effect
on the expression of sex steroid receptors in the endometrium. A recent study in our '
laboratory (Vani et al., 2007) has shown that the local expression of sex steroid
receptors, in particular ERa and PR, are perturbed. Thus it was desirable to investigate
the effect of this GnRH antagonist administration on expression of the enzymes that
control availability of ligands for ER and PR - estrogens and progesterone and DHEA to
androstenedione. 3(3HSD-1 and -2 are involved in the biosynthesis of all active steroids
by catalysing one of the first steps, the conversion of pregnenolone to progesterone.
17PHSD-2 and -5 (AKR1C3) act to modulate the availability of androgens and
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estrogens. The key reactions of these enzymes have been summarised previously in
Table 5.1. Thus, expression of 17PHSD-2 and AKR1C3 (17PHSD-5) and 3pHSD-l and
-2 were examined in endometrium exposed to GnRH antagonist treatment.
The aims of this chapter were to investigate the effects of GnRH antagonist treatment on
endometrial expression of steroid metabolising enzymes, at both an mRNA and protein






7.2 Materials and Methods
7.2.1 Subjects and tissue resource
Ethical approval and informed consent were obtained from all subjects. Five parous
women who had come forward as oocyte donors were recruited as the study group.
These women were donating eggs for use in fertility treatment by other patients and
were not undergoing fertility treatment themselves.
Members of the study group underwent oocyte stimulation using the local assisted
conception protocol as described by Thong et al. (2003). Briefly, recombinant FSH
(Gonal-F, Serono, UK) treatment began on day 4 of their menstrual cycle to stimulate
the ovaries. Cetrorelix (a GnRH antagonist) was administered daily from day 7 or 8,
when follicles were measured to have reached 11mm and a transvaginal ultrasound was
used to monitor the ovarian response. When 3 follicles with a diameter of at least 17mm
were identified, hCG was administered to trigger oocyte maturation. Oocytes were
retrieved 35-36 hours after hCG. Progesterone was then administered via a pessary every
12 hours from 2 days after oocyte retrieval until the endometrium was to be sampled.
This is shown in schematic form in Figure 7.1. Endometrial biopsies were collected 8-10
days after hCG administration using a pipelle sampling device. These samples were
used for immunohistochemistry.
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Eight parous women with regular menses (25-35 days) were recruited as controls. These
subjects were asked to provide a urinary sample on alternate days from day 10 of their
cycle and LH levels in these samples were measured. Endometrial biopsies were
performed 6-10 days after the peak of a urinary LH surge as shown in Figure 7.1. These
women attended the gynaecology clinic for sterilisation or other complaints excluding
menstrual problems or infertility. In all these women, the last menstrual period,
endometrial histology and serum estradiol and progesterone levels were consistent with
the mid secretory phase of the cycle, as the putative window of implantation falls within
this phase.
Endometrial tissue was fixed in 4% paraformaldehyde then imbedded in paraffin for
immunohistochemistry. Additional tissue was frozen at the point of collection in liquid
nitrogen and stored at -70°C.
Study group: Cetrorelix
Gonal - F Progesterone
D1 start D4 start D8 scan; hCG OR EB




Urinary LH surge EB
Figure 7.1 Diagrammatic representation of the Edinburgh Assisted Conception
Protocol. D=day of cycle; hCG= human chorionic gonadotrophin administration;
OR=oocyte retrieval; EB=endometrial biopsy (from Vani et al., 2007).
206
7.2.2 RNA extraction and reverse-transcriptase PCR
RNA extraction was performed using Trizol (Invitrogen) as described in section 2.3.3.
The resulting RNA was treated with DNAsel, Amp grade lU/pg RNA in DNasel
reaction buffer for 15 minutes at room temperature and the reaction stopped by the
addition of EDTA. Reverse-transcriptase PCR was performed using standard methods as
described in 2.4.
7.2.3 Taqman Quantitative Real-Time PCR
QRT-PCR was performed using standard methods as described in Chapter 2.5.
Oligonucleotide forward and reverse primers and oligonucleotide Taqman probes were
used to detect sequences of interest. The probes were commercially available from
Applied Biosystems' Assay on Demand service or designed as previously described by
Burton et al. (2003). The primer/probe sets from the Assay on Demand service were pre-
validated and the sequences are not available. The reference numbers were given









Analysis of data and statistical analysis was performed as described in section 2.5 and
the data were log-transformed to allow statistical analysis on the small sample set and an
unpaired t-test was performed.
7.2.4 Immunohistochemistrv
Immunohistochemistry was performed using antibodies specific to 3PHSD and
17PHSD-5 and standard methods as described in 2.7 and using biotin-conjugated
secondary antibodies and ABC-Elite avidin biotin peroxidase complex (Vector).
Immunoreactivity was detected using DAB (Dako).
All the antibodies used were described previously in 5.2.4. The 3PHSD antibody, as
described previously, detects both 3PHSD-1 and -2. A suitable antibody was not
available for 17PHSD-2. Semi-quantitative visual analysis was conducted by two




7.3.1 33HSD mRNA expression
Low levels of 3(3HSD-1 mRNA were seen in mid-secretory control endometrium and
these levels were further reduced in GnRH antagonist treated endometrium. This was
found to be statistically significant (p=0.01). 3(3HSD-2 mRNA was expressed at very
low levels in mid-secretory endometrium, but was not detectable at all in GnRH-
antagonist treated endometrium after 40 cycles of QRT-PCR. For comparison, 3[3HSD-2
mRNA was detected in the control samples after 38 cycles of QRT-PCR. These data are
shown in Figure 7.2.
7.3.2 33HSD protein expression
3pHSD protein was predominantly expressed in the glandular and surface epithelia of
both GnRH-antagonist treated endometrium and control endometrium. The protein was
expressed at low levels and expression did not differ significantly between control and
treated endometrium. These data are shown in Figure 7.3. Charts showing






Figure 7.2 Expression of 3(3HSD-1 and -2 mRNA in GnRH-antagonist treated
endometrium compared to normal mid-secretory endometrium (control), mean ±
SEM. The comparator was an untreated control sample. A=3pHSD-1,
B=3pHSD-2. It was not possible to conduct statistical analysis on the 3(3HSD-2
data as the mRNA was not detectable in one of the groups.
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Figure 7.3 Immunolocalisation of 3|3HSD protein in GnRH-exposed
endometrium (treated) compared to normal mid-secretory stage endometrium
(control), +ve= positive control, human placenta, -ve=negative control, pre-
immune serum. Scale bar=10 microns.
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7.3.3 17BHSD mRNA expression
17PHSD-2 expression was downregulated in GnRH-antagonist-treated endometrium
compared to mid-secretory stage control endometrium. This was found to be statistically
significant although levels were low in both treated and untreated endometrium
(p=0.02). 17|3HSD-5(AKR1C3) mRNA expression was downregulated in GnRH-
antagonist-treated endometrium compared to mid-secretory stage control endometrium.
There was only sufficient RNA of suitable quality left available for 170HSD-2 transcript
analysis in two samples in the study group, therefore it was not possible to perform valid
statistical analysis on 17(3HSD-5 data. These data are shown in Figure 7.4.
7.3.4 AKR1C3 (17BHSD-5) protein expression
AKR1C3 (17PHSD-5) protein was expressed in the glandular epithelia and endothelial
cells of both GnRH-antagonist-treated and untreated endometrium. Immunoreactivity
was intense in both groups and did not differ significantly between treatment and control
groups. These data are shown in Figure 7.5. Charts showing immunoscores are included








Figure 7.4 Expression of 17pHSD-2 and AKR1C3 (17PHSD-5) mRNA in GnRH-
antagonist treated endometrium compared to normal mid-secretory
endometrium (control), mean ± SEM. A=17pHSD-2, B=17pHSD-5.The
comparator was an untreated control sample. *p<0.05 compared to untreated
control.
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Figure 7.5 immunolocalisation of AKR1C3 (17(3HSD-5) protein in GnRH-
antagonist treated endometrium (treated) compared to mid-secretory
endometrium (control), +ve= positive control, human kidney, -ve=negative
control, primary antibody substituted for matched IgG. Scale bar=10 microns.
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7.4 Discussion
FSH and GnRH antagonist treatment is a widely used regime for controlled ovarian
stimulation as part of IVF/ICSI cycles. The effects of this treatment on the endometrium,
especially in relation to embryo implantation, have not been investigated in detail.
Histological advancement of the endometrium has been reported (Kolibianakis et al.,
2002); however, there are no reports investigating sex steroid metabolism during the
putative window of implantation (mid secretory phase). Thus a number of enzymes
involved in regulation of sex steroid availability were investigated in endometrium that
had been exposed to GnRH antagonist treatment.
3PHSD-1 and -2 are predominantly responsible for the synthesis of progesterone from
the less active pregnenolone and can also produce androstenedione from less active
precursors. 17PHSD-2 and 17PHSD-5 (AKR1C3) are both involved in the metabolism
of androgens and estrogens. 17PHSD-2 converts active androgens and estrogens to their
less potent forms, whereas 17PHSD-5 (AKR1C3) acts in the reverse direction and makes
active steroids available. The relative ratio of these two enzymes may be a key factor in
determining availability of sex steroids.
Both 3PHSD-1 and -2 mRNA were downregulated in GnRH antagonist treated
endometrium. Levels were very low in mid-secretory control endometrium, but were
lower still in GnRH antagonist treated endometrium. 3PHSD-1 was only detectable at
negligible levels; however 3PHSD-2 was not detectable at all in the study group. 3PHSD
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protein was localised to the glandular and surface epithelia in both control and GnRH-
antagonist-treated endometrium. Expression was not found to be significantly different
between the two groups. 3pHSD-l and -2 act to synthesise progesterone from
pregnenolone, thus a reduction in expression of these enzymes will lead to a
downregulation in local production of progesterone. It has been proposed that a number
of factors affecting implantation e.g. growth factors, hormones, cytokines are under the
control of progesterone, thus this alteration may have implications for the success of IVF
treatments using GnRH antagonists. However the implication of the data showing no
alteration in 3(3HSD protein expression between treated and untreated endometrium is
that the upregulation of sex steroid hormones resulting from GnRH antagonist treatment
does not have a significant effect on 3|3HSD protein expression, and consequently
suggests 3[3HSD is not a key factor in influencing endometrial receptivity in these
women. Conversely, it may be the case that immunohistochemistry is not a sensitive
enough technique to detect small changes in protein expression that may be significant.
3J3HSD can also act further downstream in the steroid biosynthesis pathway, converting
DHEA to androstenedione, a less potent androgen. This may also have implications for
the endometrium although the precise roles of androgens in the female reproductive tract
are still to be determined.
The cognate receptors for these steroids have been described in normal endometrium.
Lessey et al. (1988) found progesterone receptor (PR) to be detected in the glands and
stroma of the endometrium, with expression greatest in the stromal cells in the secretory
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phase. Studies in our laboratory (Vani et al., 2007, in press) have found PR to be
downregulated in the endometrial glands and stroma following GnRH antagonist
treatment. The downregulation of both the enzymes that synthesise progesterone
(3PHSD-1 and -2) and PR suggest GnRH antagonist treatment causes a decrease in
progesterone action in the human endometrium, which may have an effect on
endometrial receptivity.
Catalano et al. (2003) showed that progesterone action on estrogen-primed endometrium
e.g. following fertility treatment can make the endometrium receptive to implantation.
Conversely, progesterone withdrawal returns the endometrium to a non-receptive state.
The downregulation of 3PHSD and PR seen in the endometrium following GnRH
antagonist treatment in these present studies would have the equivalent effect of
progesterone withdrawal, thereby supporting the theory of reduced endometrial
receptivity following IVF treatment with GnRH antagonists.
This study by Catalano et al. (2003) also identified 12 genes whose expression was
altered following progesterone withdrawal (by RU486 treatment) in secretory
endometrium. These data included genes involved in apoptosis, transcription, stress and
particularly cell signalling. Some of the genes downregulated by progesterone
withdrawal are members of two important signalling pathways, the JAK/STAT and JNK
pathways. These pathways are used by cytokines and growth factors and represent a
possible mode of action for the failure of implantation seen in GnRH antagonist IVF
protocols.
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Catalano et al. (2007) reported results of a further study utilising a gene microarray to
identify progesterone-regulated genes. More than 500 genes were found to be altered
following progesterone antagonist (RU486) administration, including chemokines,
which are known inflammatory mediators (Critchley et al., 1999), MMPs, which are
vital in tissue breakdown and members of the Wnt signalling pathway which has been
proposed to be involved in implantation and signalling between the endometrium and
embryo (Miller and Sassoon, 1998; Mohamed et al., 2005).
Expression of 17pHSD-2 mRNA was also downregulated in GnRH antagonist treated
endometrium. This enzyme acts to convert estrogens and androgens into less active
forms. 17(3HSD-5 (AKR1C3), which carries out the reverse of the reactions catalysed by
17|3HSD-2, (produces active androgens and estrogens) was also studied. Expression of
both 17|3HSD-2 and -5 mRNA was decreased in endometrium exposed to GnRH
antagonists. 17[3HSD-2 reduction was found to be significant; however it was not
possible to conduct statistical analysis on the 17[3I ISD-5 mRNA data. There was a
greater downregulation in expression at an mRNA level of 17PHSD-5 than 17PHSD-2,
thus the ratio of these enzymes is likely to be altered, favouring 17PHSD-2. 17PSHD-2
acts to inactivate estrogens and androgens. Thus the predicted alteration in the balance
of these enzymes would reduce the available levels of estradiol and testosterone.
Estrogen is also thought to play a vital role in implantation, and the reduction in estrogen
levels may lead to failure of implantation either by direct perturbation of estrogen action
or by disrupting the balance of sex steroids required for endometrial receptivity. Like
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3(3HSD, 17(3HSD-2 also acts on androgen metabolism and this role may have further
effects on endometrial receptivity and implantation.
Estrogen acts via the estrogen receptor (ER), whose expression has also been well
characterised in the endometrium. ERa is expressed in both glands and stroma, at lower
levels in secretory endometrium than the proliferative phase (Garcia et al., 1998; Lessey
et al., 1988). ER(3 was described by Critchley et al. (2001a) to be expressed in the
glands, stroma and endothelial cells. ER|3 was also found to be downregulated in late
secretory endometrium. Vani et al. (2007, in press) found ERa mRNA to be
downregulated in GnRH antagonist treated endometrium, although there was no
significant difference in protein expression between treatment and control groups.
The probable favouring of 17(3HSD-2 action and corresponding decrease in ERa mRNA
expression suggest estrogen deprivation in GnRH antagonist treated endometrium. This
may contribute to the endometrial advancement reported in GnRH antagonist treated
endometrium and also to the overall disturbance of the balance of sex steroid hormones
and receptors required for appropriate endometrial receptivity and subsequent
implantation.
There was no significant difference in 17PHSD-5 protein expression detectable between
GnRH antagonist treated and untreated endometrium. This could further support the
theory of the balance of 17PHSD action to be tipped in favour of 17pHSD-2 as implied
by the mRNA data. The current lack of availability of a suitable antibody for
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immunolocalisation of 17J3HSD-2 protein has prevented confirmation of mRNA
observations at a protein level.
The controls for this study were healthy fertile women. There could be an argument that
this was not the best control group, as women undergoing assisted conception have
altered physiological steroid levels and possibly also alterations to the endometrium.
Additionally, oocyte donors received progesterone supplementation in the mid secretory
phase of the cycle to mimic a true treatment cycle. This is routine in most cycles of
IVF/ICSI (Beckers et al., 2002), which may add an element of bias. However the aim of
this study was to try to elucidate the differences between the endometrium at the time of
embryo implantation in a natural cycle and following FSH and GnRH antagonist
treatment, thus this was felt to be the most appropriate control group.
There has only been one previous report on the effects of GnRH antagonist treatment on
the endometrium compared to normal mid secretory endometrium (Simon et al., 2005).
However this study investigated ER and PR expression following Ganirelix treatment.
This is the first time local steroid ligand availability has been studied in human
endometrium following GnRH antagonist treatment.
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Concluding remarks






3PHSD-1 4 n/a Progesterone, testosterone 4
3pHSD-2 4 <—> Progesterone, testosterone 4
17pHSD-2 4 n/a Androstenedione, estrone
AKR1C3 4 <—> Testosterone, estradiol <—>
(17pHSD-5)
These studies have shown a trend for downregulation in both the metabolism and action
via receptors of estradiol and progesterone in the endometrium following GnRH
antagonist treatment use as part of assisted conception protocols. These data may have
implications for endometrial receptivity and consequently implantation rates. Further
investigation is required to determine the mechanism by which local modulation of sex
steroid availability and activity influence endometrial receptivity. The expression
patterns of the enzymes studied in this chapter are summarised in Table 7.4, and the
potential effects on sex steroid availability have been postulated.
221
Chapter 8:
General discussion and conclusions
222
8.1 Findings of this thesis
Studies in this thesis were designed to investigate steroid metabolism and pre-receptor
signalling in human endometrium across the menstrual cycle. This was carried out by
studying expression patterns of steroid metabolising enzymes and their cognate
receptors using QRT-PCR and immunohistochemistry. Additionally, regulation of the
1 lpHSDs and cognate receptors was investigated in vitro, and the steroid metabolising
enzymes were examined in two clinical situations: endometrial tissue exposed to locally
delivered LNG and endometrium exposed to the consequences of administration of a
GnRH antagonist.
In Chapter 3, the expression of 11 flHSD-1 and -2, GR and MR in normal endometrium
and first trimester decidua were investigated. These studies were conducted using QRT-
PCR to measure relative levels of mRNA at each stage of the menstrual cycle, and
immunohistochemistry to study protein expression and localisation in the tissues. These
studies showed that 1 lpHSD-1 mRNA expression was greatest at the time of
menstruation, and was also increased in first trimester decidua. This pattern was
replicated at a protein level, although this was not found to be statistically significant.
This is the first time 11 [3HSD-1 expression has been studied in such detail in human
endometrium, and is the first report of 11 pHSD-1 protein expression in this tissue. Smith
et al. (1997) had previously shown there to be low levels of 11PHSD-1 activity in
endometrial tissue homogenates in the presence of NADP+. However, in tissue
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homogenates, 11PHSD-1 is known to behave as a dehydrogenase, converting cortisone
to Cortisol in the presence of NADP+ (Lakshmi & Monder, 1988; Bujalska et al., 2005).
Thus, this study may not represent a true picture of 11 pHSD-1 activity in vivo across the
menstrual cycle. Due to the opportunistic nature of tissue sample collection, it was not
possible to perform a detailed study of 11 PHSD-1 activity across the menstrual cycle
using carefully staged endometrial biopsies. However the expression studies conducted
here allow us to make inferences about the action of these enzymes across the menstrual
cycle. The greatly increased expression of 11 PHSD-1 mRNA in menstrual endometrium
indicated that there was a drive for increased Cortisol synthesis at the time of
menstruation. It is likely that this is in order to modulate the inflammatory response
associated with this process. Implantation is now also accepted to be an inflammatory
event, due to the remodelling associated with decidualisation. These studies showed also
a large increase in 11 PHSD-1 expression, both at a mRNA and protein level, in first
trimester decidua, further suggesting a role for increased Cortisol in order to modulate
local inflammatory events.
11PHSD-2 expression was previously studied in greater depth, by Smith et al.(1997),
who investigated protein expression by immunohistochemistry, and assay of enzyme
activity in the endometrium. However they only compared proliferative and secretory
endometrium; whereas the present study investigated the menstrual cycle in greater
depth. To the best ofmy knowledge there are no previous reports of 11 PHSD-2 mRNA
expression across the menstrual cycle. Observations showed that there appeared to be
greater levels of 11 pHSD-2 than 11 PHSD-1 at least at the level ofmRNA, i.e. 1 lpHSD-
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2 was detectable in fewer QRT-PCR cycles. It suggests that in normal, non-pregnant,
non-menstrual endometrium, 11 (3HSD-2 dominates, restricting Cortisol availability by
producing cortisone. In menstrual endometrium and first trimester decidua, however, the
ratio would be switched more in favour of 11 PHSD-1 and Cortisol production, to
modulate the inflammatory response. While the present studies on the expression of
11PHSD-2 protein in human endometrium are in agreement with the findings of Smith et
al. (1997), the stages of the menstrual cycle have been investigated in greater detail.
In order for glucocorticoids to elicit a response, they must be able to bind and activate a
receptor. Thus, the appropriate receptor must be available. Cortisol's anti-inflammatory
action occurs via a signalling pathway initiated by binding to GR. Thus, GR expression
across the menstrual cycle was of interest. GR mRNA was found to be significantly
increased in menstrual endometrium compared to the other stages of the menstrual cycle.
This corresponds with the increased Cortisol that is likely to be available following the
increased 11PHSD-1 expression seen at menstruation, meaning Cortisol can act to
modulate the inflammatory response. GR in human endometrium has been previously
studied (Bamberger et al., 2001; Henderson et al., 2003). GR mRNA has been
previously reported to be expressed across the menstrual cycle with no significant
difference. Neither of these studies looked specifically at menstrual endometrium
however, and that is where these present studies have found significant results. However
there was not a significant increase in GR mRNA expression in first trimester decidua to
correspond with the increased 11 pHSD-1 expression.
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This is the first known report ofMR expression in human endometrium. MRmRNA is
expressed across the menstrual cycle. Expression is greatest in mid-secretory
endometrium. This is the time when progesterone rises, in preparation for implantation.
This could further enhance the earlier hypothesis that progesterone acts as an MR
antagonist to prevent fetal damage. Alternatively, progesterone could be a regulator of
MR expression.
MR protein is expressed throughout the menstrual cycle in the glandular epithelium,
with some expression in stromal and endothelial cells. This is unlike most other nuclear
hormone receptors which are localised to stromal cells (Henderson et al., 2003; Perrot-
Applanat et al., 1994; Maia et al., 2001; Slayden et al., 2001). ERa and ERP are,
however, located in both the glands and stroma. More interestingly, despite being a
nuclear hormone receptor, MR is predominantly localised to the cytoplasm. A previous
report (Sartorato et al., 2004) showed MR to be cytoplasmic in expression, with the
ability to translocate to the nucleus when ligand is bound. This may be the case here, as
some nuclear staining is seen in first trimester decidua, when 1 ipHSD-1 levels are high.
However little is known about aldosterone in human endometrium, so it is not possible
to further elaborate on this hypothesis. As MR is not activated by progesterone, it would
not be expected that progesterone could induce this translocation.
Chapter 4 focussed on the regulation of the 11 pHSD system and associated receptors by
11^la, and has expanded upon the work of Rae et al. (2004a,b) in our laboratory. Rae et
al. (2004a) investigated the effect of IL-1 a on 11 pHSD-1, -2 and GR in ovarian surface
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epithelial cells, and this present study aimed to expand that knowledge of Cortisol
signalling in cellular structures of the female reproductive tract, and investigate whether
epithelial cells in a different environment behaved differently.
The present study found that 11PHSD-1 mRNA was indeed upregulated by IL-la in a
population of epithelially-enriched endometrial cells. This was suggestive that epithelial
cells behave similarly in response to IL-la, regardless of their tissue location. This
hypothesis was further supported by a trend towards increased GR expression in
response to IL-la treatment in this same cell population. Although this result was not
statistically significant, it was consistent with the findings of Rae et al. (2004a), who
found a small but significant increase in GR mRNA expression in response to IL-1 a.
A similar response to IL-la was observed in 11 PHSD-1 expression in endometrial
stromal cells. Expression was upregulated in response to IL-la treatment. However, the
level of upregulation in stromal cells was roughly 5 times less than that observed in
epithelially enriched cells. This is perhaps suggestive that 11 PHSD-1 responds to IL-la
similarly in the different cells of the female reproductive tract, but the vast difference in
the fold change in expression implies that there are also differences between the cell
types. The epithelially enriched cells showed the greatest response to IL-la, thus these
are the cells which are most important in generating the 11PHSD-1 increase which leads
to increased Cortisol at times of inflammation.
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A third cell population was studied, consisting of mixed cells sampled from near the
endometrial surface with a brush. These were mainly fibroblast-like cells, with some
epithelial cells. This cell population responded differently to IL-la, in that it alone had
no significant effect on 11(3HSD-1 expression, however when Cortisol was added,
expression significantly increased. This was suggestive of a level of spatial as well as
cellular control of 1 ipHSD-1 expression. IL-la is a pro-inflammatory cytokine,
however it has been shown to act to increase expression of the anti-inflammatory steroid
Cortisol. This shows the precise level of control at work in the human endometrium.
There were drawbacks with this study, in that the cell separation method was perhaps
not optimal, and a pure population of epithelial cells was not available. However the
difference in fold change in expression between 1 IpHSD-1 in epithelially enriched cells
and stromal cells indicates that an epithelial cell response was measurable.
These data suggest that many, if not all, cells in the female reproductive tract respond in
a broadly similar manner to IL-1 a; however there are differences between cell types and
tissue locations in the level of this response.
In Chapter 5 the expression of a number of enzymes involved in the metabolism of sex
steroids were investigated using QRT-PCR and immunohistochemistry. The 3PHSD
isoforms were investigated; these are involved in the synthesis of all steroid hormones,
by catalysing the conversion of pregnenolone to progesterone. 3pHSDs are also involved
in the metabolism of androgens.
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Two previous studies have investigated 3|3HSDs in human endometrium, a notable one
being by Rhee et al. (2003). This study utilised immunohistochemical methods to detect
3(3HSD in human endometrium, finding stronger immunoreaetivity in secretory than
proliferative endometrium. Rhee et al. (2003) only compared proliferative and secretory
endometrium, so the present study investigated 3PHSD expression across the menstrual
cycle in greater detail using an antibody raised against human recombinant 3PHSD-2
which similarly detects 3PHSD-1. In agreement with Rhee et al. (2003), 3PHSD was
predominantly expressed in the glands. However in contrast to this earlier report, the
current study found no significant difference in expression across the menstrual cycle.
Rhee et al. (2003) used RT-PCR to identify which 3PHSD isoform was present, and
showed it was 3PHSD-1. 3PHSD-1 and-2 mRNA expression were measured
quantitatively in the studies in this thesis and neither isoform was detectable in
endometrium, consistent with the very low levels of 3PHSD protein. 3PHSD-1 mRNA
was detected in first trimester decidua, thus it is likely that this is indeed the isoform
detected by the antibody.
The incredibly low levels of 3pHSD protein in human endometrium suggest that there is
no need for local progesterone synthesis or androgen metabolism by this enzyme in
normal endometrium. However, expression is upregulated in first trimester decidua,
when elevated progesterone levels are maintained, suggesting a function of 3PHSD in
maintaining these elevated progesterone levels.
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Additionally, the AKR1C group of enzymes were studied. This group performs a large
number of reactions, controlling the expression and activity of members of all three sex
steroid families. Hitherto few data have been available about expression and regulation
of AKR1C enzymes in the female reproductive tract. AKR1C1-1C3 were shown to be
expressed in the uterus (Penning et al., 2000), but no quantitative or spatio-temporal
studies were published until 2006 when Ito et al. showed expression of AKR1C3
(17[3HSD-5) in proliferative and secretory endometrium. QRT-PCR in the present study
showed AKR1C1-3 to be expressed in human endometrium and first trimester decidua,
however AKR1C3 (17[lHSD-5) was the only member of the enzyme family whose
expression differed significantly at any stage of the menstrual cycle. Its expression was
upregulated in the early secretory stage of the cycle, immediately following ovulation,
when circulating estrogen levels begin to fall.
Only AKR1C3 (17J3HSD-5) protein expression was studied due to the lack of suitable
antibodies for the other enzymes. Strong expression was detected in the vasculature,
specifically in the endothelial cells. Sex steroid receptors are generally not expressed in
these cells, with the exception of ER(3 (Critchley et al., 2001a). Thus it is likely that
AKR1C3 has a role in estrogen activation in these cells. AKR1C3 (17PHSD-5) protein
was also expressed in the glandular and surface epithelia across the menstrual cycle.
The existence of a 17flHSD "switch" has been hypothesised in this chapter, in light of
the expression pattern of AKR1C3 (17J3HSD-5) mRNA being the reciprocal of
17flHSD-2 (Burton et al., 2003), the enzyme that catalyses the opposite reactions.
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However previous studies including that of Casey et al. (1994), showed a differing
pattern of 17(3HSD-2 mRNA expression, and the opposing expression patterns of
17PHSD-2 and AKR1C3 (17pHSD-5) were not seen at a protein level. Thus it has not
been possible to prove or disprove this hypothesis.
Chapters 6 and 7 studied the enzymes featured in previous chapters in the endometrium
in two clinical situations, following usage of the levonorgestrel-releasing intra uterine
system (LNG-IUS), a progestogen only contraceptive; and treatment with recombinant
FSH and a GnRH antagonist as part of treatment for sub-fertility.
Many previous studies have investigated the effects of the LNG-IUS, in particular in
relation to the problem of breakthrough bleeding. However the causes of this common
reason for discontinued use (Findlay, 1996) are not yet fully understood. To the best of
my knowledge, the work of Burton et al. (2003) is the only known report of any of the
steroid metabolising enzymes of interest in the endometrium following LNG-IUS use.
17PHSD-2 expression was upregulated in the first three months of LNG-IUS use, but
cellular levels then returned to normal (Burton et al., 2003).
A number of steroid metabolising enzymes were found in the present study to be
upregulated in response to LNG-IUS use. Some of these enzymes have opposing effects,
such as lipHSD-1 and -2, 3PHSD-1 and AKR1C1, yet all were upregulated. This shows
there is an overall increase in steroid metabolising enzymes when the LNG-IUS is used,
which would lead to greater steroid metabolising activity, and potentially a disruption in
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the balance of local steroid availability. This could disrupt the endometrium leading to
aberrant bleeding patterns. In particular, the 11 (3HSD system is known to affect
angiogenesis (Small et al., 2005). Both lipHSD-1 and -2 were upregulated in this study,
thus the overall balance of cortisone and Cortisol would likely be altered.
These changes in mRNA expression were generally not mirrored at a protein level
however, either changes were observed but were not statistically significant, or no
change occurred. This may be due to a delay in translation, or simply due to the fact that
immunohistochemistry as not as sensitive and quantitative a technique as QRT-PCR.
The other clinical situation studied in this thesis was that of GnRH antagonist use in
fertility treatment. This study aimed to investigate the effect of this treatment on sex
steroid hormone metabolising enzymes in endometrium. There are been reports of
reduced pregnancy rates when this type of fertility treatment is used (Al-Inany, 2002).
The current study was carried out alongside the work of Vani et al., (2007) on the
expression of sex steroid receptors in endometrium as a result of this treatment regime.
Both 3[3HSD-1 and -2, and 17[3HSD-2 and AKR1C3 (17(3HSD-5) were downregulated
in endometrium that had been treated with a GnRH antagonist. No significant difference
was observed at a protein level. Again, these data show that exogenous steroid treatment
leads to a perturbation in sex steroid metabolising enzyme expression levels, and
presumably in the steroids modulated by these enzymes. This perturbation may be in
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part responsible for the problems associated with these treatments such as breakthrough
bleeding and reduced implantation rates.
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8.2 Conclusions
Steroid signalling is a vital part of the control of the female reproductive system, and the
availability and actions of these steroids in human endometrium vary across the
menstrual cycle. This variation in steroid action controls many of the key events in the
human endometrium, including menstruation and implantation.
In order for steroid hormones to elicit this tight control, they themselves are tightly
regulated at a pre-receptor level by a number of factors. One vital group of factors are
steroid metabolising enzymes, which have been the focus of this thesis.
These studies have shown that there is a notable capacity for steroid hormone
metabolism and regulation within the human endometrium. These steroid metabolising
enzymes are one of the mechanisms in place that allow the tight regulation of the tissue
injury and repair process that occurs in every menstrual cycle. In addition, it has been
observed that exogenous steroid manipulation in clinical situations causes an alteration
in many of these enzymes. These findings should provide an insight into the problems
and discomfort suffered by woman using these treatments. Additionally, these studies
have begun to elucidate the control of the lipHSD enzyme system by cytokines. Future
studies will expand this knowledge and enhance our understanding of the mechanisms
by which these enzymes act.
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8.3 Future Studies
The studies presented in this thesis have shown the expression of steroid metabolising
enzymes in endometrium across the menstrual cycle, in first trimester decidua, and
following treatment with exogenous steroids. Suitable antibodies were not available for
immunohistochemistry to study AKR1C1,1C2 and 17PHSD-2, hence when antibodies
become available this requires to be performed. Dual immunohistochemistry to co-
localise steroid metabolising enzymes and cognate receptors should be conducted to
establish the interactions between them. In addition, co-localisation of lipHSD-1 and
CD56, a uNK cell marker, would inform if the increased lipHSD-1 expression in
menstrual endometrium and first trimester decidua was due to an influx of uNK cells.
Studies of enzyme activity by measuring conversion of radiolabelled steroids would
complete these descriptive investigations.
Following on from these studies, there are a number of functional studies that would tell
us more about the role of these enzymes, such as knockouts or knock-downs in either
animal models or by gene silencing in cells using RNAi. Alternatively, treatment with a
GR or other receptor antagonist would allow an initial investigation of steroid hormone
depletion, but would not allow evaluation of the effect of withdrawal of a particular
enzyme.
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The studies on regulation of the 11 |3HSD system are the beginning of a much wider
study. The effects of other cytokines, primarily TNFa, IL-1(3, IL-4, -6 and -8 on this
system are to be investigated, and similar studies to be conducted on the other enzymes.
Also, due to the inability to obtain a unique population of epithelial cells, the results
could be confirmed by repeating the experiments using an immortalised endometrial
epithelial cell line. Cell lines could also be utilised to conduct similar studies on other
endometrial cell types, in particular endothelial cells and uterine natural killer cells.
ELISA protein expression assays could be utilised to strengthen the existing mRNA
data.
The studies on endometrium following exogenous steroid treatment provide the first data
suggesting perturbation of steroid metabolism. Again, enzyme activity studies would
provide functional data. Comparison with other situations involving hormone
manipulation could prove useful, such as the effect of hormone replacement therapy in
post-menopausal women.
The GnRH antagonist study could be expanded to conduct a direct comparison between
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Figure A1: 11 (3HSD-1 protein expression across the menstrual cycle
(immunoscores). Box and whisker plots: the box represents the 25th and 75th
percentiles, and whiskers represent the minimum and maximum values. The
heavy bar represents the median value. M=menstrual, P=proliferative,
ES=early secretory, MS=mid secretory, LS=late secretory, D=first trimester
decidua. A=glands in functional layer, B=stroma in functional layer,
C=vessels in functional layer, D=surface epithelium, E=glands in basal layer,
F = vessels in basal layer. 11 (3HSD-1 immunoreactivity was not seen in the

































Figure A2: 11(3HSD-2 protein expression across the menstrual cycle
(immunoscores). Box and whisker plots: the box represents the 25th and 75th
percentiles, and whiskers represent the minimum and maximum values. The
heavy bar represents the median value. M=menstrual, P=proliferative,
ES=early secretory, MS=mid secretory, LS=late secretory, D=first trimester
decidua. A=glands in functional layer, B=stroma in functional layer,
C=vessels in functional layer, D=surface epithelium, E=glands in basal layer,
F= vessels in basal layer. There was no 11(BHSD-2 immunoreactivity in the






—i i—■ "i"'—i i




















































Figure A3: GR protein expression across the menstrual cycle
(immunoscores). Box and whisker plots: the box represents the 25th and 75th
percentiles, and whiskers represent the minimum and maximum values. The
heavy bar represents the median value. M=menstrual, P=proliferative,
ES=early secretory, MS=mid secretory, LS=late secretory, D=first trimester
decidua. A=glands in functional layer, B=stroma in functional layer,
C=vessels in functional layer, D=surface epithelium, E=glands in basal layer,





























































































Figure A4: MR protein expression across the menstrual cycle
(immunoscores). Box and whisker plots: the box represents the 25th and 75th
percentiles, and whiskers represent the minimum and maximum values. The
heavy bar represents the median value. M=menstrual, P=proliferative,
ES=early secretory, MS=mid secretory, LS=late secretory, D=first trimester
decidua. A=glands in functional layer, B=stroma in functional layer,
C=vessels in functional layer, D=surface epithelium, E=glands in basal layer,
F=stroma in basal layer, G= vessels in basal layer.
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Figure A5: 3(3HSD protein expression across the menstrual cycle
(immunoscores). Box and whisker plots: the box represents the 25th and 75th
percentiles, and whiskers represent the minimum and maximum values. The
heavy bar represents the median value. M=menstrual, P=proliferative,
ES=early secretory, MS=mid secretory, LS=late secretory, D=first trimester
decidua. A=glands in functional layer, B=stroma in functional layer,
C=vessels in functional layer, D=surface epithelium, E=glands in basal layer,
F= vessels in basal layer. No 3(3HSD immunoreactivity was seen in the























































































Figure A6: AKR1C3 (17(3HSD-5) protein expression across the menstrual
cycle (immunoscores). Box and whisker plots: the box represents the 25th
and 75th percentiles, and whiskers represent the minimum and maximum
values. The heavy bar represents the median value. M=menstrual,
P=proliferative, ES=early secretory, MS=mid secretory, LS=late secretory,
D=first trimester decidua. A=glands in functional layer, B=stroma in
functional layer, C=vessels in functional layer, D=surface epithelium,
E=glands in basal layer, F= vessels in basal layer. No AKR1C3
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Figure A7: 11 (3HSD-1 protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores).
Box and whisker plots: the box represents the 25th and 75th percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. M=menstrual, P=proliferative, ES=early
secretory, MS=mid secretory, LS=late secretory, D=first trimester decidua.
A=glands in functional layer, B=stroma in functional layer, C=vessels in
functional layer, D=surface epithelium, E=glands in basal layer, F=vessels in




Figure A8: 11pHSD-2 protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores)
Box and whisker plots: the box represents the 25th and 75th percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. P=proliferative phase pre-insertion,
S=secretory phase pre-insertion, 1M=1 month post-insertion, 3M= 3 months
post-insertion, 6M=6 months post-insertion, 12M=12 months post-insertion.
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Figure A9: GR protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores).
Box and whisker plots: the box represents the 25th and 75in percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. P=proliferative phase pre-insertion,
S=secretory phase pre-insertion, 1M=1 month post-insertion, 3M= 3 months
post-insertion, 6M=6 months post-insertion, 12M=12 months post-insertion.
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Figure A10: MR protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores).
Box and whisker plots: the box represents the 25th and 75th percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. M=menstrual, P=proliferative, ES=early
secretory, MS=mid secretory, LS=late secretory, D=first trimester decidua.
A=glands in functional layer, B=stroma in functional layer, C=vessels in
functional layer, D=surface epithelium.
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Figure A11: 3(BHSD protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores).
Box and whisker plots: the box represents the 25th and 75th percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. P=proliferative phase pre-insertion,
S=secretory phase pre-insertion, 1M=1 month post-insertion, 3M= 3 months
post-insertion, 6M=6 months post-insertion, 12M=12 months post-insertion.
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Figure A12: 17|3HSD-5 protein expression across the menstrual cycle, in first
trimester decidua and in pseudo-decidualised endometrium (immunoscores).
Box and whisker plots: the box represents the 25th and 75in percentiles, and
whiskers represent the minimum and maximum values. The heavy bar
represents the median value. M=menstrual, P=pro I iterative, ES=early
secretory, MS=mid secretory, LS=late secretory, D=first trimester decidua,























Figure A13: 3(3HSD protein expression in endometrium following GnRH
antagonist treatment (treated) compared to untreated mid-secretory
endometrium (control) (immunoscores). A=glands, B=vessels, C=surface


























Figure A14: AKR1C3 (170HSD-5) protein expression in endometrium
following GnRH antagonist treatment (treated) compared to untreated mid-
secretory endometrium (control) (immunoscores). A=glands, B=vessels,
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Abstract
Key reproductive events, such as menstruation and implantation, are considered to be inflammatory processes and glucocorticoids act as anti¬
inflammatory agents. The balance ofexpression of types 1 and 2 1 lfl-hydroxysteroid dehydrogenases (11 (3HSD) controls the availability ofCortisol
to bind to the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Expressron profiles of glucocorticoid-metabolising enzymes and
(heir cognate receptors have been characterized in the reproductive tract. We propose that factors that peripherally promote glucocorticoid action
are part of an anti-inflammatory response to tissue remodelling in human endometrium. Protein and mRNA expression in endometrium were
investigated using immunohistochemistry and quantitative real-time PCR. There was up-regulated expression of 11 (JHSD-1 at menstruation and
in first trimester decidua. 1 l(3HSD-2 and GR were expressed across the cycle. The MR expression pattern across the cycle and in decidua implies
progesterone may also play a regulatory role. The precise roles and interactions of these proteins require further investigation.
© 2005 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Ovulation, implantation and menstruation are pivotal repro¬
ductive events, all ofwhich involve extensive tissue remodelling
and subsequent repair. A number of factors mediate this remod¬
elling, and these factors are regulated by steroids and cytokines.
Steroids involved in the reproductive system include androgens,
estrogens and glucocorticoids. Prereceptor signalling events and
metabolism associated with these steroids are likely to be key in
the regulation of such tissue remodelling.
The 11 ^-hydroxysteroid dehydrogenase family (llfJHSDs)
are enzymes that catalyze glucocorticoid metabolism, regulat¬
ing the availability of active glucocorticoid (Cortisol in humans
and corticosterone in rats) and their inactive metabolites (corti¬
sone and dehydrocorticosterone, respectively.) Glucocorticoids
are crucial in the inflammatory response that accompanies tis¬
sue remodelling. Pro-inflammatory cytokines elicit an increased
activation of Cortisol from cortisone in many tissues, suggesting
local Cortisol activation, by 11 [51 ISDs. This was first shown by
Escher et al. (1997), in renal glomerular mesangial cells. Studies
* Corresponding author. Tel.; +44 131 242 6442; fax; +44 131 242 6440.
E-mail address: j.i.mason@ed.ac.uk (J.I. Mason).
on up- and down-regulation ofCortisol levels by 11PHSD-1 and
-2 in inflammatory responses have been conducted at ovulation
(Hillier and Tetsuka, 1998), in kidney, liver and fat (Seckl et al.,
2004), and in bone (Cooper et al., 2001). Deficiencies in the reg¬
ulation of 1 I pi ISD can cause problems including liver failure,
obesity, and metabolic and cardiac disorders. Thus it is likely
that 11 (31 ISDs play a similar role in the reproductive tract.
There are two characterized 11 USDs in humans, encoded
by two separate genes, located on different chromosomes, and
with only 14%homology (Albistonetal., 1994). 11 (311SD-1 was
first identified in liver (Lakshmi andMonder, 1988) and acts pre¬
dominantly as an NADPH-dependent reductase, although in the
presence ofNADP+ it can also act as a dehydrogenase convert¬
ing Cortisol to cortisone. Human 1 l(3HSD-2 was cloned in 1994
by Albiston et al. (1994) and was first identified in kidney. This
enzyme is a unidirectional NAD+-dependent dehydrogenase.
Studies have been carried out on the expression patterns
of these enzymes in the female reproductive tract. The signal
work on the expression of 11 (51 ISDs in the endometrium, was
conducted by Smith et al. (1997). They performed immunohisto¬
chemistry on endometrial tissue samples, collected at curettage
from women with regular menstrual cycles, supported by west¬
ern immunoblotting and activity assays to build an expression
profile. It was found that lipiISD-2 protein was expressed in
0303-7207/$ - see front matter© 2005 Elsevier Ireland Ltd. All rights reserved.
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the luminal and glandular epithelia, with heterogeneous expres¬
sion in some tissue sections. Levels of 1 l(3HSD-2 activity were
found to be higher in the secretory phase than in proliferative
phase endometrium. The activity of 11 (3HSD-1 in endometrium
was also assayed with constant levels of activity found across
the cycle; however, the overall level of 11 (311SD-1 activity was
lower than that of 11J3HSD-2.
There has been no definitive study of the expression profile
of 11 (311S13-1 protein in endometrium, due to the current lack of
an antibody (commercial or academic) proven suitable for west-
em immunoblotting and immunohistochemistry of endometrial
samples. Arcuri et al. (1996) studied the effects ofvarious steroid
treatments on endometrial stromal cells, and found progesterone
increased expression of 11 (3HSD-1, estrogen alone had no effect
while the combination of estrogen and progesterone potenti¬
ated the effect of progesterone. They also found 11 (3 USD-1
up-regulation to be a feature of decidualisation in these cultured
cells. Koyama and Krozowski (2001) assayed the enzymic activ¬
ity of lshikawa cells, an endometrial carcinoma cell line. They
found 11 (3 USD activity increased in a dose-dependent manner
when measured with Cortisol as substrate. NAD+ was preferred
to NADP+ as a cofactor, suggesting predominant ll(3HSD-2
activity.
Real-time PCR (QRT-PCR) was used to study 11(3HSD-1
and -2 transcripts in murine placenta and uterus (Thompson et
al., 2002). 11 (111SD-1 and -2 were detected in the stroma of
decidua, 11 (II ISO-1 mRNA was expressed in the epithelial cells
of the endometrium, whereas type 2 was in the stroma. 11 (3HSD-
1 was observed in human decidua by western immunoblotting
(Ricketts et al., 1998).
The expression pattern of the receptors for Cortisol is also
relevant. The primary receptor for Cortisol is the glucocorticoid
receptor (GR), but Cortisol also has a high affinity for the miner-
alocorticoid receptor (MR). Excess Cortisol binding to MR can
cause disorders such as apparent mineralocorticoid excess. For
this reason, 1 lpHSD-l is normally found co-localised withGR,
while 11 (3HSD-2 is commonly found in MR-expressing tissues.
The tissue distribution ofGR in endometrium has been reported
(Bamberger et al., 2001; Henderson et al., 2003). Both studies
showed GR to be expressed in the stroma and endothelial cells of
blood vessels of the endometrium. Henderson et al. (2003) also
found GR in the glandular epithelium of first trimester decidua.
Little is currently known about the expression profile of MR in
human endometrium.
2. Materials and methods
2.1. Tissue collection
Informed consent and ethical approval was obtained on all tissue sam¬
ples. Full thickness endometrial tissue was collected from a number of patients
undergoing hysterectomy or laparoscopic sterilisation procedures, and the stage
of the cycle estimated by histological dating, reported date of last menstrual
period (LMP) and serum estradiol and progesterone levels. Decidual tissue
was collected from women in the first trimester of pregnancy undergoing elec¬
tive termination of pregnancy. The tissue samples were fixed overnight in
10% neutral-buffered formalin at 4°C, rinsed and stored in 70% ethanol and
routinely wax-embedded. 5 pm sections were cut for immunohistochemical
staining. Additional biopsies from the endometrium of the same patients were
collected and stored in RNAlater (Ambion, Huntingdon, UK), an RNA stabili¬
sation reagent used to obtain RNA.
Uterine natural killer cells were isolated as previously described. (Henderson
et al.. 2003). Briefly, 1 x 108 decidual cells were suspended in 300 |xl buffer
(PBS/2mM EDTA/1% human AB serum). After the addition of 0.5% human y-
globulins in PBS and 100 \i\ CD56 magnetic cell sorting microbeads (Miltenyl
Biotech, Bergisch Gladbach, Germany), the suspension was incubated at 4°C
for 20 min. The cells were washed, resuspended in buffer, and applied to a Var-
ioMACS magnet (Miltenyl Biotech). The column was washed, and the CD56+
cells were eluted and resuspended in RPMI/10% fetal calf serum. The purity of
the decidual NK cells was greater than 97%, as confirmed by flow cytometry.
2.2. RNA extraction and reverse-transcriptase PCR
To obtain RNA, endometrial samples frozen at —70 °C in RNAlater were
extracted using the Qiagen RNeasy Midi Kit (Qiagen, Crawley, UK) according
to the manufacturer's instructions. Tissue was homogenised using a hand-held
homogeniser, and extraction was performed using the kit During the extraction
process the samples were treated with DNase I (Qiagen) in order to remove
any contaminating genomic DNA. After extraction the RNA concentration and
quality were assessed using an Agilent bioanalyzer (Agilent Technologies, South
Queensferry, West Lothian, UK). The RT-PCR reaction was performed in a
10 pi volume of reaction solution containing the following: lx Taqman RT
buffer, 25 mM magnesium chloride, deoxyNTPs, random hexamers,Multiscribe
reverse transcriptase, RNase inhibitor and nuclease-free water (reagents from
Applied Biosystems, Cheshire, UK), and 200 ng of template RNA was added.
The RT reaction was conducted at 25 °C for 60 min, 48 °C for 45 min and 95 °C
for 5 min for one cycle. Samples were then stored at —20 °C.
2.3. Quantitative real-time PCR (QRT-PCR)
Oligonucleotide forward and reverse primers, and oligonucleotide Taqman
probes were used to detect the sequences of interest. The probes used were
commercially available, from ABI UK (Assay-on-demand), or designed as
previously described (Henderson et al., 2003). Reaction mixtures were made
containing ABI Taqman Master Mix, specific forward and reverse primers and
probe for the gene of interest, and primers and VIC-Iabelled probe for riboso-
mal 18S RNA (Applied Biosystems). This reaction mix was then transferred to
an optical plate, and the QRT-PCR reaction was performed using an ABI 7900
Sequence Detection System (Perkin-Elmer Applied Biosystems, USA).
In the analysis of data, all values are given relative to an internal control of
18S ribosomal RNA. All samples were then compared to a proliferative endome¬
trial sample.
Data from QRT-PCR were analysed by one-way analysis of variance.
2.4. Immunohistochemistry
Immunohistochemistry was performed by standard methods using
horseradish-peroxidase-conjugated secondary antibodies, and ABC-Elite avidin
biotin peroxidase complex (Vector Laboratories Inc., Peterborough, UK).
Immunoreactivity was detected using the chromagen, 3,3/-diaminobenzidine
(DAB). The commercially obtained primary antibodies used were against
ll^HSD-2 (PC545, The Binding Site, Birmingham, UK) and GR (NCL-
GCR. Novo Castra, Newcastle-upon-Tyne, UK). The MR monoclonal antibody
(MRN2-2D6) was one of a series produced by immunizing mice with a pep¬
tide corresponding to aminoacids 64-82 of the rat mineralocorticoid receptor
(SKEKHELLPYIQQDNSRSG-C) conjugated to keyhole limpet hemocyanin.
Resulting lymphocytes were fused with SP-2-mIL6 myeloma cells. This anti¬
body is an IgG2b isotype and cross-reacts with the human mineralocorticoid
receptor.
2.5. Scoring and analysis of immunohistochemistry
Immunostaining in tissue sections was analysed semi-quantitatively on a
four-point scale, where 0 = no staining, 1 = some staining, 2 =moderate staining
and 3 = intense staining. All sections were scored blind by two investigators.


























Fig. 1. Expression of llfSHSD-1 mRNA across the cycle, in first-trimester
decidua, and uNK cells, mean ± S.E. M, menstrual; P, proliferative; ES, early
secretory; MS, mid-secretory; LS, late-secretory; D, deciduas; uNK, uterine
natural killer cells. *P <0.05.
These results were analysed by a non-parametric method, the Kruskal-Wallis
test, followed Dunn's post hoc multiple comparison test.
2.6. Western immunoblotting
Tissue was weighed, chopped roughly, placed in four volumes ofhomogenis¬
ing buffer (10 mM Tris, 0.3M sucrose and ImM EDTA, pH 7.4), then
homogenised using an electric homogeniser. Tissue homogenate was aliquoted
and frozen at — 80 °C for later use. Protein concentration of the tissue
homogenate was determined (Bradford, 1976) using a Cobas Fara centrifugal
analyser and BSA as standard. The homogenate sample was diluted 2:1 with
sample loading buffer containing SDS, (3-mercaptoethanol, bromophenol blue
and glycerol. The protein was resolved on a 10% SDS-PAGE gel and transferred
to an Immobilon-P membrane (Millipore, Watford, UK). The blot was probed
with the mouse monoclonal anti-MR primary antibody, followed by blocking
overnight in a 3% milk solution, then horseradish peroxidase-conjugated rabbit
anti-mouse IgG was applied as the secondary antibody, followed by chemilu-
minescence detection (Perbio Science UK Ltd., Cramlington, Northumberland,
UK).
3. Results
3.1. Expression of llfHSD-1 in human endometrium
Levels of I I jfMSD-1 mRNA were measured and validated
using specific Taqman primers and probes. There were very
low levels of I 1 (iNSD- i mRNA in normal endometrium,
and this did not differ significantly between proliferative and
secretory phases. The levels of 11 (3HSD-1 mRNA in men¬
strual endometrium were significantly increased in compari¬
son to in the rest of the cycle (f <0.05). Levels of mRNA
were also increased in first trimester decidua. There was also
some increase in I lpllSD-1 mRNA levels in uterine natu¬
ral killer cells (uNK cells), a group of phenotypically unique
cells that increase in number prior to pregnancy, in compar¬
ison to non-pregnant endometrium. These data are shown in
Fig. 1.
3.2. Expression of 11 flHSD-2 in human endometrium
11 (3HSD-2 was expressed in normal endometrium through¬
out the menstrual cycle at higher levels than 11 (3HSD- I. There
was no increase in ll(3HSD-2 mRNA levels in menstrual























Fig. 2. Expression of Il(3HSD-2 mRNA across the cycle, in first-trimester
decidua, and uNK cells, mean ± S.E. M, menstrual; P, proliferative; ES, early
secretory; MS, mid-secretory; LS, late-secretory; D, deciduas; uNK, uterine
natural killer cells. /'>0.05.
of 11 ptiSD-2 mRNA in first trimester decidua did not differ
significantly from those in normal endometrium. 11 (51ISD-2
mRNA was not present in uNK cells. These data are shown in
Fig. 2.
11 (31ISD-2 protein expression and localisation was stud¬
ied across the menstrual cycle and in first trimester decidua.
11PHSD-2 was expressed in the cytoplasm. 11(3HSD-2 protein
was localised in the glandular epithelium in both the functional
and basal layer of the endometrium across the cycle, and at a
higher level in first trimester decidua. Low levels of the protein
were seen in the stroma of the functional layer, with an increase
in first trimester decidua compared to normal endometrium.
11 pHSD-2 protein was not present in the stroma of the basal
layer. There was negligible expression in the endothelial cells
of blood vessels of the both layers across the cycle, but some
expression was seen in these cells in the functional layer of first
trimester decidua. There was moderate expression of 11 pHSD-
2 protein in the surface epithelium of normal endometrium,
and higher levels in first trimester decidua. Expression did
not vary in any part of the endometrium across the normal
menstrual cycle. Fig. 3 illustrates 1 ipHSD-2 immunoreactivity
studies.
3.3. Expression of the glucocorticoid receptor (GR) in
human endometrium
Expression ofGR mRNA was also assessed by Taqman QRT-
PCR (Fig. 4). It was found that the mRNA was present in
normal endometrium at low levels across the cycle, and in first
trimester decidua, at levels that did not differ significantly. How¬
ever, expression levels were higher in menstrual endometrium
and uNK cells. This observation supports our previous findings
(Henderson et al., 2003). Fig. 5 illustrates this expression pattern
of GR immunoreactivity in endometrium and decidua.
GR protein was expressed in the stroma at fairly high lev¬
els. There was no significant difference in expression across the
cycle or in first trimester decidua. Expression ofGR was low in
glandular epithelium across the cycle. There was a significant
increase in expression in decidual glands. (P< 0.001) There was
high expression of GR in the endothelial in both functional and
basal layers of the endometrium, and in first trimester decidua,
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Fig. 3. Immunohistochemical staining showing expression of 1 l(3HSD-2 in the
functional layer of human endometrium and first trimester decidua brown stain¬
ing represents positive 11J3HSD-2 immunoreactivity, blue stain is a negative
counterstain. (A) Proliferative phase endometrium, top left inset shows human
kidney as a positive control, (B) Secretory phase endometrium and (C) first
trimester decidua, bottom right inset shows human endometrium as a negative
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Fig. 4. Expression of GR mRNA across the menstrua! cycle, in first trimester
decidua and uNK cells, mean ± S.E. M, menstrual; P, proliferative; ES, early
secretory; MS, mid-secretory; LS, late-secretory; D, decidua, uNK, uterine nat¬
ural killer cells. *P<0.05.
3.4. Expression of the mineralocorticoid receptor in human
endometrium
MR mRNA was expressed throughout the menstrual cycle
in non-pregnant endometrium. It was also expressed in first-
trimester decidua and in an isolated population of uNK cells.
Expression levels are significantly higher in mid-secretory phase
endometrium than in the proliferative phase, corresponding to
an increase in circulating progesterone. MR mRNA levels then
fell significantly in the late secretory phase, at the time of pro¬
gesterone withdrawal. There was an increase in the level ofMR
mRNA expression in first trimester decidua, again correspond¬
ing to increased progesterone concentrations, but this result was
not found to be statistically significant. Negligible MR mRNA
was present in uNK cells. These data are shown in Fig. 6.
Preliminary immunohistochemical studies have shown that
MR protein is expressed variably in both the nucleus and cyto¬
plasm in different tissues. In human kidney there was MR
expression in the cytoplasm, and punctate nuclear staining was
also seen. In human endometrium there seemed to be predomi¬
nantly cytoplasmic staining in the mid-secretory phase; however,
nuclear staining was prominent in first trimester decidua. These
observations are illustrated in Fig. 7. The fidelity of the anti¬
body was confirmed by western immunoblotting of endometrial
and placental samples as shown in panel D of Fig. 7 (MR has a
molecular weight of 107 kDa).
The expression patterns of 113HSD-1 and -2 enzymes, GR
and MR throughout the menstrual cycle are summarised in the
schematic diagram in Fig. 8.
4. Discussion
with no significant difference across the cycle. Expression of
GR protein increased across the cycle in the surface epithelium,
from negligible expression in the proliferative and early secre¬
tory phases to weak expression in the late secretory phase. There
was high expression of the protein in first trimester decidua.
Fig. 5 illustrates patterns of immunoreactivity in the functional
layerof the endometrium. These data again support our previous
data (Henderson et al., 2003).
We have shown here that 11 (3HSD-2 enzyme is expressed
in the cytoplasm of the glands in both the functional and basal
layers of normal human endometrium, and also at low levels
in the stroma of the functional layer. The level of expression
remains constant across the menstrual cycle. Levels of 11(3HSD-
2 protein are increased in first trimester decidua, suggestive that
1 l(3HSD-2 may well be involved in trophoblast invasion at the
onset of pregnancy, by regulating ligand access to the GR and
76 S.E. McDonald et al. /Molecular and Cellular Endocrinology 248 (2006) 72-78
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Fig. 5. Immunohistochemical staining showing expression of GR in the func¬
tional layer of human endometrium and first trimester decidua. Brown staining
indicates positive GR immunoreactivity, blue stain is a negative counterstain. (A)
Proliferative phase endometrium, (B) secretory phase endometrium and (C) first
trimester decidua. Bottom right inset shows human endometrium as a negative
control. G, glandular epithelium.
thereby preventing cortisol-mediated inhibition of matrix met-
alloproteinases (MMPs).
There was a large increase in 11J3HSD-1 mRNA levels in
endometrium at the time of menstruation in comparison to
endometrium at other stages of the menstrual cycle. This may
reflect an anti-inflammatory response, as both decidualisation
and menstruation involve extensive remodelling of tissue. Cor¬
respondingly, levels of GR mRNA are also increased at men¬
struation. There may also be a link between 11 (3HSD-1 activity





















Fig. 6. Expression of MR mRNA across the menstrual cycle, in first trimester
decidua and uNK cells. M, menstrual; P, proliferative; ES, early secretory; MS,
mid-secretory; LS, late-secretory; D, deciduas; uNK, uterine natural killer cells.
*P<0.05.
also been shown that MMP levels are modulated by activation
of the hypothalamic-pituitary-adrenal axis, ofwhich Cortisol is
a product (Yang et al., 2002). Glucocorticoids are potent regula¬
tors of extracellular matrix degrading enzymes, ofwhichMMPs
are a large group. 11 fJHSD-1 mRNA levels were also greatly
increased in uNK cells. These are a phenotypically unique cell
type that increase in number in response to progesterone in
the non-pregnant secretory phase. The uNK population further
increases in the first trimester of pregnancy. The increase in
11J3HSD-1 mRNA expression in first trimester decidua may be
due in part to expression of the mRNA in these uNK cells, a
major component of the leukocyte population in first trimester
decidua.
Other roles have been proposed for 1 1 (11 ISDs in the
endometrium and decidua. It is widely documented that
11 [3HSD-2 levels are high in placenta, in order to protect the
fetus from high levels of circulating maternal glucocorticoids.
Within the placenta, 11 fil ISD-2 has been localised to the syn-
cytiotrophoblast (Krozowski et al., 1995). This is the same cell
type that invades decidua in the first trimester of pregnancy, and
thus may contribute to the increased levels of 11 (3HSD-2 seen
in first trimester decidua.
11 (II ISDs may also be involved in the regulation of var¬
ious cellular events, by modulating glucocorticoid availabil¬
ity, including proliferation (Bigsby and Young, 1993), apop-
tosis (Terada et al., 1991; Jo et al., 1993), and biosynthe¬
sis of hormones, growth factors and enzymes such as MMPs
(Makrigiannakis et al., 1992; Salamonsen and Woolley, 1996).
Hoffman et al. (1984) also suggested glucocorticoids may be
involved in inhibition of implantation. This could explain the
increase in 11 (3HSD-2 seen in first trimester decidua, to increase
the synthesis of cortisone, and thus decrease Cortisol levels,
removing the inhibitory effect.
GR was expressed in the stroma across the menstrual cycle
and in decidualised endometrium. Levels in the endometrial
glands were up-regulated in first trimester decidua. This con¬
firms data previously published (Henderson et al., 2003). GR
is predicted to be co-localised with 11 [3I1SD-1, thus both the
ligand (Cortisol) and the receptor are present in the same cells.
Both GR and 11 (3HSD-1 mRNA levels are up-regulated in first




Fig. 7. Immunohistochemical staining showing expression of MR in the func¬
tional layerofhuman endometrium and human kidney. Brown staining illustrates
positive MR immunoreactivity, blue stain is a negative counterstain. (A) Secre¬
tory phase endometrium, (B) first trimester decidua and (C) human kidney.
Bottom right inset shows human endometrium as a negative control. (D) Western
immunoblot showing MR (molecular weight 107 kDa) in human endometrium
(50 p,g protein) and placenta (20 pug protein). Endo, endometrium; Plac, pla¬
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Fig. 8. Schematic diagram summarising expression patterns of 11 fSHSD-1 and
-2 enzymes, GR and MR across the menstrual cycle.
trimester decidua, and also in menstrual endometrium. Corti¬
sol binding to GR is a vital step in the pathway that elicits an
anti-inflammatory response to tissue remodelling.
Cortisol has a greater affinity for MR than for GR, and can
act as a potent mineralocorticoid when it binds to MR. Excess
binding of Cortisol to MR can cause a number of disorders, in
particular apparent mineralocorticoid excess and hypertension.
(Wilson et al., 1995, cited by Smith et al., 1997) In order to
prevent this, 1 ipHSD-2 is normally co-localised with MR. MR
mRNA studies have shown that this indeed seems to be the case.
MR is expressed across the normal menstrual cycle, and in first
trimester decidua, with an increase at the time of increased ovu¬
latory progesterone concentrations, and a drop in expression
when progesterone is withdrawn, suggestingMR is directly reg¬
ulated by progesterone. Preliminary immunohistochemical data
shows that MR expression in human endometrium is primar¬
ily cytoplasmic; however in first trimester decidua expression is
both cytoplasmic and nuclear. This corresponds with the pattern
of lipHSD-1 expression, regulating the availability of ligand
to bind MR. When 11(11 LSD-1 levels, and thus Cortisol levels,
are low, MR expression is predominantly cytoplasmic. In first
trimester decidua, when 11 (3HSD-1 levels (and thus Cortisol lev¬
els) are elevated, MR is seen in nuclei also. This suggests that
MR translocates to the nucleus when ligand is bound, as also
reported (Sartorato et al., 2004).
Interestingly, mRNA studies in uterine natural killer cells
have shown that these cells express 11(3HSD-1 and GR, however
have negligible 113HSD-2 orMR expression. There is currently
little known about the precise role of these cells; however, it
appears that glucocorticoid function is required whereas min¬
eralocorticoid action is not. As there is very little MR present,
1 I (11ISD-2 is not required to protect from excess Cortisol bind¬
ing. Previous studies have shown lipHSD-1 mRNA and pro¬
tein to be expressed in murine splenic lymphocytes (Zhang
et al., 2005), and in human monocytes upon differentiation to
macrophages (Thieringer et al., 2001). 11 (1MSD-2 was not seen
to be present in either cell type.
Expression patterns of these steroid metabolising enzymes
and their cognate receptors are vital in understanding pivotal
78 S.E. McDonald et al. / Molecular and Cellular Endocrinology 248 (2006) 72—78
reproductive events, such as menstruation and implantation, as
this information will allow development of new treatments for
reproductive disorders.
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BACKGROUND; There are concerns of reduced pregnancy rates with the use of gonadotrophin-releasing hormone
antagonists (GnRH antagonists) in IVF/ICSI cycles. Sex steroids and their metabolizing enzymes in the endometrium
may play a vital role in embryo implantation. This study has evaluated the levels and localization of sex-steroid recep¬
tors and metabolizing enzymes, 3 (3-hydroxysteroid dehydrogenases (3(3HSD) and selected 17J3-HSD (17(3HSD), in
mid-luteal endometrium of women treated with GnRH antagonist (Cetrorelix) and recombinant FSH (rFSH;
Gonal-F) with luteal phase progesterone supplementation. METHODS: Mid-luteal phase endometrial biopsies
were obtained from oocyte donors undergoing ovarian stimulation and from control women with regular periods.
Iminunohistochemistry and real-time quantitative—polymerase chain reaction (QRT-PCR) were used to compare
protein and mRNA expression of progesterone receptor (PR), estrogen receptor a (ERa), estrogen receptor (3
(ER|3), androgen receptor (AR), 3(3HSD1, 3J3HSD2, 17(3HSD2 and 17(3HSD5. RESULTS: Cetrorelix-rFSH treat¬
ment caused a mid-luteal suppression of PR protein expression in the endometrial stroma, surface epithelium and
glands, although expression in the glands of control samples was variable. In contrast, the treatment caused an
increase in PR staining in perivascular cells. No other significant differences in protein expression were observed
between the two groups. mRNA levels of AR, ERa, 3(3HSD1 and 17(3HSD2 were significantly reduced in the treatment
group. PR mRNA levels were also reduced by GnRH antagonist-rFSH treatment, but the difference was not signifi¬
cant. CONCLUSIONS: Changes in the expression of sex-steroid receptors and metabolizing enzymes may lead to
alterations in the activity and intracellular availability of estrogens, progestogens and androgens in endometrium
of women treated with Cetrorelix and rFSH. Their impact on embryo implantation merits further evaluation.
Keywords: endometrium; GnRH antagonists; recombinant FSH; sex-steroid receptors; steroid metabolizing enzymes
Introduction
Gonadotrophin-releasing hormone antagonists (GnRH anta¬
gonists), e.g. Cetrorelix and Ganirelix, are now widely used
in assisted conception treatments (Albano et al., 2000; Oli-
vennes et al., 2000; The European and Middle East Orgalutran
Study Group, 2001; The North American Ganirelix Study
Group, 2001). They cause rapid suppression of LH levels and
have been found to reliably prevent premature LH surges as
a part of controlled ovarian hyperstimulation (COH) in IVF/
ICSI treatment (Albano et al., 2000). Their use shortens the
treatment cycle and also reduces the total amount of required
gonadotrophins. Furthermore, they appear to reduce the
incidence of ovarian hyperstimulation syndrome (Ludwig
et al., 2001; Al-Inany et al., 2006). However, in comparison
to the 'long protocol' with GnRH agonists, with the use of
GnRH antagonists there is an ongoing debate regarding preg¬
nancy rates. Whereas some studies have found similar preg¬
nancy rates (Ludwig et al., 2001), others have raised concerns
about a drop in pregnancy rates (Al-Inany et al., 2006).
Despite the advances in assisted conception practices,
pregnancy rates are ~20-25%. In stimulated cycles, the endo¬
metrium is exposed to supraphysiological steroid hormone
levels during the follicular phase and this might be responsible
for an altered steroid receptor expression profile in the early
luteal phase (Papanikolaou et al., 2005). After treatment
with recombinant FSH (rFSH) and a GnRH antagonist, endo¬
metrial histological advancement at the time of oocyte
© The Author 2007. Published by Oxford University Press on behalf of the European Society ofHuman Reproduction and Embryology.
All rights reserved. For Permissions, please email: journals.permissions@oxfordjoumals.org
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retrieval has been observed (Kolibianakis et al., 2002). There
are limited data however on the state of the endometrium
during the putative window of implantation. Although not
clearly defined, the window of implantation is described as
from Day 5 to Day 10 after the LH surge (Sharkey and
Smith, 2003).
GnRH antagonists and rFSH may impact the processes of
implantation through direct effects on the endometrium or
indirectly through sex steroid availability and activity.
Estrogens (Norwitz et al., 2001; Ma et al., 2003), progesto¬
gens (Lessey, 2003) and probably also androgens (Apparao
et al., 2002) are thought to play vital, but as yet not fully
defined, roles in the complex mechanisms underlying endo¬
metrial development leading up to and after embryo implan¬
tation. These hormones act via their cognate receptors. An
alteration of the receptor expression profile could lead to
changes in the function of the respective steroid hormone.
Intracellular ligand availability could also determine endo¬
metrial receptivity. The enzyme 3(3-hydroxysteroid dehydrogen-
ase/55-84-isomerase (3(3HSD) is involved in the biosynthesis of
all classes of active steroids. Pregnenolone is converted to pro¬
gesterone under the effect of 3(3HSD in the human endometrium
and this might be crucial for implantation and maintenance of
pregnancy. In the secretory phase, 3(3HSD is moderately
expressed in the glandular epithelium of the endometrium
(Rhee et al., 2003).
The enzymes 17f3HSD2 and 17(3HSD5 have been identified
in the human endometrium. The 17(3HSD5 transforms not
only androstenedione to testosterone and estrone to estradiol
(E2), but also progesterone to 20-hydroxyprogesterone. In
the endometrium, its expression has been localized to the
surface epithelium and the vascular endothelium (Pelletier
et al., 1999). The 17(3HSD2 has a major role in the inacti-
vation of E2 to estrone. It is also responsible for converting
androgens to less potent forms, while also activating pro¬
gesterone. It is expressed in endometrial glandular epithelium,
and is up-regulated by progesterone (Maentausta et al., 1993).
The availability of various androgenic ligands to bind to the
androgen receptor (AR) may be influenced by the local pre¬
sence of 17(3HSD2 (Burton et al., 2003). The activity of
17(3HSD2 has been localized predominantly in the glandular
epithelium but also in the endometrial stroma. It has been pos¬
tulated that the antiestrogen action of progesterone in the
endometrial glands is mediated through this enzyme (Casey
et al., 1994; Burton et al., 2003).
The aim of this study was to compare the physiological mid-
luteal endometrium with the endometrium during the putative
window of implantation after treatment with rFSH and GnRH
antagonists, by mimicking the exact conditions that would be
expected to occur in an IVF/ICSI treatment cycle. We aimed
to determine the endometrial intracrinology in relation to
expression of sex-steroid receptors and steroid metabolizing
enzymes during the putative window of implantation.
Materials and Methods
First, we studied the sex-steroid receptor expression during the mid-
secretory phase (Table 1). Sex-steroid receptor protein expression
was studied with immunohistochemistry (IHC), and the mRNA
expression was studied with real-time quantitative-polymerase
chain reaction (QRT-PCR). Second, we evaluated the steroid metabo¬
lizing enzymes expression during the mid-secretory phase (Table 1).
Enzyme expression was studied with IHC, and mRNA expression
was studied with QRT-PCR.
Patient characteristics
Institutional ethical approval was obtained and all women gave
informed written consent. The study group consisted of parous
women volunteers who had come forward to donate oocytes. These
women underwent a cycle of ovarian stimulation as per the Edinburgh
Assisted Conception Unit's protocol (Thong et al., 2003). The rFSH
(Gonal-F; Serono, UK) was commenced on Day 4 of the menstrual
cycle. All donors commenced ovarian stimulation at the dose of
150 IU. GnRH antagonist, Cetrorelix, was commenced at a dose of
0.25 mg daily on Day 7 or 8 of their cycle once two or more follicles
had reached the size of 11 mm diameter. Ovarian response was mon¬
itored by transvaginal ultrasound from Day 4. When the three largest
follicles measured >17mm, oocyte maturation was triggered by the
administration of a single s.c. injection of 10 000 U human chorionic
gonadotrophin (hCG) (Profasi; Serono). Oocyte retrieval was per¬
formed 35-36 h after hCG administration. Progesterone (Cyclogest;
Alpharma, UK) vaginal pessaries (200 mg) were administered 12
hourly starting 2 days after oocyte retrieval and up to the day of endo¬
metrial sampling. A pipelle endometrial biopsy (EB) was conducted
8-10 days after hCG administration.
The control group consisted of 12 healthy parous women with
regular menses (25-35 days). Endometrial biopsies from eight of
these women were available for the IHC studies. The women were
asked to provide a urine sample on alternate days from Day 10 of
their last menstrual period (LMP). Urinary LH levels were measured.
An EB was performed 6-10 days after the peak of a urinary LH surge
(Fig. 1). Only parous women who attended the gynaecology clinics
with requests for sterilization or other complaints excluding menstrual
problems or infertility were included in the control group.
From the control subjects, endometrial tissue from a subset of five
parous women was available for QRT-PCR studies. In these women,
the LMP, endometrial histology and serum progesterone levels were
all consistent with mid-luteal phase of the cycle. This subset was
chosen on the basis of mRNA quality. Since we were comparing
mRNA expression in the mid-secretory phase during the putative
window of implantation, it was appropriate to include mid-secretory
phase endometrium from fertile women with confirmed ovulation.
Endometrial biopsies were conducted during the mid-luteal stage of
the cycle (Fig. 1). Serum progesterone level was checked at the time of
the EB to confirm mid-luteal stage. All endometrial samples were his¬
tologically classified as per the Noyes criteria (Noyes et al., 1950).
Endometrial tissue was fixed in 4% paraformaldehyde then embedded
in paraffin for immunohistochemical analysis. In addition, endome¬
trium was also frozen at the point of tissue collection in liquid nitrogen
Table 1: Details of study biopsy analyses
Control, mean age Study, mean age
(years) (n) (years) (n)
/'-value
Sex-steroid receptors and mRNA expression
IHC 38(8) 31(5)
QRT-PCR 41 (5) 31 (4)
Steroid metabolizing enzymes and mRNA expression




















Day 1 start Urinary LH surge EB
of menses
Figure 1: Timing of EB in the study and control group
OR, oocyte recovery, EB, endometrial biopsy
and stored at — 70°C. RNA was extracted from frozen endometrial
tissue.
The expression of progesterone receptor (PR), estrogen receptor a
(ERa), KRfS and AR and enzyme expression of 3J3HSD and
17|3HSD5 were studied with 1HC. The 3HSD antibody recognizes
both human 3(iHSD I and 3(3HSD2 enzymes. No documented anti¬
bodies were commercially available for 17J3HSD2 enzyme and
hence no immunochemistry was performed for this enzyme.
The PR, ERa, ER(3 and AR mRNA and 3(3HSD types 1 and 2 and
17fSHSD types 2 and 5 mRNA levels were studied with QRT-PCR.
Immunohistochemistry
Paraffin sections (5 p,m in thickness) were dewaxed in histoclear for
10 min and then rehydrated in descending grades of alcohol to distilled
water (dH20). The sections were washed in dHjO. After this, an
antigen retrieval step was performed. After a 10-min wash in
0.01 M phosphate-buffered saline (pH 7.4) (PBS, Sigma, Dorset,
UK), endogenous peroxidase activity was blocked. This was done
by incubating the sections in 3% hydrogen peroxide in dH20 for
10 min at room temperature. Tissue sections were then washed for
10 min in PBS. This was followed by 15 min incubation with avidin
(Vector Laboratories Ltd, Peterborough, UK) at room temperature.
After a rinse in PBS for 2 min, the sections were incubated with
biotin (Vector Laboratories Ltd) for a further 15 min at room tempera¬
ture. Following a 2-min wash in PBS, normal horse serum (NHS, Vec-
tastatin, Vector Laboratories) was applied to each tissue section. This
was followed by incubation for 20 min in a humidified chamber at
room temperature. The excess serum was removed and the primary
antibody was applied. The negative control for the primary antibody
was substituted with mouse immunoglobulin G (mlgGl, Sigma) or
rabbit pre-immune serum at the same concentration.
After the primary antibody incubation, the sections were washed
between each stage for 10 min in PBS + Tween 20. The secondary
antibody was then applied. To identify positive staining, the peroxi¬
dase substrate diaminobenzidine (Dako, Cambridge, UK) was used
as chromogen for demonstration of epitope. Tissue sections were
washed in dH20 and counterstained with Harris's haematoxylin
(a non-specific purple nuclear stain), dehydrated in ascending grades
of alcohol and mounted from xylene using pertex mounting medium.
A similar protocol was used for immunostaining of all receptors.
Table 2 summarizes the incubation conditions for immunolocalization
of each of the epitopes studied. Commercially available antibodies
were used for immunolocalization of endometrial PR. ERa, ER(3
and AR. The 3pHSD rabbit polyclonal antibody was raised against
recombinant human 3pH.SD2 and recognizes both human 3pHSDl
and 3|jHSD2 with similar affinity (S.E. McDonald and J.I. Mason,
Table 2: IHC protocols
Protein of Antigen retrieval Avidin-biotin Primary antibody Negative control
interest Pressure cook (PC) pretreatment
Microwave (MW)
PR MW No Monoclonal mouse anti-PR antibody Mouse IgG
Buffer—0.01 M Na Citrate Novocastra, Newcastle, UK Sigma
1:40 in NHS 1:800
ERa MW No Monoclonal mouse anti-ERa antibody Mouse IgG
Buffer—0.01 M Na Citrate Dako Sigma
1:400 in PBS 1:2400 in PBS
ER(3 PC No Monoclonal mouse anti-ER[3 antibody NRS/TBS/BSA
Buffer—0.05 M Glycine/0.01% Serotec, Oxford, UK
EDTA (pH 8) NRS/TBS/BSA
AR PC Yes Monoclonal mouse anti-AR antibody Mouse IgG
Buffer—0.01 M Na Citrate Biogenex, CA, USA Sigma
1:240 1:300
Overnight incubation at 4°C
30HSD No antigen retrieval performed Yes Polyclonal rabbit anti-3(3HSD (recognizes both Pre-immune serum
isoforms) 1:500 in NGS/PBS/BSA
1:500 in NGS/PBS/BSA
Professor Ian Mason, University of Edinburgh
17J3HSD5 PC Yes Monoclonal mouse anti-17(3HSD-5 Mouse Ig
Buffer—0.01 M Na Citrate (pH 6) 1:200 in NHS/PBS/BSA Sigma
Professor Penning, University of Pennsylvania 1:300 in NHS/PBS/BSA
(Lin et al., 2004)
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unpublished observations). A mouse monoclonal antibody against
human 17HSD5 (Lin et al., 2004) was a generous gift from Dr
Trevor Penning (University of Pennsylvania, Philadelphia, USA).
Although we used a mouse monoclonal against human 17(3HSD2 in
an earlier study (Burton et al., 2003), neither this nor any commercial
17HSD2 antibody were currently available, and hence no immuno-
chemistry was performed for this enzyme.
RNA extraction and reverse transcription
Frozen samples of endometrium stored at — 70°C were homogenized
and then total RNA was extracted using Trizol (Invitrogen Life Tech¬
nologies Ltd, UK) according to the manufacturer's instructions. The
genomic DNA was removed by subjecting the RNA to DNAse treat¬
ment. After extraction, the concentration and quality of RNA were
assessed using an Agilent bioanalyzer (Agilent Technologies, South
Queensferry,West Lothian, UK). The reverse transcription (RT) reac¬
tion was performed as described previously (Henderson et al., 2003;
McDonald et al., 2006). In brief, a I Op.I volume of reaction solution
containing the following: 1 x Taqman RT buffer, magnesium chloride,
deoxyNTPs, random hexamers, Multiscribe reverse transcriptase,
RNase inhibitor and nuclease-free water (reagents from Applied Bio-
systems, Cheshire, UK) was used. An amount of 200 ng of template
RNA was added. The RT reaction was conducted at 25'C for
60 min, 48°C for 45 min and 95°C for 5 min for one cycle. An
RT-negative control had template RNA but no multiscribe enzyme
included, and an RT H20 had template RNA replaced by nuclease-free
water. Negative controls were included in every run. The samples
were then stored at — 20"C.
Quantitative real-time PCR
The primer/probe sets were designed using the Primer Express
program (PE Applied Biosystems) as described previously (Henderson
et al., 2003) or purchased from PE Applied Biosystems' Assay on
Demand service. Where possible these were chosen to span an
intron to further reduce the chance of spurious readings due to
genomic DNA contamination. The sequences of the primer/probe
sets and their location within the specified cDNAs are given in
Table 3. The 18S primers and probe were purchased from PE
Applied Biosystems. A Taqman real-time PCR mix was then prepared
containing final concentrations of Taqman universal PCR master mix
(lx), ribosomal 18S forward and reverse primers, and probe (50 nM;
PE Applied Biosystems), and forward and reverse primers (300 nM)
and probe for the sequence of interest (200 nM; PE Applied Biosys¬
tems). Wells were sealed with optical caps and the PCR was run on
the Perkin-Elmer ABI Prism 7900 (PE Applied Biosystems) using
standard conditions.
Taqman QRT—PCR was carried out with primers and probes
specific for the PR, ERa, ERp, AR, 30HSD types 1 and 2 and
17pHSD types 2 and 5. The validated primers and probes for
3(iHSDl, 3pHSD2 and 170HSD5 were 'Assay on Demand' products
supplied by PE Applied Biosystems and these primers were
intron-spanning.
Scoring, data presentation and statistical analysis
of immunoreactivity
The immunostaining intensity of epitopes in all tissue sections was
assessed in a semi-quantitative manner on a four point scale: 0, no
staining; 1, mild/minimal immunostaining; 2, moderate immunostain¬
ing and 3, intense immunostaining. All tissue sections were scored
blind by at least two observers. The semi-quantitative IHC data
were analysed using the Mann-Whitney test. The QRT-PCR data




In the patients treated with a rFSH-GnRH antagonist, almost
all biopsies with adequate tissue showed histological features
consistent with mid-secretory phase of the cycle. In one
biopsy, there were features suggestive of advancement of the
dates and this was reported to be consistent with early to mid-
secretory phase endometrium.
We examined the immunoexpression of PR, ERa, ERp,
AR, 3PHSD and !7(3HSD5 at five cellular locations, i.e.
endometrial glands, stroma, surface epithelium, vascular
endothelium and perivascular cells. The mRNA transcripts of
PR, ERa, ERP, AR, 3pHSDI, 3PHSD2, 17pHSD2 and
17PHSD5 were evaluated.
Table 3: Steroid receptor primer and probe sequences used for amplification by real time QRT-PCR
Primer/probe Sequence Position Accession no.
AR forward GTACCCTGGCGGCATGGT 951-1016 L29496
AR reverse CCCATTTCGCTTTTGACACA 951-1016 L29496
AR probe AGCAGAGTGCCCTATCCCAGTCCCA 951-1016 L29496
ERB1 forward CCTGGCTAACCTCCTGATGCT 1459-1480 AB006590
ERB1 reverse CCACATTTTTGCACTTCATGTTG 1529-1552 (r) AB006590
ERB1 probe AGATGTTCCATGCCCTTGTTACTCGCA 1499-1525 (r) AB006590
ER forward TGATTGGTCTCGTCTGGCG 1523-1541 NM_000125
ER reverse CATGCCCTCTACACATTTTCCC 1602-1624 (r) NM.000125
ER probe TGCTCCTAACTTGCTCTTGGACAGGAACC 1572-1600 NM_000125
PR forward CAGTGGGCGTTCCAAATGA 2151-2170 NM_000926
PR reverse TGGTGGAATCAACTGTATGTCTTGA 2709-2233 (r) NM_000926
PR probe AGCCAAGCCCTAAGCCAGAGATTCACTTT 2170-2199 NM_000926
17pHSD-2 forward TGTCAGCAGCATGGGAGGA 731-803 Lll 708
17PHSD-2 reverse GGTCACAGCCGCCTTTGAT 731-803 Lll 708
17|3HSD-2 probe CCCCAATGGAAAGGCTGGCATCTT 731-803 Lll 708
30HSD1 Assay on demand Hs00426435_m 1
33HSD2 Assay on demand Hs00605123_ml
17pHSD5(AKRlC3) Assay on demand Hs00366267_m 1
The positions of the sequences are given within the cDNA identified by the accession number; r denotes reverse strand.
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Table 4: Immunohistochemical semi-quantitative scores
Glands Stroma Surface Vascular endothelium Perivascular cells
epithelium
PR 0.003*'" 0.019*'" 0.019*'" >0.99 0.023*'b
ERa 0.057 0.213 >0.99 No immunoreactivity 0.769
seen
ER|3 0.523 0.063 0.694 0.271 0.446
AR 0.379 0.379 0.826 0.464 0.464
3j3HSD 0.235 No immunoreactivity 0.522 0.361 No immunoreactivity
seen seen
17PHSD5 0.465 No immunoreactivity 0.411 0.404 No immunoreactivity
*P < 0.05 denotes statistical significance (Mann—Whitney test).
"PR was down-regulated in endometrial glands, stroma and surface epithelium of women treated with rFSH and GnRH antagonist.
bPR was up-regulated in the perivascular cells in the endometrium of women treated with rFSH and GnRH antagonist.
Immunohistochemistry
Sex-steroid receptors
PR immunoexpression (Table 4, Figs 2A and 3) Compared with
endometrium from untreated women, endometrium exposed to
Gonal-F and Cetrorelix showed significantly reduced immu¬
noexpression in stroma (P < 0.05) and surface epithelium
(P < 0.05). Conversely, PR immunoreactivity was signifi¬
cantly increased in the perivascular cells (P < 0.05). The
difference in PR immunoexpression in the glands was signifi¬
cant (P < 0.05), but we observed a marked variability in
expression among the biopsies in the control group. ERa immu¬
noexpression (Table 4, Figs 2B and 3) Mild immunoexpression
of ERa was observed at most cellular locations. No ERa
immunoexpression was observed in the vascular endothelium.
No significant differences were observed in endometrial ERa
immunostaining between the two groups of women. ER/3
immunoexpression (Table 4, Figs 2C and 3) ER(3 immunoex¬
pression at most cellular locations was consistently strong
with or without treatment with GnRH antagonist and rFSH.
Stromal expression was less intense, but overall no significant
differences were observed in endometrial ER3 immunoexpres¬
sion between the two groups of sub jects. AR immunoexpression
(Table 4, Fig. 2D) AR immunoexpression was negligible in
the glandular epithelium with or without COH treatment.
Stromal immunoexpression of AR was moderate, but overall
no significant differences were observed in endometrial AR
immunostaining between the two groups of subjects.
Steroid metabolizing enzymes
3jiHSD immunoexpression (Table 4, Figs 2E and 4)
Irrespective of COH, expression of 3(3HSD in the glands,
surface epithelium and endothelium was at a low level. No
immunoexpression was seen in stroma or in perivascular
cells. No significant differences were observed in endometrial
3(3HSD immunostaining between the two groups of subjects.
17fillSD5 immunoexpression (Table 4, Figs 2F and 4)
Moderate to intense 17(3HSD5 immunoexpression was
observed in the endometrial glands, and surface epithelium
with or without treatment. No immunoexpression was observed
in stroma, however, negligible immunoexpression was
observed in perivascular cells. Moderate immunoexpression
was observed in the vascular endothelium. No significant
differences were observed in endometrial 17(}HSD5 immuno¬
staining between the two groups of subjects.
Quantitative real-time PCR (Table 5, Fig. 5)
Sex-steroid receptors
QRT-PCR demonstrated a statistically significant reduction in
the amount of endometrial ERa mRNA (P — 0.02) and AR
mRNA (P=0.01) in COH treated women compared with the
controls. Although the level of PR mRNA was reduced in the
COH group, the difference was not significant (P = 0.12).
No significant differences were observed in the amount of
ER(3 mRNA (P = 0.96) between the two groups.
Steroid metabolizing enzymes
The 33HSD1 mRNA (P = 0.01) and I7|3HSD2 mRNA (P =
0.02) levels were significantly reduced in the COH group. In
relation to 3(iHSD2 and 17|3HSD5 QRT-PCR, sufficient
RNA was only available in 1 and 2 study samples, respectively.
Hence in these cases, the sample size was too small for analy¬
sis. However, expression of adrenal/gonadal-specific 3|3HSD2
transcripts is predicted to be minimal in endometrium and the
relative 3(3HSD1/33HSD2 transcript ratio observed in the one
sample is supportive of a minimal 3(3HSD2 contribution to
endometrial 3(3HSD.
Discussion
The use of rFSH and a GnRH antagonist is an effective and
reliable regime for controlled ovarian stimulation as a part of
IVF/ICSI treatment cycles. However, its effects on the endo¬
metrium especially in relation to embryo implantation have
not been evaluated in detail. Although histological advance¬
ment of the chronological stage of the endometrium has been
observed at the time of oocyte retrieval (Kolibianakis et al.,
2002), the endometrial sex-steroid receptor protein and
mRNA expression levels during the putative window of
implantation, to our knowledge, have not been reported. Fur¬
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Figure 2: Immunoreactivity scores in endometrial glands, stroma,
surface epithelium, endothelium and perivascular cell compartments
of women in the mid luteal phase of cycle (control group) and in
women who have received COH and a GnRH antagonist (study group)
(A) PR, (B) ERa, (C) ERp, (D) AR (E) 3pHSD enzyme and
(F) 17PHSD5 enzyme. Note decreased PR in endometrial stroma
(P — 0.019), surface epithelium (P = 0.019) and glands (P = 0.003),
and increased PR in perivascular cells (P = 0.023). Box-and-whisker
plots: box represents the 25th and 75th percentiles, whiskers represent
the 10th and 90th percentiles and the heavy bar represents the
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Figure 3: Immunohistochemical localization of steroid receptors in
human endometrium of women in the mid-luteal phase of cycle
(control group) and in women who have received rFSH and a GnRH
antagonist (study group)
(A) PR immunostaining in endometrium from untreated women in
mid-luteal phase—intense stromal (S) and surface epithelial (SE)
immunoreactivity (A) inset: note low level of perivascular immunos¬
taining (arrows). (B) PR immunostaining in the endometrium from
women treated with a GnRH antagonist and rFSH—reduced stromal
and surface epithelial immunostaining. (B) inset: more intense peri¬
vascular cell immunostaining (arrows). (C) ERa immunostaining in
endometrium from women treated with rFSH and a GnRH antagon¬
ist—mild immunostaining at all cellular locations. (C) inset: absent
immunostaining in the vascular endothelium (arrow). (D) ERp immu¬
nostaining in endometrium from women treated with rFSH and a
GnRH antagonist—strong immunoreactivity in all cell types. (D)
inset: strong ERp immunostaining in vascular endothelium. Scale
bar — 20 microns. G, glands
of steroid metabolizing enzymes and their mRNA transcripts
during the window of implantation in the mid-luteal phase of
the cycle.
Here, we report a significant difference in PR protein
expression in women treated with rFSH and GnRH antagonist.
Significant down-regulation of PR protein expression in
the endometrial stroma and surface epithelium was observed.
A significant up-regulation was observed in the perivascular
cells in women treated with Cetrorelix and Gonal-F. PR immu-
noexpression in the endometrial glands was reduced in the
treatment group, although the expression in the controls was
variable. No significant differences were observed in the
protein expression of ERa, ERp, AR, 3PHSD or 17PHSD5.
Quantitatively, there was a significant reduction in the levels
of ERa mRNA, AR mRNA, 3PHSD1 mRNA and 17PHSD2
mRNA in the treatment group. No significant difference was
observed in the amount of ERp mRNA transcripts between
the two groups of women, and although PR mRNA was
reduced in the treatment group, the difference was also not
significant.
Healthy fertile women were recruited as the control group.
We acknowledge that women undergoing assisted conception
are a different group with alterations in physiological steroid
levels and possibly in the endometrium. Hence, recruiting
untreated parous women as a control group may not be the
2986
Mid-luteal endometrial intracrinology after COH
G
■ yVV-i,l*s63Kfc ; ,JA ,* ♦ -v. - • .
,|T ;
-'trfl cv. -i M|
f*- •.• >'' *• n f f • 1^ if /* /« .- C * <.■'■■■> mm: ■ '<-*■ ?■' ".J
fTx.-vif-_ K • w ,v> %mm*» ' * '• ' «*> »' ' ' •#
i Ctr* 11 "V«V. {.®^K I
jf- G
3p V #?<; • A y&irWF■••'- .- 70. S s£*L-. .'*** .' *( mm 'v1-
A* - fi, I't-t.JT
■ --. ■ vi . v... . * . „ * . •.. hw ' »<j« • - ..Or
•--"t»" var.v SBH^BIBh \ mjlfc • £W». ,
Figure 4: Immunohistochemical localization of selected steroid metabolizing enzymes in human endometrium of women in the mid-luteal phase
of cycle (control group) and in women who have received rFSH and a GnRH antagonist (study group)
(A) 3pHSD immunostaining in endometrium from untreated women in mid-secretory phase—low level immunostaining at most cellular
locations. (A) inset: low level immunostaining in vascular endothelium (arrow). (B) 3(3HSD immunostaining in the endometrium from
women treated with rFSH and GnRH antagonist—low level immunostaining at most cellular locations. (B) inset: 3pHSD negative—no immu¬
nostaining. (C) 17PHSD5 immunostaining in endometrium from untreated women in mid-secretory phase—moderate immunostaining in glands
(G) and surface epithelium (SE). No immunostaining in stroma (S). (C) inset: moderate immunostaining in vascular endothelium (arrow). (D)
17fSHSD5 immunostaining in endomeuium from women treated with rFSH and GnRH antagonist—moderate immunostaining in glands and
surface epithelium. No immunostaining in stroma. (D) inset: 17(3HSD5 negative—no immunostaining. Scale bar = 20 microns
ideal equivalent comparison. However, our aim was to try and
understand the differences between the physiological state of
embryo implantation, which occurs in the mid-luteal phase in
a natural ovulatory cycle, and in rFSH and a GnRH antagonist















*P < 0.05 denotes statistical significance (/-test after log transformation),
"indicates reduction of mRNA level in the study compared with control
group.
treated endometrium. Hence, it was appropriate to include
untreated fertile ovulatory women in the control group.
In the subjects in the control group, an LH surge was
detected using an alternate day urinary LH protocol. We
acknowledge that urinary LH measurement may not be the
most accurate way of checking the timing of ovulation.
However, it is possible to identify the window of implantation
on the basis of an alternate day urinary LH dating protocol.
First, the window of implantation is thought to extend over
Days 5-10 after the LH surge. Hence, even with urinary LH
dating, we are likely to identify the putative window of implan¬
tation. Second, it is theoretically possible that the difference of
1 or 2 days could influence the result. We have however dated
the endometrium not only by LH dating, but also by histologi¬
cal dating and mid-luteal serum progesterone concentration at
the time of EB. We are thus confident that the endometrium
was sampled during the mid-luteal stage and certainly during
the window of implantation. There are no data to suggest that
a difference of 1 or 2 days is likely to have a major impact
on the sex-steroid receptor expression. Indeed with the excep¬

























































































Figure 5: Quantitative evaluation of sex-steroid receptors and steroid receptor metabolizing enzymes mRNA expression of women in the mid-
luteal phase of cycle (control group) and in women who have received COH and a GnRH antagonist (study group)
(A) PR, (B) ERa, (C) ERp, (D) AR, (E) 3(3HSD1 enzyme and (F) !7fiHSD2 enzyme. All endometrial tissue samples were compared with an
internal control (comparator) obtained during the mid-luteal phase of the menstrual cycle. ERa mRNA (P = 0.02) and AR mRNA (P = 0.01)
levels were significantly reduced in endometrial tissue from women treated with a GnRH antagonist and rFSH. 3pHSDl mRNA (P = 0.01)
and 17(jHSD2 mRNA (P = 0.02) levels were significantly reduced in the endometrial samples from women treated with a GnRH antagonist
and rFSH. Note scale(Y axis) in E and F differs from A-D
after treatment with ganirelix (Simon et al., 2005), where no
alteration in the steroid receptor expression was reported, we
are not aware of any data describing the steroid receptor
expression in the mid-luteal phase after treatment with rFSH
and a GnRH antagonist.
Luteal phase progesterone supplementation was adminis¬
tered to the oocyte donors (study group) to mimic an actual
treatment cycle. Evidence exists to support the use of luteal
phase progestogens after any form of down-regulation in an
IVF/ICSI treatment cycle (Beckers et al., 2003) and most
centres offer this routinely. Administering progesterone sup¬
plementation in one group (study) and not in another
(control) may add an element of bias. However, our aim was
to compare the differences in the mid-luteal phase endo¬
metrium from fertile untreated subjects, i.e. the physiological
state with the mid-luteal endometrium of women routinely
treated with a GnRH antagonist and rFSH.
This study has shown that under the effect of a GnRH antag¬
onist and rFSH with luteal phase progesterone supplemen¬
tation, there is a significant down-regulation of PR in the
surface epithelium. The observation of PR down-regulation
in the surface epithelium is in agreement with other studies
evaluating PR content in the secretory phase of a normal men¬
strual cycle. It has been suggested that under the influence of
progesterone, PR declines in the epithelium at the beginning
of the window of implantation (Lessey etal., 1996). It therefore
appears that any hormonal fluctuations that may result in the
serum due to treatment with Cetrorelix and Gonal-F have
little impact on intracellular PR in surface epithelium. In the
secretory phase of a normal menstrual cycle, significant PR
expression has been detected in the endometrial stroma
(Lessey et al., 1988). However, under the effect of a GnRH
antagonist and rFSH and with progesterone supplementation,
we found a significant down-regulation of PR in endometrial
stroma. Several genes have been localized to the endometrial
stroma and significant proportions are expressed during
the secretory phase (Yanaihara et al., 2004). Studies have
also shown an important role for progesterone in the endo¬
metrial stromal cell in induction of extracellular matrix in
relation to implantation (Nakamoto et al., 2005). A significant
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down-regulation of stromal PR could thus influence gene
expression during the secretory phase and adversely impact
endometrial receptivity. PR protein has not been identified in
the vascular endothelium (Krikun et al., 2005), but they are
abundantly expressed in the perivascular cells throughout the
menstrual cycle (Perrot-Applanat et al., 1988; Critchley
et al., 2001). In this study, PR was significantly up-regulated
in the perivascular cells of women treated with Cetrorelix
and Gonal-F. Progesterone acting on the perivascular cells
has been implicated in the modulation of endometrial blood
flow. Furthermore, cytokine control in the perivascular cells
is thought to be controlled by progesterone (Kelly et al.,
2002). These factors may well be important in the process of
embryo implantation, and alterations of PR expression could
influence these processes. PR expression in the glands of
untreated women was variable. In regular cycling women, in
the secretory phase, significant PR content was maintained in
the stroma, but diminished in the glandular epithelium
(Lessey et al., 1988). In this study, in some control biopsies,
moderate glandular PR expression was maintained however,
as evident in the box and whisker plot, there was marked varia¬
bility in expression between biopsies. The number of women
included in our study was small and this may have contributed
to the apparent trend towards an increased mid-secretory PR
expression in glands in untreated women. Furthermore, the
women included in the control group were different from
those who provided the study biopsies in the treatment group.
Whereas ideally, we would have liked to recruit the same
oocyte donors as controls to further reduce the bias, practically
it was only reasonable to seek an EB from an altruistic oocyte
donor on a single occasion. In the control group, the mid-luteal
phase was confirmed through consistency of reported LMP, cir¬
culating serum progesterone levels and histological dating. It is
interesting to note that with rFSH and a GnRH antagonist treat¬
ment, glandular PR immunoexpression declined. This obser¬
vation would be consistent with PR expression in the
secretory phase of an untreated cycle. PR mRNA levels are
known to vary during the human menstrual cycle. In the late
proliferative phase, glandular PR mRNA levels are signifi¬
cantly higher but it reduced in the secretory phase. In the
stroma, PR mRNA remains unchanged (Lau et al., 1996).
Although there was some reduction in PR mRNA levels in
the treatment group compared with the controls, the difference
was not significant. However, PR changes in whole biopsies
may not reflect the subtle changes in steroid receptor
expression that exist between individual cell types.
In regular cycling women, ERa and ER(3 have been identi¬
fied in the endometrial epithelium, stroma, glands and perivas¬
cular cells (Saunders and Critchley, 2002). Only ER(3 and not
ERa is expressed in the vascular endothelium (Critchley et al.,
2001). Wc did not observe any significant difference in immu¬
noexpression of either ERa or ERfJ in treated women. Con¬
trolled ovarian stimulation is known to lead to
supraphysiological levels of E2 and progesterone. These are
thought to affect the endometrial receptivity through the predo¬
minantly progestational effects of endometrial phase advance¬
ment and premature luteinization (Kolb and Paulson, 1997).
Hence, it appears that ER-mediated signalling appears to be
of less importance in relation to implantation compared with
PR mediated effects on the endometrium. It is interesting to
note however that quantitative RT-PCR showed significantly
reduced ERa mRNA levels in the treatment group.
AR expression is influenced by levels of circulating estro¬
gens and androgens. Epithelial AR is up-regulated by estrogens
and androgens and is inhibited by progestins (Slayden et al.,
2001; Apparao et al., 2002). AR is expressed in the endometrial
stromal cells. The intensity of expression declines from prolif¬
erative phase to mid-secretory phase. In late secretory phase,
AR expression is diminished in all cell types (Mertens et al.,
2001). We found no significant difference in protein expression
of AR in women treated with rFSH and a GnRH antagonist,
however, QRT-PCR showed significantly reduced AR
mRNA levels in the group of women treated with a GnRH
antagonist and rFSH. So far, there are very limited data on
effects of AR and AR-induced gene expression in humans.
Studies in pigs show AR in the pig endometrium during the
window of implantation and demonstrate the functional,
albeit complex, interactions of androgens and estrogens in
the regulation of uterine endometrial gene expression and
cell growth in vitro (Kowalski et al., 2004). Further studies
are needed to evaluate AR-induced gene expression in
humans and the potential impact on embryo implantation.
The 3(3HSD is weakly expressed in the glandular epithelium
of the proliferative phase and moderately expressed in the
glandular epithelium of secretory phase of the endometrium
(Rhee et al., 2003). In this study, irrespective of presence or
absence of treatment, immunoexpression of 3(3HSD in the
glands, surface epithelium and endothelium was at a low
level. No immunoexpression was seen in stroma and perivascu¬
lar cells. No significant difference was observed in endometrial
33HSD immunoexpression between the two groups of sub¬
jects. This suggests that the pre-ovulatory supraphysiological
levels of estrogen and progestogen that result from COH and
use of GnRH antagonists do not lead to any significant altera¬
tion in the levels of 3(3HSD protein during the window of
implantation. The currently available antibody against
3(3HSD recognizes both forms of human 3|3HSD enzymes,
types 1 and 2. Hence it is not possible to comment on
changes in the amounts of 33HSD1 protein. However, RNA
studies indicate that 3(3HSD1 mRNA transcripts may be chan¬
ging. We observed a significant reduction in 3(3HSD1 mRNA
in women treated with a GnRH antagonist and rFSH. The
33HSD1 is responsible for the conversion of inactive pregne¬
nolone to active progesterone and of dehydroepiandrosterone
to androstenedione. A reduction in 3(3 HSD1 transcripts will
ultimately lead to a reduction of intracellular progesterone. In
the presence of altered PR expression, as we observed with
IHC, it is likely that the reduced ligand availability for
hinding to PR leads to a disturbance in the dynamics of
ligand-receptor interaction. This may affect progesterone-
mediated signaling pathways including alterations in gene
expression profiles thereby affecting the receptivity of the
endometrium.
The 17(3HSD5 transforms androstenedione to testosterone
and also progesterone to the inactive 20-hydroxyprogesterone,
and in the endometrium its immunoexpression has been
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localized to the surface epithelium and the vascular endo¬
thelium (Pelletier et al., 1999). Our findings are in agreement
with previous reports. We did observe moderate to intense
17(3HSD5 immunoexpression in endometrial surface epi¬
thelium and vascular endothelium. However, in this study we
also observed moderate 17fJHSD5 immunoexpression in the
endometrial glands. No immunoexpression was observed in
stroma and negligible immunoexpression was observed in the
perivascular cells. No significant difference was observed in
the 17(3HSD5 immunoexpression between the two groups of
subjects. We observed a significant reduction of 17(3HSD2
mRNA in women treated with rFSH and a GnRH antagonist.
Since 17(3HSD2 is involved in the inactivation of E2 to
estrone and converting androgens to less potent forms, it is
likely that higher levels of intracellular E2 and androgens
persist thereby further disturbing the balance between estrogen,
progesterone and androgens. This may further affect the endo¬
metrial development leading to suboptimal endometrial
receptivity.
We have identified only one previous report comparing the
effects of a GnRH antagonist treatment on mid-luteal phase
endometrium to the state of the mid-luteal endometrium in a
natural ovulatory cycle (Simon et al., 2005). However, that
study only examined ER and PR expression 7 days after an
LH surge. The GnRH antagonist used in that study was Ganir-
elix. In this study, we used Cetrorelix and to our knowledge this
is the first report describing the ER, PR and AR expression as
well as the steroid metabolizing enzymes expression in a
GnRH antagonist treated mid-luteal phase endometrium.
The reason, why so few studies have addressed the mechan¬
isms of endometrial receptivity in IVF/ICSI cycles during the
window of implantation is due to the difficulty in obtaining, for
detailed studies, endometrial biopsies at this phase of the treat¬
ment. Hence, most of the relevant studies have been performed
on only small numbers of subjects.
Conclusions
In summary, to our knowledge, this is the first report describing
the effects of a GnRH antagonist and rFSH on sex-steroid
receptor and steroid metabolizing enzymes expression in mid-
secretory phase endometrium. This study has shown that under
the effect of rFSH and a GnRH antagonist with progesterone
supplementation, significant alterations occur in endometrial
intracrinology at a time when the endometrium would be
expected to be most receptive for implantation. The impact
of these observations on embryo-endometrial interaction
requires further evaluation.
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